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 Abstract 
17β-HSD2 is a new promising target for the treatment of osteoporosis. In the first part of 
this thesis, a rational approach to overcome metabolic instability of the 2,5-thiophene amide 
class of 17β-HSD2 inhibitors is described, as well as a general overview of the occurring 
biotransformation in this series of molecules (Chapter 2.I). This information was then used 
to design and synthesize a new class of compounds, bearing a 1,4-phenyl amide core, which 
proved to be metabolically stable, potent inhibitors of both human and mouse 17β-HSD2 
and selective over human and mouse 17β-HSD1 and ERs. The best compound in the series, 
II.17a is therefore a potential candidate for pre-clinical animal studies, prior to human 
studies (Chapter 2.II). 
Cell viability experiments, using an MTT assay, indicated that cell toxicity might constitute 
a drawback for II.17a. A preliminary study to address cell toxicity and maintain good 
inhibitory activity is also presented (Chapter 2.III). 
In the second part of this thesis (Chapter 2.IV) the theoretical basis for the treatment of 
NSCLC, through inhibition of 17β-HSD1, is given. The knowledge gained about metabolic 
stability of 2,5-thiophene amides is exploited to design and synthesize new potent, selective 
and metabolically stable 17β-HSD1 inhibitors. Compound IV.15 completely inhibits the 
growth of NSCLC Calu-1 cell at low nanomolar concentration, suggesting new treatment 
option for patients affected with NSCLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 Zusammenfassung 
17β-HSD2 ist ein neues vielversprechendes Target für die Behandlung von Osteoporose. Im 
ersten Teil dieser Arbeit wird ein rationaler Ansatz, die metabolische Instabilität der 2,5-
Thiophenamid Klasse zu überwinden, beschrieben (Kapitel 2.I). Die erlangten Erkenntnisse 
wurden genutzt um eine neue Verbindungklasse mit 1,4-Phenylamid Core zu entwerfen und 
zu synthetisieren. Diese Verbindungen sind metabolisch stabile potente Hemmstoffe von 
humanem und murinem 17β-HSD2 und selektiv gegenüber den entsprechenden 17β-HSD1 
Isoformen und ERs. Mit der besten Verbindung dieser Serie II.17a ist es gelungen einen 
potentiellen Kandidaten für präklinische Tierstudien zu synthetisieren (Kapitel 
2.II).Toxizitätsstudien an menschlichen Zellen zeigten jedoch, dass diese Verbindung nicht 
frei von toxischen Effekten ist. Eine vorläufige Studie mit dem Ziel dieses Handikap zu 
überwinden und gleichzeitig die Hemmaktivität zu erhalten, wird in Kapitel 2.III 
vorgestellt.Im zweiten Teil dieser Arbeit (Kapitel 2.IV) wird die theoretische Basis für die 
Behandlungvon NSCLC durch Hemmung von 17β-HSD1 vorgestellt. Das in dieser Arbeit 
erlangte Wissen über die metabolische Stabilität der 2,5-Thiophenamide wurden beim 
Design und der Synthese neuer, potenter, selektiver und metabolisch stabiler 17β-HSD1 
Hemmstoffe angewandt. Verbindung IV.15 hemmt bereits bei nanomolaren 
Konzentrationen vollständig das Wachstum von NSCLC Calu-1 Zellen. Diese Erkenntnisse 
eröffnen neue Behandlungswege für Patienten mit NSCLC. 
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1. Introduction 
1.1 Endocrine system and steroidal hormones 
1.1.1 Hormones and sexual hormones 
Hormones are signal transmitter, produced by endocrine cellsand released in the circulatory 
system to regulate the physiology of target organs. 
Several physiological processes, such as regulation of temperature and blood pressure, 
metabolism, control of the reproductive cycle, stimulation or inhibition of growth and other 
activities are under the control of these chemical substances named hormones. 
Hormones mainly act on the target cells by modulating the kinetic of enzymatic reactions, 
by controlling the transport of molecules through the cell membrane and by controlling the 
expression of genes and the synthesis of proteins. 
Hormones production is regulated through a complex system, which ensures a fine 
modulation of the molecules release (Figure 1). 
The production of a hormone from a peripheral gland, such as adrenal or thyroid, starts with 
the production from the hypothalamus of a releasing hormone (RH). The RH stimulates the 
pituitary to release a glandotropic hormone, which in turn stimulates the target gland to 
secrete the specific hormonal molecule. 
The hormones produced from the peripheral gland exert a negative feedback, by inhibiting 
the hormonal production from the hypothalamus and the pituitary. This mechanism of 
regulation is known as the hypothalamus-pituitary axis.(Monticelli, 2013) 
 
Figure 1.Mechanism of regulation of hormones release. The concentration of the effector 
hormone regulates the activity of the hypothalamic-pituitary axis. 
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From a chemical point of view hormones can fall into four main classes: amino acid 
derivatives (i.a. melatonine and thyroxine), polypeptides and proteins (i.a. vasopressin), 
eicosanoids (i.a. arachidonic acid) and steroids (i.a. sex hormones). 
At the same time signals of chemical nature released from a cell can influence (Figure 2) 
(Voet and Voet, 2011; Labrie, 1991):
 
 The cell itself (autocrine activity) 
 Neighboring cells (paracrine activity) 
 Distant cells, after release in the circulation (classical endocrine activity) 
Complementary to the well-known autocrine, paracrine and endocrine activities a so called 
intracrine activity (Figure 2) has been described in 1988 by Labrie et al. (Labrie et al., 
1988). The concept of intracrine activity was coined to describe “a system, where locally 
produced androgens and/or estrogens exert their action in the cells where synthesis took 
place, without release in the extracellular space”. 
 
Figure 2.A cell can secrete hormones, which can influence the cell itself, a neighbouring 
cell, a distant cell or after modification the cell where the modification itself takes place. 
Red points: active hormons; Green triangles: inactive hormons. 
Steroidal hormones are lipophilic molecules, which are derived from cholesterol. Sex 
hormones belong to the class of the steroidal hormones. Two main classes have been 
identified: 1) Androgens, which are the male sex hormones, such as androstenedione (A-
dione), testosterone (T) are mainly produced in the testes and dihydrotestosterone (DHT) 
mainly in the prostate, although a small but physiologically important amount is produced in 
the adrenal cortex. 2) Estrogens, which are the female sex hormones, such as estradiol (E2) 
and estrone (E1) are mainly produced in the ovary and in the placenta.  
Estrogens and androgens have a variety of effects on both the sexual organs and diverse 
target tissues.Estrogens promote the development of female sexual characteristics, are 
associated with energy homeostasis and metabolism, prevent the loss of bone in male and 
female and play a role in vasoprotection (Koos, 2011; Simpson et al., 2005; Gruber et al., 
2002). 
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Testosterone, along with dihydrotestosterone is responsible for the development of male 
sexual characteristics as well as for mood, sexual drive and desire. They are also linked to 
bone formation, metabolism and erythropoiesis (Ferrucci et al., 2006; Snyder et al., 2000; 
Burger, 2006). 
1.1.2 Biosynthesis of androgens and estrogens 
In the endocrine tissues, cholesterol is the deposit steroid and it is converted to estrogens, 
progesterone or androgens when the tissue is stimulated by the glandotropic hormone. A 
simplified view of the biosynthesis pathway is depicted in Figure 3. 
The cholesterol is converted into pregnenolone, via cleavage of the lateral chain and is in 
turn transformed either in progesterone by the 3β-hydroxysteroid dehydrogenase (3β-HSD) 
or in 17α-hydroxypregnenoloneby the 17α-hydroxylase (CYP17) (Ryan and Smith, 1965). 
The next step involves the cleavage of the bond between C-17 and C-18, which leads to 
dehydroepiandrosterone(DHEA).It is catalyzed by the CYP17 itself (Nakajin and Hall, 
1981).  
The DHEA is then converted by 3β-HSD into 4-androsten-3,17-dione (A-dione)which can 
be converted into testosterone by 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3), 
whereas 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyses the opposite 
reaction. 
Aromatase (CYP19) through aromatisation of the A ring and cleavage of the methyl C-19 
catalyses the conversion of androstenedione and testosterone into estrone and estradiol, 
respectively.The principal substrate for extra-ovarian aromatase activity in women is 
androstenedione (Bulun et al., 2000). 
17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) and 17β-hydroxysteroid 
dehydrogenase type 2 (17β-HSD2) catalyse the inter-conversion between estrone and 
estradiol. 
It is of interest to notice that whereas in pre-menopausal women estrogens are mainly 
produced in the ovaries, after menopause occurrence, the estrogen production moves to 
peripheral tissues, such as adipose tissue or skin(Bulun et al., 2001) and the precursors of 
almost all of the sex steroids are of adrenal origin (Jansson, 2009). 
Testosterone, which is in males the main circulating hormone is synthesized in testes and 
adrenals, starting from cholesterol. The main routes of the biosynthesis of testosterone have 
already been described and are depicted in Figure 3. 
In target tissues, like in the prostate, testosterone can be converted to 5α-dihydrotestosterone 
by the 5α-reductase (Figure 3). It is the most active androgen (Dorfman and Ungar, 1965). 
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Figure 3.Simplified view of estrogens and androgens synthetic pathway. CYP11A1: 
cholesterol desmolase; CYP17: 17α-hydroxylase/17,20-lyase;3β-HSD: 3β-hydroxysteroid 
dehydrogenase/Δ5-Δ4isomerase; CYP19: aromatase; 17β-HSD: 17β-hydroxysteroid 
dehydrogenase; S5AR: 5α-reductase. 
The sex hormones achieve their effects via the sex hormone receptors, intracellular 
receptors, which function as transcription regulators, by altering the transcription of specific 
target genes. 
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Estrogens interact with the estrogen receptors (ERs) ERα(Walter et al., 1985) and 
ERβ(Kuiper et al., 1996) and androgens interact with the androgen receptor (AR)(Trapman 
et al., 1988). 
Estrogens and androgens are also produced in men and women, respectively (Simpson et al., 
2005; Burger, 2002; Miller and Auchus, 2011; Stocco, 2011). 
Androgens are formedin females from circulating precursors (such as DHEA and 
androstenedione). They have been found to be beneficial for bone mineral density and 
decreased risk of anemia. 
In males certain peripheral target tissues express aromatase, which facilitates the conversion 
of circulating testosterone to estradiol and androstenedione to estrone. In men, estrogen 
insensitivity has been associated to a loss of bone mineral density and premature 
atherogenesis (Koos, 2011; Simpson et al., 2005; Gruber et al., 2002). 
1.2 17β-HSD2 and 1 in the steroidal hormone synthesis 
1.2.1 17β-hydroxysteroid dehydrogenases (17β-HSDs) 
In general HSDs are oxidoreductases, which interconvert ketones to the corresponding 
secondary alcohols, using NADPH/NAD
+
 as cofactor. Steroid hormones are the main 
substrate, but some HSDs are involved in the metabolism of different non-steroidal 
compounds (Hoffmann and Maser, 2007; Maser, 1995; Matsunaga et al., 2006). 
 
Figure 4. General reactions catalysed by 17β-HSDs. 
With the exception of 17β-HSD5, belonging to the aldo-reductase family (AKR) (Penning 
and Byrns, 2009), the remaining 17β-HSDs are members of the short chain 
dehydrogenase/reductase (SDR) protein family (Prehn et al., 2009). 
17β-HSDs play a key role in the final steps of estrogen and androgen biosynthesis and are 
tissue specifically expressed. Therefore in recent years they gained major interest as 
potential drug targets for the treatment of sex steroid hormone-related diseases. 
Fourteen different mammalian 17β-HSDs have been to date identified (Möller and 
Adamski, 2009; Meier et al., 2009; Luu-The, 2001), but only twelve have been 
characterised in human (17β-HSD6 and 17β-HSD9 only in rodents). 
All 17β-HSDs are able to transform steroid hormones in vitro and actually, the name 17β-
HSD has been in the past routinely assigned to many enzymes converting 17-ketosteroids to 
17-hydroxysteroids, regardless of the fact they can have diverse substrate specificities in 
vivo.  
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Table 1. Human 17β-HSDs. With the coloured background “reductive” 17β-HSDs. With 
the white background “oxidative” 17β-HSDs (modified and updated from (Marchais-
Oberwinkleret al., 2011)) 
Name Localisation Function Disease-association References 
17β-HSD1 
Breast, Ovary, 
Endometrium, 
Placenta, 
Lung 
Estrogen synthesis 
Breast, prostate and lung cancer, 
endometriosis (when 
overexpressed) 
(P. Vihko et 
al., 2006; 
Vihko et al., 
2005; 
Verma et al., 
2013) 
17β-HSD2 
Liver, Breast, 
Endometrium, 
Placenta, 
Prostate, 
Bones, Lungs, 
Kidney 
GI tract 
Estrogen, androgen, progestin 
inactivation 
Osteoporosis, breast, prostate and 
lung cancer, endometriosis 
(Vihkoet al., 
2006; 
Vihkoet al., 
2005; 
Drzewiecka 
and 
Jagodzinski, 
2012) 
17β-HSD3 Testis Androgen synthesis 
Pseudohermaphroditism in males 
associated with obesity when 
missing 
(Geissler, et 
al., 1994) 
17β-HSD4 ubiquitous 
Fatty acid β-oxydation, estrogen 
and androgen inactivation 
D-specific bifunctional protein-
deficiency, prostate cancer 
Zellweger syndrome when 
deficiency 
(Rasiah, et 
al., 2009) 
17β-HSD5 Prostate, Liver 
Androgen, 
estrogenandprostaglandinesynthesis 
Prostatecancer 
(Stanbrough, 
et al., 2006) 
17β-HSD6 
Not 
Characterised in 
Human 
Retinoid metabolism, 3α-3β-
epimerase 
 
(Biswas and 
Russell, 
1997) 
17β-HSD7 
Liver, Lung, 
Thymus, breast, 
ovary, placenta 
Cholesterol biosynthesis, estrogen 
synthesis 
Breast cancer 
CHILD syndrome when 
deficiency 
(Haynes et 
al., 2010) 
17β-HSD8 
Liver, Placenta, 
Kidney 
Fatty acid elongation, estrogens 
and androgens inactivation 
Polycistic kidney diease 
(Fomitcheva 
et al., 1998; 
Maxwell et 
al., 1995) 
17β-HSD9 
Not 
Characterised in 
Human 
Retinoid metabolism  
(Su et al., 
1999) 
17β-
HSD10 
Central Nervous 
System, Brain 
Isoleucine, fatty acid, bile acid 
metabolism, estrogen and 
androgens inactivation 
X-linked mental retardation 
MHBD deficiency, pathogenesis 
of Alzheimer disease 
(Froyen et 
al., 2008 ; 
Yang et al. 
2007) 
17β-
HSD11 
Liver Kidney, 
Lung, Placenta 
Estrogen and androgens 
inactivation, lipid metabolism 
 
(Breton et 
al., 2001) 
17β-
HSD12 
Breast, Liver, 
Placenta, 
Kidney, Ovary, 
Uterus 
Fatty acid elongation, estrogen 
synthesis 
Breast cancer 
(Luu-The et 
al., 2006; 
Day et al., 
2008) 
17β-
HSD13 
Liver Not demonstrated  
(Horiguchi 
et al., 2008) 
17β-
HSD14 
Liver, Placenta, 
Brain 
Estrogenand androgen inactivation, 
fatty acid metabolism 
Breast cancer, prognostic marker 
(Jansson et 
al., 2006 ; 
Lukacik et 
al., 2007) 
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A summary of the different function and disease associations for the fourteen 17β-HSDs is 
given in Table 1. 
The numbering follows the chronological order of discovery of the different 17β-HSDs. The 
one belonging to the SDR family share low sequence identity (25% - 30%) but they 
conserved all characteristics of the family, i.e. the Rossmann fold implicated in cofactor 
binding. 
Although 17β-HSDs are able to catalyse both oxidation and reduction reactions in vitro, 
they catalyse only one type of reaction in vivo, depending on the concentration of cofactors 
in cells and the preference of each 17β-HSD for a specific cofactor (Figure 5). 
 
Figure 5. Interplay between metabolism and 17β-HSDs catalysed reactions. (Figure taken 
from PhD Thesis, Spadaro, 2011) 
 
1.2.1.1 17β-HSD2 
Human 17β-hydroxysteroid dehydrogenase type 2 is composed of 387 amino acids and 
possesses a molecular weight of 42.8 kDa. It is an endoplasmic reticulum bound enzyme, 
which converts primarily the highly active 17β-hydroxysteroids (i.a. estradiol, 
testosterone,dihydrotestosterone, etc.) to their inactive keto forms (Puranen et al., 1999; Wu 
et al., 1993). No 3D-structure of the protein is available yet. 
Although 17β-HSD2 were thought to be exclusively converting sex steroids, new evidences 
indicate that this enzyme is also involved in retinoic acid metabolism (Haller et al., 2010; 
Zhongyi et al., 2007). 
17β-HSD2, as the others 17β-HSDs, is able to catalyze both oxidation and reduction 
reactions in cells, though it catalyses one reaction preferentially, based on two factors: the 
concentration of cofactor present in cells and the higher affinity for one specific cofactor. 
NAD
+
/NADH is the principal system in cells for oxidative reactions. NAD
+
function as 
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electron acceptor and the fact that its concentration is 700 times higher than its reduced state 
NADH, assures the direction of the reaction to be oxidative (Sherbet et al., 2007; Agarwal 
and Auchus, 2005). On the other hand NADPH is the main source of electrons for catalysis 
of reduction reactions and its concentration is 500 times higher than the one of the 
corresponding state NADP
+
. A part from the cofactor concentration, the different affinity of 
17β-HSD2 for different cofactors explains why it preferably catalyses the oxidative reaction 
in the cell. In fact it has been shown that the Km of NAD
+
 for 17β-HSD2 is 110 ± 10 µM, 
whereas that of NADP
+
 is 9600 ± 100 µM (Lu et al., 2002).As a member of the SDR-
family, 17β-HSD2 shares some common amino acid motifs, which are highly conserved, 
despite a very low sequence identity across the family: the T-G-xxx-G-x-G motif (“cofactor 
binding site”), the Y-xxx-K sequence (“active center”) and the N-A-G motif for the 
stabilization of the 3D structure (Puranen et al., 1994; Hwang et al., 2005; Zhongyi et al., 
2007). 
1.2.1.2 17β-HSD1 
Human 17β-hydroxysteroid dehydrogenase type 1 is composed of 327 amino acid residues 
and possesses a molecular weight of 34.9 kDa. It is a cytosolic enzyme, which mainly 
catalyses reactions between the low-active female sex steroid, estrone, and the more potent 
estradiol (Poutanen et al., 1995), though like 17β-HSD2, seems to be involved in the 
metabolism of retinoic acid (Haller et al., 2010). To date 22 crystal structures of 17β-HSD1 
are available in the protein data bank (PDB), as apoenzyme, holoenzyme or substrate 
cofactor complexes. 
17β-HSD1, which catalyses only estrogen reduction,shows a higheraffinity for NADPH, 
which is used as cofactor in the catalysis of the reductive reaction, with a Km value of 
0.03±0.01 µM (Jin and Lin, 1999) and it shares the same amino acids motifs common to the 
SDR family and described above. 
1.3 17β-HSD2 and 17β-HSD1 as drug target 
1.3.1 Osteoporosis and 17β-HSD2 
Osteoporosis (Cree et al., 2000) is a systemic disease characterised by a decline in bone 
density and quality, determined by an unmatched activity of osteoclasts and osteoblasts. The 
impairment of bone mass and microarchitecture increases bone fragility and risk of 
fractures, leading to higher risk of death and to huge costs for the healthcare system (Blume 
and Curtis, 2011). 
Different therapies are already available for the treatment of this disease (Silva and 
Bilezikian, 2011) and they include: Calcium, Vitamin D, Parathyroid hormone (PTH), 
Bisphosphonates, Selective estrogen receptor modulators (SERMs) and RANKL inhibitors 
(Borba and Mañas, 2010; Jansen et al., 2011; Pazianas et al., 2010; Johnston et al., 2000; 
McClung, 2007). Despite the large number of therapies available, none of them present a 
satisfying profile in terms of safety and efficacy. For example, bisphosphonates, with 
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alendronate as the principal drug used in the treatment of osteoporosis, are able to reduce by 
only 50% the risk of fractures of both women and men, but are associated with adverse 
effects such as osteonecrosis of the jaw and SERMs, if effective are associated with an 
increased risk of venous thromboembolism. 
The drop in E2 and T levels, naturally occurring with ageing, is the main factor driving the 
onset and progression of osteoporosis (Vanderschueren et al., 2008; Bodine and komm, 
2002).“Physiologically normal” levelsof E2 induce bone formation and repress bone 
resorption (Bodine and Komm, 2002).In fact estrogen replacement therapy (ERT) was 
successfully used in the past, for reducing the risk of fractures. Unfortunately the ERT was 
found to be associated with severe adverse effects, such as cardiovascular diseases and 
breast cancer (Chen et al., 2002). 
Since 17β-HSD2 is expressed in osteoblastic cells (Dong et al., 1998), it represents a 
promising target for the treatment of osteoporosis. In fact its inhibition might lead to a local 
increase of E2 and T levels,whose beneficial effect on bone quality has already been proved 
by ERT, and potentially leads to less adverse effects in comparison to the ERT (Figure 6). 
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Figure 6.Expected effect of 17β-HSD2 on osteoporotic bone. 
 
1.3.2 Estrogen-dependent diseases and 17β-HSD1 
Estrogens are also implicated in the development and progression of numerous diseases 
(estrogen-dependent diseases), such as breast cancer and endometriosis (Deroo and Korach, 
2006). 
1.3.2.1 Breast cancer 
Breast cancer is the most frequent cancer affecting women and, in North America, the 
second most important cause of death from cancer, after lung cancer (Jemal et al., 2008). 
This disease is most frequent in postmenopausal women and it is estradiol-dependent in 
75% of the cases (Russo et al., 2003). However, the exact mechanism by which E2 
contributes to the development of mammary cancer remains unclear. The most likely 
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hypothesis is that a higher rate of cell proliferation is induced by growth factors, whose 
synthesis is stimulated upon binding of E2 to ERα and β. Cell proliferation is oftenlinked to 
carcinogenesis. It implies DNA replication, which can lead to cancer when too many 
uncorrected errors in gene transcription take place,(Yue et al., 2005). To corroborate this 
hypothesis, there is the fact that 60% of postmenopausal breast cancer have measurable ERs 
(ER+), whereas in normal breast epithelial cells ERs are present in very low quantities 
(Cotterchio et al., 2003). 
Besides surgery treatment, which remains the mainstay treatment for breast cancer, 
radiotherapy and chemotherapy, like the endocrine therapy, are also applied. 
Gonadotropin-releasing hormone (GnRH) analoga(Emons et al., 2003), aromatase inhibitors 
(Herold and Blackwell, 2008)and sulfatase inhibitors (Aidoo-Gyamfi et al., 2009), all act by 
decreasing E2 levels. 
1.3.2.2Endometriosis 
Endometriosis is defined by the presence of endometrial cells and stroma outside of the 
uterine cavity. It is an estrogen-dependent disease.It mostly develops in women of 
reproductive age and regresses after menopause or ovariectomy. Its symptoms includepain, 
dysmenorrhea, deep dyspareunia and chronic pelvic pains as well as increased risk of 
infertility. 
The pathogenesis of endometriosis remains unclear, but two main theories have been 
proposed: metastatic implantation after the reflux of endometrial cells through the fallopian 
tubes (Sampson, 1927), and metaplastic development such as coelomic metaplasia (Meyer, 
1919). 
The regulation of sex hormones producing enzymes plays a pivotal role in the onset and 
progression of the E2-dependent endometriosis.In endometriotic tissues an aberrant 
expression of aromatase, the over-expression of 17β-HSD1, and the deficiency in 17β-
HSD2 is observed, which may lead to an accumulation of E2 (Tsai et al., 2001). 
Endometriosis is mainly treated surgically, using laparoscopy, though ovariectomy is the 
most effective therapy(Kitawaki et al., 2002). Non-selective non-steroidal anti-
inflammatory drugs (NSAIDs), which inhibit the synthesis of prostaglandins at both COX-1 
and COX-2 enzymes , are the first line pharmacological treatment for this disease, although 
the severe associated adverse effects limit their use to patients with severe endometriosis 
under clearly defined conditions (Ebert et al., 2005). Further pharmacological treatments, 
aiming to produce a pseudo-pregnancy or pseudo-menopause, includeGnRHanaloga, oral 
contraceptives and androgens (Olive and Pritts, 2001). Aromatase inhibitors and SERMs 
showed so far promising results in the treatment of endometriosis, although they are not 
listed as official therapies, yet (Racine et al., 2010; Kulak et al., 2011). 
1.3.2.3 Non-small cell lung cancer (NSCLC) 
Lung cancer is divided into small cell lung cancer (SCLC) and non-small lung cancer 
(NSCLC), which accounts for about 80% of all lung cancers and is the most common type 
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in women (Muscat and Wynder, 1995). Despite the extensive research efforts fornew 
treatments, it is one of the most lethal human malignancies. 
Several studies have demonstrated the relationship between E2 and NSCLC. E2 can 
promote the growth of both normal lung fibroblasts and lung cancer cells in vitro and in 
vivo(Weinberg et al., 2005; Stabile et al., 2002).E2 can also increase the secretion of growth 
factors such as the potent mitogen epidermal growth factor (EGF) in normal lung fibroblast 
and vascular-endothelial growth factor (VEGF) in lung cancer cell in vitro(Stabile et al., 
2002; Pietras et al., 2005). A significant decrease in the proliferation of NIH-H23 lung 
cancer cells has also been observed in vitro for siRNA-mediated knockdown of the ERs 
(Márquez-Garbán et al., 2007). Further, the majority of NSCLC tumors result positive for 
the ERs, with ER β being the predominant subtype (Omoto et al., 2001). 
Given the pivotal role of E2 in the progression of NSCLC, the possibility to interfere with 
the intratumoral synthesis of this sex hormone, has been regarded as a possible approach for 
the treatment. 
Preclinical studies with the aromatase inhibitor exemestane have been conducted with a 
positive outcome (Márquez-Garbánet al., 2009). 
Lately evidence has emerged that both 17βHSD1 and 17βHSD2 are expressed in NSCLC 
contributingto the tumor progression: the first by activating the available intratumoral E1 
and the second by catalyzing the reverse reaction, thus playing a protective role against an 
excess of E2 (Drzewiecka and Jagodzinski, 2012; Drzewiecka et al., 2015; Verma et al., 
2013). 
In recent years 17βHSD1 has come up as new drug target for the treatment of NSCLC. 
1.3.2.4 Summary 
As so far described, E2 plays a crucial role in the maintenance of physiological processes, 
such as bone metabolism, which is negatively affected by E2 deficiency and in the onset and 
the progression of a number of illnesses, which are referred to as estrogens-dependent 
diseases: breast cancer, endometriosis and NSCLC, to name the most important ones. 
A fine tuning of the local levels of estrogens seems to be possible by selectively acting on 
the two enzymes, mainly involved in the final steps of estrogens biosynthesis: 17βHSD1 
and 17βHSD2. 
The inhibition of these two enzymes seems particularly promising for the treatment of the 
mentioned diseases, in which hormone therapies or pharmacological treatments interfering 
with the endocrine system, proved a good efficacy but was associated with several adverse 
effects. 
Since 17βHSD1 and 17βHSD2 are at the endof the estrogens biosynthesis, they might be 
idel targets to interfere with, to achieve the desired estrogen modulation and at the same 
time to avoid systemic adverse effects, which emerge with the traditional endocrine 
therapies. 
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1.4 State of Knowledge 
1.4.1 Inhibitors of 17β-HSD2 
17β-HSD2 inhibitors, bearing a steroidal core, were first identified by the group of Poirier 
(Sam et al., 2000; Bydal et al., 2004). Compound A(Figure 7) was the most interesting 
among them, exhibiting an IC50 value of 6 nM, but it was no longer investigated for further 
development, because of its lack of selectivity. In addition the steroidal core of this class of 
inhibitors increases the risk of interaction between the molecule and the steroid hormone 
receptors which could result in adverse effects. 
A novel non-steroidal chiral 4,5-disubtituted cis-pyrrolidinone was discovered by Wood et 
al. (Gunn et al., 2005; Wood et al.; 2006) (Compound B, Figure 7). It showed an IC50 value 
of 50 nM, and was evaluated in a monkey osteoporosis model to establish a proof of 
concept. Slight decrease in bone resorption and increase in bone formation were observed 
subsequently to its administration, although non satisfactory pharmacokinetic profile of B 
led to strong variability in the observed effects. 
In our group several classes of non-steroidal potent and selective 17β-HSD2 inhibitors were 
published. Among them the most interesting, depicted in Figure 7, are: 1. the 
hydroxyphenylnaphth-1-ol C(Wetzel et al., 2011), which displays an IC50 of 19 nM and s.f. 
over 17β-HSD1 of 32. Further development of C was stopped because of its metabolic 
instability, as proved by testing in human liver S9 fraction (t1/2= 22 min). 2. the 2,5-
thiophene amide D(Marchais-Oberwinkler et al., 2013), with an IC50 value of 58 nM and s.f. 
over 17β-HSD1 of 116, also displayed a rather high metabolic instability (t1/2= 17 min). 3. 
The retro-N-methylsulfonamide E(Perspicace et al., 2013)showed high inhibition of 17β-
HSD2 and only moderate selectivity over 17β-HSD1 (s.f. of 10). 
 
Figure 7. Selection of the most interesting 17β-HSD2 inhibitors. 
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1.4.2 Inhibitors of 17β-HSD1 
Despite the many efforts dedicated over the past 30 years to the development of potent 17β-
HSD1 inhibitors, it is only recently that lead candidates have been reported. Most of the 
17β-HSD1 inhibitors reported are based on the steroid scaffold, including E1 and E2 
derivatives (Poirier, 2003). As in the discussed case of 17β-HSD2 inhibitors, the presence of 
residual estrogenic activity is often associated with steroidal inhibitors, constituting a major 
drawback in the further progression of these compounds. 
In order to overcome the risk of adverse effects caused by interaction with ERs or other 
steroid receptors, several classes of non-steroidal inhibitors have been developed: gossypol 
derivatives (Brown et al., 2003), phytoestrogens (Poirier, 2003), thiophenepyrimidinones 
(Messinger et al., 2006) and biphenyl ethanones(Allan et al., 2008). 
Ourgroupstrongly contributed to the field of non-steroidal 17β-HSD1 inhibitors by 
developing several classes of selective 17β-HSD1 inhibitors for the treatment of estrogen-
dependent diseases. 
As an example some of the most interesting compounds are reported in Figure 8: 1. the 
heterocyclic substituted biphenylol F(Oster et al., 2010), with an IC50 value of 8 nM and a 
s.f. of 48, was one of the first potent compound reported by our group. 2. the 
bis(hydroxyphenyl) substituted arene G (IC50= 8 nM, s.f.= 118) showed, in comparison to 
F, improved selectivity over 17β-HSD2 (Bey, et al., 2009). 3. the hydroxybenzothiazoles 
H(Spadaro et al., 2012)which showed an IC50 value of 13 nM and s.f. of 136. 4. The 
(hydroxyphenyl)naphthol I(Henn et al., 2012)displayed an IC50 value of 32 nM and s.f of 
12. Compound I also inhibited 17β-HSD1 from Callithrix jacchus, 5. the most recent 
compound J (IC50= 104 nM, s.f.= 2.4) is the most potent compound in a new class of 
inhibitors(Abdelsamie et al., 2014). 
 
Figure 8. Selection of 17β-HSD1 inhibitors. 
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1.5 Aim of the Thesis 
1.5.1 Scientific goal 
Several diseases are associated with the endocrine system and the sex steroid hormones. 
Drop in E2 and T levels which occurs in post-menopause women and in elderly men 
constitutes the main cause of osteoporosis. 17β-HSD2 is responsible for the local 
inactivation of these hormones and is expressed in bone tissue. Thus inhibition of 17β-
HSD2 might be a new promising approach for the treatment of this disease. Although the 
pyrrolidinone B has already been evaluated in a monkey osteoporosis model and its positive 
effects on bone health have been demonstrated, too strong variability in the results has also 
been reported, certainly due to non appropriate pharmacokinetic properties. 
Therefore the goal of the first part of this thesis (Chapter 2.I-2.III) is the development of 
new inhibitors which might be suitable for an in vivo study in an animal model of the 
disease and at the same time present a pharmacological profile which makes them eligible 
for future human clinical studies. The mouse animal model was selected as the target model, 
because several murine model of osteoporosis are already established. 
In order to achieve this goal, we designed a pharmacological flow chart for the development 
of new inhibitors or the optimization of in-house compounds (Figure 9). 
In order to increase our chances of obtaining suitable compounds, different calculated 
parameters were determined prior to the synthesis of new molecules. cLogP, predicted 
solubility, polar surface area (PSA), pKa and tox liability were calculated in silico, in order 
to design drug-like inhibitors. 
After testing on human and mouse 17β-HSD1 and 2 (percent of inhibition at 1 µM), the new 
molecular entities were evaluated for their metabolic stability (using human liver S9 
fraction), plasma stability and plasma protein binding (PPB). 
When the results were satisfactory the compounds were investigated with regard to their 
ability to inhibit hepatic CYP enzymes and to bind to the ERs. IC50 values were also 
determined at this point. 
The following step includes the pharmacokinetic study of the compound in the mouse, 
together with an evaluation of toxicity in HEK 293 cells (using MTT assay) and induction 
of CYP enzymes. 
A compound with positive results in all the above mentioned assays was considered suitable 
for an in vivo study and eventually for further clinical development. 
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Figure 9. Pharmacological flowchart for the development of new 17β-HSD2 inhibitors 
Whereas osteoporosis is caused by decreased levels of E2 and T, the so called estrogen 
dependent diseases depend on E2 presence. As previously listed, breast cancer, 
endometriosis and NSCLC are mainly estradiol-dependent. 17β-HSD1 and 17β-HSD2 are 
expressed in different amounts in estrogens target cells and play a pivotal role in the 
regulation of the growth of cancer tissues as well as endometrial tissue. Since 17β-HSD1 
catalyses the last step in E2 biosynthesis, it is considered the key-target to block peripheral 
E2 production, with few or no adverse effects associated. 
The in vivo efficacy of 17β-HSD1 inhibitors to reduce  estrogen stimulated growth in breast 
cancer and endometriosis has already been proved, although up to date no 17β-HSD1 
inhibitor has entered clinical trial yet. 
Thereby the main goal of the second part of this thesis (Chapter 2.IV) is the development of 
new potent and selective 17β-HSD1 inhibitors, with a particular focus on their metabolic 
stability, in order to provide new chemical entities which might be successful in an animal 
and human in vivo study. 
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In recent years strong evidence of the pivotal role of 17β-HSD1 and 17β-HSD2 in the 
progression of NSCLC has emerged, although no experimental evidence of the effect of 
17β-HSD1 inhibitors is available yet (Verma, et al., 2013). In vitro testing of the best new 
17β-HSD1 inhibitor on a suitable NSCLC cancer cell line, to investigate the effect on cell 
growth should be performed. 
1.5.2 Working strategy 
1.5.2.1 Optimization of 17β-HSD2 inhibitors foran in vivo proof of concept 
Metabolic stability optimization and metabolite identification of 17β-HSD2 inhibitors 
(Chapter 2.I): Although several classes of potent and selective 17β-HSD2 inhibitors were 
already synthesized, none of them presented an adequate metabolic stability. It was 
therefore decided to put the focus on this aspect first. A set of 11 2,5-thiophene amide 
compounds described by our group and carefully chosen as differing from one another by 
one structural change only, were tested for their metabolic stability using human liver S9 
fraction, in order to gain information about the potential site of metabolism. 
Taking into account the gathered information, a series of new compounds was designed and 
synthesized. Three strategies were followed (Figure 10): 1) exchange of the potential 
metabolic liability, according to the results of the starting experiment; 2) bioisosteric 
replacement of the central thiophene ring; 3) lowering of the cLogP. 
Furthermore the metabolic pathway of three inhibitors, belonging to the 2,5-thiophene 
amide class, was investigated.The exact structure of the metabolites of one of these 
inhibitors was elucidated. 
 
Figure 10. Structure overview of the metabolic stability optimization strategies. t1/2= half 
life in human liver S9 fraction. Compounds K and L are displayed as examples of the 11 
tested compounds. 
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Discovery of selective and metabolically stable compounds inhibiting both the Human 
and Mouse 17β-HSD2 (Chapter 2.II): The aim of the second project was to obtain new 
compounds which could inhibit both the mouse and the human 17β-HSD2 and still retainthe 
metabolic stability of some of the inhibitors synthesized in the first project. 
As starting point 25 previously described 17β-HSD2 inhibitors, belonging to the 2,5-
thiophene amide, 1,3-phenyl amide and 1,4-phenyl amide class, were tested for m17β-
HSD2 inhibition, in order to elaborate a comparative Structure Activity Relationship (SAR) 
and to develop an optimization strategy. 
Combining the gathered information together with the knowledge obtainedabout metabolic 
stability presented in chapter 2.I, a small library of inhibitors, where the substitution pattern 
and the physicochemical nature of substituents on the A and C rings was varied, was 
designed and synthesized. The general structure of the compounds included in this chapter 
is presented in Figure 11. 
 
 
Figure 11.Structure overview of the compounds included in chapter 2.2. 
Overcome of the cytotoxicity of the 1,4-biphenyl amide inhibitors (Chapter 2.III): In 
chapter 2.IIa lead candidate compound is discovered which potently and selectively inhibits 
the human and mouse 17β-HSD2 and which is metabolically stable. However this lead 
compound was found to be cytotoxic. In chapter 2.3 a preliminary study is presentedon a 
successful strategy to decrease cytotoxicity, without loss in 17β-HSD2 inhibitory activity. 
Decrease in cytotoxicity is achieved by disrupting the planarity of the biphenyl moiety 
(Figure 12). 
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Figure 12. Structure overview of the compounds included in chapter 2.III. 
1.5.2.2 Discovery of potent, selective and metabolically stable 17β-HSD1 inhibitors 
Taking into account the information regarding 17β-HSD1/2 inhibitory activity and 
metabolic stability gathered in chapter 2.I, a series of new inhibitors was designed. 
Structural modification of the thiophene derivatives (exchange of the thiophene by furane 
ring, introduction of substituents on the phenyl residues of the molecules) has been studied 
to increase 17β-HSD1 inhibitory activity and reverse the selectivity in favour of 17β-HSD1. 
A structure overview of the compounds included in chapter 2.IV is presented in Figure 13. 
 
Figure 13. Structure overview of the 
compounds included in chapter 2.IV 
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2. Results 
 
2.1 Metabolic stability optimization and metabolite identification of 2,5-
thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors 
Emanuele M. Gargano, Enrico Perspicace, Nina Hanke, Angelo Carotti, Sandrine Marchais-Oberwinkler 
and Rolf W. Hartmann 
This manuscript has been published as an article in the journal 
European Journal of Medicinal Chemistry, 2014, 87, 203-219 
         Paper I 
 
Abstract 
17β-HSD2 is a promising new target for the treatment of osteoporosis. In this paper, a 
rational strategy to overcome the metabolic liability in the 2,5-thiophene amide class of  
17β-HSD2 inhibitors is described, and the biological activity of the new inhibitors. 
Applying different strategies, as lowering the cLogP or modifying the structures of the 
molecules, compounds 27, 31 and 35 with strongly improved metabolic stability were 
obtained. For understanding biotransformation in the 2,5-thiophene amide class the main 
metabolic pathways of three properly selected compounds were elucidated. 
 
1. INTRODUCTION 
Osteoporosis[1] is a systemic disease in which an unmatched activity of osteoclasts and 
osteoblasts leads to a decline in bone density and quality. It is also correlated with an 
increased risk of bone fracture. Osteoporosis is observed in 40% of postmenopausal 
women[2]. Considering the progressive ageing of the population this number is expected to 
constantly increase in the near future[3] and osteoporosis is therefore considered as a 
serious public health concern. 
The available therapies today (bisphosphonates and selective estrogen receptor 
modulators) lack of a satisfying profile in terms of safety and efficacy. Bisphosphonates, 
with alendronate as the principal drug used in the treatment of osteoporosis, are effective in 
both postmenopausal women[4] and men[5, 6], though they are able to reduce the risk of 
fracture by only 50% and are associated with adverse effects such as osteonecrosis of the 
jaw. Raloxifene is, among the selective estrogen receptor modulators (SERMs), one of the 
most often used compounds for the treatment of osteoporosis[7]. SERMs are efficient too, 
but, as bisphosphonates, endowed with several adverse effects, such as an increased risk of 
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venous thromboembolism. As a consequence, the finding of new, safer and more effective 
treatments for osteoporosis is of particular importance for public health. 
It has been proven that an important player in the maintenance of bone health is the 
physiological, pre-menopausal concentration of the estrogen estradiol (E2). That induces 
bone formation and represses bone resorption by acting on the osteoblasts[8]. Estrogen 
replacement therapy (ERT) was used in the past in postmenopausal osteoporosis patients[9, 
10], successfully reducing the risk of fractures but increasing the incidence of 
cardiovascular diseases and breast cancer[10, 11], which was the reason for the cessation of 
this therapy. It has also been shown that testosterone (T) has beneficial effects on bone 
formation[12, 13]. 
Hence, an optimal strategy for the treatment of osteoporosis should be that to inducing a 
local increase inE2 concentration in bone tissue, without affecting the systemic levels of E2. 
Such an effect might be achieved by inhibiting 17β-hydroxysteroid dehydrogenase type 
2[14] (17β-HSD2), an enzyme that catalyzes the conversion of the highly active 17β-
hydroxysteroids into the low inactive 17-ketosteroids, that is the estrogen E2, and the 
androgen testosterone (T) into their inactive oxidatedforms estrone (E1) and Δ4-androstene-
3,17-dione (A-dione), respectively (Chart 1). The biological counterparts, 17β-
hydroxysteroid dehydrogenase type 1 (17β-HSD1) and 17β-hydroxysteroid dehydrogenase 
type 3 (17β-HSD3) catalyse the reverse reactions. Inhibitors of 17β-HSD1are potential 
drugs for the treatment of breast cancer and endometriosis and have recently been described 
in a series of papers by us[15, 18]. 
As 17β-HSD2 is expressed in osteoblasticcells[19-21], its inhibition should lead to the 
desired local increase of E2 and T levels in bone tissue. 
Ideally, the new 17β-HSD2 inhibitors should, in addition to their activity on the target 
enzyme, be selective over 17β-HSD1 and should have no affinity for the estrogen receptors 
(ER) α and β in order to avoid E2 related adverse effects. 
The discovery of potent and selective nonsteroidal inhibitors of 17β-HSD2 has been 
already reported by our research group[22-30]. 
As drugs encounter formidable challenges to their stability in vivo, it is not sufficient to 
only focus on potency in the development process of a drug candidate. It is also important to 
profile the metabolic stability of a lead series and improve it when this constitutes a 
potential liability. As 17β-HSD2 should be inhibited with constancy to locally increase the 
E2 levels and to maintain them high over the time needed to re-establish  bone metabolism, 
the development of  very metabolically stable inhibitors is particularly important. The 
enhancement of the metabolic stability of a class of inhibitors is a very difficult task for the 
medicinal chemist but could strongly favor the emergence of potential preclinical 
candidates[31]. 
As a consequence, we decided to test three of our most promising, previously 
reported17β-HSD2 inhibitors (compounds 1-3) for their metabolic stability in human liver 
microsomes S9 fraction (Chart 2), a powerful tool to explore both phase Ι and phase ΙΙ 
major metabolic reactions[32]. 1, 2 and 3 represent very good compounds in terms of 
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enzymatic inhibitory potency and selectivityover 17β-HSD1, however, they do not exhibit a 
satisfying stability displaying short half-lifes between 4 and 38 min.  
In this report, we describe the analysis of the metabolic profile of some representative in 
house inhibitors, the design of new, more stable inhibitors based on the results from these 
studies, as well as their synthesis and biological evaluation. In addition three inhibitors were 
investigated for their specific metabolic fate in order to understand the particular 
biotransformation of this class of molecules. 
 
Chart 1. Interconversion of E2 to E1 by 17β-HSD2 and 17β-HSD1, and T to A-dione by 17β-
HSD2 and 17β-HSD3. 
 
Chart 2. Previously described 17β-HSD2 inhibitors. 
2. INHIBITOR DESIGN 
2.1 Stability towards human S9 fraction  
Different hepatic enzymes can be responsible for the metabolic transformation of a 
compound and it frequently happens that small structural changes on the molecule lead to a 
switch of the responsible metabolic enzyme[33], a phenomenon known as “metabolic 
switching” [33]. As a consequence introduction of several structural changes in the scaffold 
of a compound is not an appropriate method to evaluate liabilities of single moieties as 
changes in the core structure could have switched the main site of metabolism.  
Therefore a set of 11 selected compounds described by our group[24, 25] and carefully 
chosen as differing from one another by one structural change only, were tested for their 
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phase Ι and ΙΙ metabolic stability using human liver S9 fraction (Table 1), in order to find 
out the potential sites of metabolism.  
From the comparison of compound 1 with 2 (t1/2 = 17 min and 38 min, respectively) it 
appears that the methoxy group on the A ring in meta position is unfavorable for metabolic 
stability compared to the methyl group, whereas the presence of a meta dimethyl amino 
group (compound 4, t1/2 = 29 min) provides a similar stability as the methylated derivative2 
(t1/2 = 38 min). 
The exchange of the methoxy group (5) for a methyl (6) on the C ring results also in a 
slight increase in metabolic stability (t1/2 = 12 min for 5vs 20 min for 6) 
Compound 5 bears an additional fluorine in ortho position on the A ring in comparison to 
compound 1. However introduction of this fluorine atom does not improve the stability of 
compound 5 (5, t1/2 = 12 min vs 17 min for 1). 
Comparison of the unsubstituted inhibitor 7 (t1/2 = 38 min), with 8 (t1/2 = 1 min) bearing 
anhydroxy group on the A ring and with 9 (t1/2 = 4 min) having an OH on the C ring shows 
that the phenolic OH group enhances the metabolic degradation of this class of compounds. 
This result was also observed in presence of a methylene linker in compound 3, bearing an 
OH on the C ring and having a half-life of 4 min. On the other hand, the nature of 
substituents on the A ring (in the presence of the OH group on the C ring) plays an 
important role in the stabilization, as addition of the methyl group alone (10, t1/2 = 17 min) 
or a hydroxy group (11, t1/2 = 20 min) slightly increases the metabolic stability. Compounds 
3, 10 and 11, in comparison with compound 1 have in their core two additional potential 
metabolic sites: the methylene linker and the phenolic group (liable for phase ΙΙ metabolic 
attack). Despite the increase in liable metabolic sites their half-lives (t1/2 = 17 min and 21 
min, respectively) are still in the range of compound 1. 
In summary none of the tested inhibitors showed a satisfying metabolic stability profile 
(Table 1). However, from these results it is obvious that 1. the methyl group on the A ring is 
less prone to metabolic degradation than the methoxygroup ( compounds 1 and 2). 2. 
thephenolic hydroxy substituent on both the A ring or the C ring is subject to fast 
metabolism (compounds8 and 9), which can be slightly slowed down by introduction of 
substituents on the other ring (compounds 10 and 11). 
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Table 1.Half-life in Human Liver Microsomes S9 fraction. 
 
compd R1 R2 n Inhibitor t1/2 (min) 
1 m-OMe -OMe 0 17
a
 
2 m-Me -OMe 0 38
a
 
3 o-F, m-OMe -OH 1 4
b,c
 
4 m-N(Me)2 -OMe 0 29
a
 
5 o-F, m-OMe -OMe 0 12
b,c
 
6 o-F, m-OMe -Me 0 20
a
 
7 -H -H 0 38
b,c
 
8 m-OH -H 0 1
b,c
 
9 -H -OH 0 4
b,c
 
10 m-Me -OH 1 17
a
 
11 o-OH -OH 1 21
a
 
a Inhibitor tested at a final concentration of 3 µM, 1mg/ml, pooled human liver S9 fraction (IVT, Xenotech or TCS Cellworks), 1 
mM NADPH regenerating system, 0.75 mM UDPGA, 0.05 mM PAPS, incubated at 37°C for 0, 5, 15, 30 and 45 minutes 
bInhibitor tested at a final concentration of 1 µM, 1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 2 mM NADPH 
regenerating system, 1 mM UDPGA and 0.1 mM PAPS, incubated at 37°C for 0, 5, 15 and 60 minutes.  
c Mean of at least two determinations, standard deviation less than 25%. 
 
2.2 Design of inhibitors 
In the inhibitor design we took into account the information we had gained from the 
metabolic stability results. In addition we tried to modify some other moieties that have the 
potential of being metabolically labile. Doing this we kept in mind the structure-activity and 
structure-selectivity relationshipsobtained in our previous studies[24, 25]. 
As the methyl group resulted to be more stable than the methoxy group on the A and C 
ring , we decided to exchange each methoxy group with a methyl function and then to 
explore the effect of this substitution pattern on both activity and metabolic stability. It was 
also observed that most of the compounds with a hydroxy group in the presence of the 
methylene linker, known to be a critical point for metabolism, scored the worst results in 
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terms of metabolic stability. However since a hydroxy group is needed for activity[25] in 
the series of compounds having the methylene linker, we decided to stop further structural 
modifications on this series. Therefore compounds without linker with the general structure 
A, depicted in Chart 3 were synthesized. 
The thiophene is also described as a potential site of metabolism[34]. Therefore, we tried 
to modify it by bioisosteric replacements using benzene, furane and thiazole (general 
structure B). 
Moreover, it has been reported[35] that thelipophilicity parameters likecLogP couldplay an 
important role for the metabolic stability. Very often the simple strategy to lower the cLogP 
was appropriate to improve the metabolic stability of a compound. Therefore some 
inhibitors, modified at the A ring with a moiety reducingcLogP were designed (general 
structure C, Chart 3). 
 
Chart 3. Designed inhibitors. 
Furthermore, we profiled the metabolic pathway of the newly synthesized 
dimethylphenylthiophene12 (Chart 4) looking for the major metabolites resulting from the 
mono-oxidation of the phenylthiophene part (Chart 4). 
In order to identify the main metabolites, especially the one coming from mono-oxidation of 
the phenylthiophene fragment, we synthesized different hydroxylated derivatives of 12 
bearing one additional oxygen in the positions that are likely to be attacked by the 
metabolizing enzyme (represented by the general structures D and E, Chart 4). 
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Chart 4. Structures of the most probable metabolites of 12. 
3. RESULTS 
3.1. Chemistry 
The synthesis of the 2,5-thiophene derivatives (compounds 12-23,25-27,36-38 and40) and 
the 2,5-furane derivatives (compounds 31-34) is depicted in Scheme 1. The 5-
bromothiophene-2-carbonic acid chloride and the 5-bromofuran-2-carbonic acid  chloride 
were obtained from the corresponding carboxylic acids 36c or 31b by reaction with SOCl2 
and subsequently reacted with different anilines (Method A), providing the intermediates 
12a-23a,25a-27a,36b, 37b, 40b and 31a-34a in good yields. Subsequently, Suzuki coupling 
(Method B) using tetrakis(triphenylphosphine)palladium and cesium carbonate in a mixture 
DME/EtOH/H2O (1:1:1, 3 mL) as solvent and microwave irradiation (150°C, 150 W for 20 
minutes), afforded the desired 2,5-thiophene derivatives 12-23,25-27,36a, 37a, 40a and the 
2,5-furane derivatives 31-34. Methoxy compounds 36a and 37a were submitted to ether 
cleavage using boron trifluoride-dimethyl sulfide complex yielding the hydroxy compounds 
36 and 37. The aldehyde function of compound 40a was reduced to primary alcohol using 
NaBH4 to provide compound 40. The synthesis of the 4-hydroxy-thiophene (compound 38) 
is also depicted in Scheme 1 and followed the same synthetic pathway starting from the 5-
bromo-4-methoxythiophene-2-carboxylic-acid 38c. The methoxy group in position 4 of the 
thiophene (compound 38a) was cleaved using boron trifluoride-dimethyl sulfide complex 
and yielded the hydroxy compound 38. 
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Scheme 1. Synthesis of 2,5-thiophene derivatives 12-23, 25-27, 36-38 and 40 and 2,5-
furane derivatives 31-34.
a 
The synthesis of compound 30 was performed following the method depicted in Scheme 2. 
The intermediate 30b was synthesized starting from 5-bromo-1,3-thiazole 30c applying a 
Suzuki-Miyaura cross-coupling reaction with m-tolylboronic acid, using microwave 
irradiation. The acidic hydrogen in position 2 of the thiazole30b was easily removed using 
n-butyl lithium. The anion obtained reacted immediately with a dry flow of carbon dioxide 
leading to the corresponding carboxylate 30a which was subsequentlyactivated using oxalyl 
chloride and reacted with 3-methyl-N-methylaniline to afford compound 30. 
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Scheme 2. Synthesis of compound 30.
a
 
The 1,4-disubstituted phenyl derivative 35 was obtained following a two-step procedure 
(Scheme 3). First, amidation was carried out by reaction of 4-bromobenzoyl chloride 35b 
withN,3-dimethylaniline 35c (Method A) providing the brominated intermediate 35a. 
Suzuki coupling (Method B) afforded the final product 35. 
 
Scheme 3. Synthesis of compound 35.
a
 
The synthesis of the 3-hydroxy-N-methyl-N,5-di-m-tolylthiophene-2-carboxamide 
(compound 39) is depicted in Scheme 4. The ethyl 3-hydroxy-5-(m-tolyl)thiophene-2-
carboxylate (compound 39d) was obtained through the Fiesselmannthiophene synthesis[36] 
by reaction of the β-ketoester39e and the ethyl thioglycolate39f, according to the described 
procedure[36].The hydroxy group of compound 39d was protected using MeI to afford 
compound 39cin a moderate yield. The saponification of the ester function of 39c was 
carried out using potassium hydroxide in water/THF (1:1) mixture, affording the 
corresponding carboxylic acid 39b. Amidation was performed by reaction of 39b with N,3-
dimethylaniline, using the standard condition (method A), leading to the methoxy 
compound 39a. The methoxy group of 39a was cleaved, using boron trifluoride-dimethyl 
sulfide complex and yielded the hydroxyderivative39. 
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Scheme 4. Synthesis of compound 39.
a
 
3.2.Biological 
3.2.1. Inhibition of human 17β-HSD2 and selectivity over human 17β-HSD1 in cell-free 
assays. 
The synthesized compounds were tested for their ability to inhibit 17β-HSD2 and 17β-
HSD1 using enzymes from placental source according to described methods[37-39]. 
Inhibitory activities of compounds 12-40 are shown in Tables 2-5, either as IC50 values or as 
percent of inhibition values determined at 1 µM. Compounds showing less than 10% 
inhibition at this concentration were considered to be inactive. 
Influence of lipophilic substituents on rings A and C . 
In the 2,5-thiophene class the methoxy groups in rings A and C can be replaced by methyl 
groups, without significantly affecting 17β-HSD2inhibitory potency and selectivity over 
17β-HSD1, as it becomes apparent from comparing 1, 2and 12 (IC50 = 58 nM, s.f. = 116; 68 
nM, s.f.= 112; 52 nM, s.f. = 83, respectively). This suggests that the methoxy groups on 
both rings do not function as H bond acceptors. Most likely the methyl substituents, being 
either part of a methoxy group or being directly connected to rings A and C, form important 
lipophilic interactions with the enzyme. This assumption is further supported by comparison 
of12 with the corresponding compound without substituents on rings A and B, 24[25], 
which is only moderately active (percent inhibition at 1 µM, 48 %). 
Encouraged by this result, nine compounds including all possible combinations of methyl 
substitutions on ring A and C were synthesized (compounds 12-20), in order to investigate 
the influence of the methyl group position on the biological profile in this class of 
compounds. The substitution pattern indeed appears to be critical for both the 17β-
HSD2inhibitory potency and the selectivity over 17β-HSD1 as indicated by the wide range 
of inhibitory activities displayed by compounds 12-20(Table 2). 
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Table 2.Inhibition of human 17β-HSD2 and 17β-HSD1 by biphenyl-2,5-thiophene amide 
derivatives 12-24 with different substitution patterns on the A and C rings in cell-free 
systems. 
 
compd R1 R2 
Inhibition 
IC50 (nM)
a
 or % of inhibition at 1µM
a
 
Selectivity 
factor
d
 
cLogP
e
 
17β-HSD2b 17β-HSD1c 
1 m-OMe m-OMe 58 nM 6728 nM 116 3.68 
2 m-Me m-OMe 68 nM 7616 nM 112 4.38 
12 m-Me m-Me 52 nM 4306 nM 83 4.77 
13 p-Me m-Me 58 nM 3825 nM 66 4.77 
14 o-Me m-Me 715 nM 4570 nM 7 4.77 
15 m-Me o-Me 380 nM 1177 nM 3 4.77 
16 p-Me o-Me 225 nM 698 nM 3 4.77 
17 o-Me o-Me 14% ni nd 4.77 
18 m-Me p-Me 892 nM 2687 nM 3 4.77 
19 p-Me p-Me 772 nM 1562 nM 2 4.77 
20 o-Me p-Me 27% 50% nd 4.77 
21 m-Me, p-Me m-Me 33 nM 11576 nM 352 5.23 
22 m-Me m-Cl 327 nM 9412 nM 29 5.03 
23 m-Cl m-Me 474 nM 2144 nM 5 4.87 
24 H H 48% 14% nd nd 
ni: no inhibition, nd: not determined 
aMean value of at least two determinations, standard deviation less than 25%.  
bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor NAD+, 1500 µM.  
cHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 µM.  
dIC50(17β-HSD1)/IC50(17β-HSD2).  
eCalculated data. 
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The best 17β-HSD2 inhibitory potencyassociated with the best selectivity over 17β-HSD1 
was achieved for compounds with the C ring bearing a methyl in meta position while on 
ring A the methyl can be in either in meta or para position (compounds 12 and 13, IC50 = 52 
nM and 58 nM; s.f. = 83 and 66, respectively). The selectivity factor is slightly decreased in 
comparison to the reference compounds 1 and 2. Compound 14 with the methyl on the C 
ring in meta position and the methyl on the A ring in ortho position shows significantly 
decreased 17β-HSD2 inhibitory potency(IC50 = 715, s.f. = 7), indicating that the geometry 
of the A ring is critical for activity. 
Substitution of the C ring with a methyl in ortho position, together with the A ring being 
either para or metamethyl substituted, leads to a slight decrease in 17β-HSD2 inhibitory 
potency and to an increase in 17β-HSD1 inhibition, providing compounds with a poor 
selectivity factor (compounds 15 and 16, IC50 = 380 nM and 225 nM and s.f. = 3 and 3, 
respectively). If both A and C rings are ortho substituted, 17β-HSD2 and17β-HSD1 activity 
are strongly decreased (compound 17, 14% inhibition and no inhibition for 17β-HSD2 and 
17β-HSD1 at 1 µM, respectively). 
Substitution of the C ring with a methyl group in para position in combination withameta 
or para substituted A ring led to compounds with moderately decreased 17β-HSD2 
inhibition and decreased selectivity over 17β-HSD1 (compounds 18 and 19, IC50 = 892 nM 
and 772 nM, s.f. = 3 and 2, respectively). Ortho substitution of the A ring coupled with para 
substitution of the C ring, surprisingly leads to an inversion of selectivity (compound 20, 
26% and 50% inhibition of 17β-HSD2 and 17β-HSD1 at 1 µM, respectively). 
In the 2,5-thiophene class the highest inhibition is observed for acompound showing am,p-
dimethyl substitution on the A ring and a meta methyl substitution on the C ring (compound 
21, IC50 = 33 nM, s.f. = 352), indicating that the positive effect on the activity of the two 
methyl groups on the A ring is additive. Furthermore, the presence of the two methyl groups 
increases the selectivity over 17β-HSD1. Compound 21 turns out to be the most active and 
selective compound in this class. 
The exchange of the methyl in meta position on either the Aor the C ring with a chlorine 
decreases both 17β-HSD2 inhibitory potency and selectivity over 17β-HSD1 (compounds 
22 and 23, IC50 = 327 nM and 474 nM, s.f. = 29 and 5, respectively). The importance of the 
molecular electrostatic potential (MEP) for the ability of 17β-HSD2 and 17β-HSD1 
inhibitors to establish a π-stacking interaction with aromatic amino acids from the active site 
has been recentlydiscussed[40]. The decrease in the 17β-HSD2 inhibition of compounds 22 
and 23 can be explained by the difference in the MEPs of the two aromatic rings, elicited by 
the exchange of the methyl group with a chlorine. This exchange on the A ring seems to be 
favorable for the 17β-HSD1 inhibitory potency (compound 23, IC50 = 2144 nM for 17β-
HSD1). 
The introduction of lipophilic substituents on ring A and C increases cLogP values for 
compounds 12-23 slightlycompared to 1 and 2 (Table 2).However, the values are still below 
5, which should be sufficient for an acceptable bioavailability[41]. Since lipophilic 
compounds are usually more susceptible to phase Ι metabolism[35], in a second step we 
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tried to lower cLogP of the 2,5-thiophene derivatives by exchanging the methylphenyl A 
ring for different heterocycles like 2-methylpyridinyl 25, 3-methylpyridininyl 26 or 1-
methyl-1H-pyrazolyl 27 (Table 3).  
The calculated LogP values of compounds 25, 26 and 27 are lower and therefore 
advantageous for their bioavailability compared to the one of compound 12 (3.38, 3.45 and 
2.46 for 25, 26 and 27, respectively, 4.77 for 12, Table 2 and 3). 
Table 3. 2,5-thiophene amides N-containing heterocycle as A ring 25-27. Inhibition of 
human 17β-HSD2 and 17β-HSD1. 
 
compd Ring A 
% inhibition at 1 µM
a
 
cLogP
d
 
17β-HSD2b 17β-HSD1c 
25 
 
18% n.i. 3.38 
26 
 
28% n.i. 3.45 
27 
 
16% n.i. 2.46 
ni: no inhibition 
aMean value of at least two determinations, standard deviation less than 25%. 
bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor NAD+, 1500 µM. 
cHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 µM. 
dCalculated data. 
However the exchange of the A ring with these heterocycles led to a strong decrease in 
activity (compounds 25, 26 and 27: 18%, 28% and 16% inhibition at 1 µM, respectively). 
Once again the change in the MEP of the A ring might be responsible for this decreased 
activity. 
As the methyl substituents on rings A and C in the 2,5-thiophene class were discovered to 
be very well tolerated by 17β-HSD2, especially in meta position, and to induce a good 
selectivity over 17β-HSD1 they will be maintainedfor the subsequent modifications.  
Influence of the central core 
In a previous study[42], the central 2,5-thiophene-carboxamide of 2 was replaced by a 
thiazole-2-carboxamide and by a thiazole-5-carboxamide (compounds 28 and 29, IC50 
values 296 nM and 621 nM, s.f. = 63 and 8, respectively, Table 4). Comparison of the 
potency of 28 and 29,indicates that the thiazole-2-carboxamide is better in terms of 17β-
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HSD2 inhibition and selectivity over 17β-HSD1 in presence of a methoxy group in position 
3 on the C ring.As we had experienced that in the 2,5-thiophene class the methoxy group 
can be replaced by a methyl (compound 12) we decided to synthesize the thiazole-2-
carboxamide with a methyl group on the A and C ring (compound 30, IC50 = 499 nM, s.f. = 
51). This structure modification leads to a 2-fold decrease in activity compared to 
compound 28, indicating that as observed in the 2,5-thiophene class, no crucial interaction is 
achieved by the oxygen atom of the methoxy group.  
In addition the introduction of the methyl substituent in the thiazole-2-carboxamides  did 
not sufficiently improve 17β-HSD2 inhibitory potency to make them superior to the 2,5-
thiophene amides as already described by us[42]. 
The replacement of the 2,5-thiophene for a 2,5-furane ring is detrimental for the 17β-
HSD2 inhibitory potency as shown by compounds 31-34. The strongest inhibition of 17-
HSD2 was achieved by compound 34 (38% inhibition at 1µM), demonstrating that the 
furane ring is not a suitablebioisostere for the thiophene in these compounds, in contrast to 
observations made in other compound classes[43]. The furane is less aromatic than the 
thiophene (electron rich system) because the electronegativity of the oxygen renders the 
electron pair on this atom less available for resonance. This makes the furane less suitable 
for π-stacking interactions. The electrostatic potential of the thiophene and furane 
derivatives are therefore different which might explain the decreasein the activity associated 
with the furanes. 
Finally the replacement of the central ring by a 1,4-diphenyl substitution leads to compound 
35, with an IC50 value of 1126 nM and a s.f. of 10. The exchange of the thiophene with a 
benzene decreases 17β-HSD2 inhibition moderately. However, in comparison with the 
furane series, in the benzenes some selectivity over 17β-HSD1 is sustained (Table 4). 
Table 4.Exchange of the central core B. Inhibition of human 17β-HSD2 and 17β-HSD1.
 
compd X Y Z R1 R2 
Inhibition 
IC50 (nM)
a or % of inhibition at 1µMa 
Selectivity 
factor
d 
cLogP
e 
17β-HSD2b 17β-HSD1c 
2 H H S m-Me -OMe 68 nM 7616 nM 112 3.68 
12 H H S m-Me -Me 52 nM 4306 nM 83 4.77 
28 H N S m-Me -OMe 296 nM 18663 nM 63 4.19 
29 N H S m-Me -OMe 621 nM 4821 nM 8 3.91 
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30 H N S m-Me -Me 499 nM 25302 nM 51 4.58 
31 H H O m-Me -Me 14% 31% nd 3.86 
32 H H O m-OMe -Me ni 16% nd 3.17 
33 H H O o-F, m-OMe -Me 34% 26% nd 3.62 
34 H H O m-Me, p-Me -Me 38% 46% nd 4.32 
35 - - - - - 1126 11541 10 4.93 
ni: no inhibition, nd: not determined  
aMean value of at least two determinations, standard deviation less than 25%.  
bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor NAD+, 1500 µM.  
cHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 µM.  
dIC50(17β-HSD1)/IC50(17β-HSD2).  
eCalculated data. 
The exchange of the central thiophene ring of 12 (cLogP = 4.77) by thiazole (30, cLogP = 
4.58) and by furane (31-34, cLogP = 3.86, 3.17, 3.62 and 4.32, respectively) lowers the 
cLogP value, whereas it is slightly increased in case of the benzene derivative35; (cLogP = 
4.93, Table 4). However, all compounds show cLogP values in range, which is acceptable 
for a good bioavailability according to literature[41].
 
3.2.2. Hydroxy derivatives of12 and their precursors. 
Oxydation often occurs during metabolism and in some cases leads to highly active 
metabolites. Several oxidation products derived from 12 were synthesized and evaluated for 
their biological activity in vitro (Table 5). 
Table 5.Inhibition of human 17β-HSD2 and 17β-HSD1 by the possible major metabolite of 
12 and its precursors in cell-free systems. 
 
compd Y Z R1 R2 
Inhibition 
IC50 (nM)
a
 or % of inhibition 
at 1µM
a
 
Selectivity 
factor
d
 
cLogP
e
 
17β-HSD2b 17β-HSD1c 
12 -H -H m-Me m-Me 52 nM 4306 nM 83 4.77 
36a -H -H m-Me, p-OMe m-Me 66% 11% nd 4.45 
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36 -H -H m-Me, p-OH m-Me 62% 22% nd 3.93 
37a -H -H m-Me, m- OMe m-Me 56% 28% nd 4.43 
37 -H -H m-Me, m- OH m-Me 53% 13% nd 3.94 
38a -OMe -H m-Me m-Me 59% ni nd 4.47 
38 -OH -H m-Me m-Me 64% ni nd 4.00 
39a -H -OMe m-Me m-Me 127 nM 16732 nM 132 4.36 
39 -H -OH m-Me m-Me 67% 24% nd 4.77 
40a -H -H m-CHO m-Me 62% ni nd 3.84 
40 -H -H m-CH2OH m-Me 55% ni nd 3.39 
ni: no inhibition, nd: not determined  
aMean value of at least two determinations, standard deviation less than 25%. 
bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor NAD+, 1500 µM.  
cHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 µM.  
dIC50(17β-HSD1)/IC50(17β-HSD2).  
e Calculated data. 
Introduction of an additional methoxy group in para position of compound 12 (ortho to 
methyl) leads to compound 36a (Table 5) showing a significantly decreased activity (66% 
inhibition at 1 µM). A similar loss in activity is observed for the hydroxylated compound 36 
(62% inhibition at 1 µM), indicating that in this position introductionof groups like a 
methoxy or hydroxy is not well tolerated. 
This effect is also observed with the introduction of a second substituent in meta position 
of ring A in compound 12 (Table 5). In fact compound 37a, bearing an additional methoxy 
group and compound 37, with an additional hydroxy group in meta position, show a similar 
inhibitory potencyover 17β-HSD2 but lower than the one of the monomethyl12 (56% and 
53% inhibition at 1 µM, respectively) or the monomethoxy1 (IC50 value 58 nM). This result 
indicates that no additive effect is obtained by addition of both methoxyand methyl group in 
meta position, perhaps due to a steric hindrance. 
The introduction of a methoxy group or a hydroxy group in position 4 of the thiophene 
resulting in compounds 38a and 38 (59% and 64% inhibition at 1 µM, respectively) is 
detrimental for activity. This might be due to conformational effects on the phenylA ring, 
steric hindrance in the binding site or repulsion of the polar groups caused by the lipophilic 
environment in the binding cavity. 
On the other hand, a methoxy group in position 3 of the thiophene leading to compound 
39a (Table 5), decreases activity only slightly in comparison to 12 (IC50= 127 nM and 52 
nM, respectively) whereas selectivity is increased (s.f. = 132 and 83, respectively). 
Exchanging this methoxy by a hydroxy group (compound 39) leads to a decreased activity 
(67% inhibition at 1 µM, Table 5). This indicates that in position 3 of the thiophene a 
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lipophilic group is tolerated whereas a hydrophilic substituent, such as a hydroxy, is 
detrimental for activity. 
Exchange of the methyl group on ring A of compound 12 by an aldehyde (compound 40a) 
or by a CH2OH group (40) decreases inhibitory potency (62% and 55% inhibition at 1µM, 
respectively, Table 5). 
3.3. Affinity for the Estrogen Receptors  
17β-HSD2 inhibitors should have no affinity for the estrogen receptors (ERs) α and β in 
order to avoid potential ER mediated adverse effects. Compounds 12, 13, 21, 22, 30 and 35 
have been tested according to described methods[44] and the results have been expressed in 
terms of percent [
3
H]-E2 displaced from the receptor by the inhibitor (Table 6). Shortly, 
ERα or ERβ were incubated with [3H]-E2 and test compound. Subsequently the percent 
[
3
H]-E2 displaced from the receptor by the inhibitors was determined, which were tested at 
concentrations 1000 times higher than the one of [
3
H]-E2 (Table 6). All inhibitors tested 
were able to displace less than 50% of [
3
H]-E2 from the corresponding receptor at this 
concentration. In terms of Relative Binding Affinity (RBA), their RBA values are <0.1% for 
both ER α and β, indicating a low binding affinity. 
Table 6.Percentage of [
3H]E2 displaced from the ERα and β for selected compounds
 
compd Ring B R1 R2 
Percentage of [
3
H]E2 displaced by the 
inhibitor
a,d
 
Estrogen Receptor αb Estrogen Receptor βc 
12 
 
p-Me o-Me 12 21 
13 p-Me m-Me 11 34 
21 m-Me, p-Me m-Me 5 4 
22 m-Me m-Cl 16 11 
30 
 
m-Me m-Me 9 0 
35 
 
- - 8 11 
aMean value of at least two determinations, standard deviation less than 25%.  
bRecombinant human receptor, ERα 1 nM, [3H]E2 3 nM.  
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cRecombinant human receptor, ERβ 4 nM, [3H]E2 10 nM.  
dInhibitor tested at 1000 fold the [3H]E2 concentration, 3µM for ERα, 10 µM for ERβ. 
3.4. Metabolic stability in human S9 fraction.  
We evaluated the most promising inhibitors for metabolic stability using human liver S9 
fraction according to described methods[45-47]. Briefly, incubations were run with the S9 
fraction, cofactors (for phase Ι and ΙΙ reaction) and inhibitor. The concentration of the 
remaining test compound at the different time points was analyzed by LC-MS/MS and the 
results expressed as half-lifes (t1/2) and reported in Table 7. 
Table 7.Half-life of representative compounds measured in Human Liver Microsomes S9 
fraction. 
 
compd Ring B Ring A R1 R2 R3 
Inhibitor
c
 
t1/2(min)
a,b
 
1  - m-OMe m-OMe -Me 17 
12 
 
- m-Me m-Me -Me 19 
13 - p-Me m-Me -Me 15 
16 - p-Me o-Me -Me 22 
21 - m-Me, p-Me m-Me -Me 20 
22 - m-Me m-Cl -Me 32 
41 - o-F, m-OMe m-OMe -H 117 
30 
 
- m-Me m-Me -Me 5 
31 
 
- m-Me m-Me -Me 92 
35 
 
- - - -Me >120 
25 - 
 
- - -Me 21 
27  
 
- - -Me 82 
aExtrapolated value. Mean of at least two determinations, standard deviation less than 25%.  
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b 1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 2 mM NADPH regenerating system, 1 mM UDPGA and 0.1 mM 
PAPS at 37°C for 0, 5, 15 and 60 minutes.  
cInhibitor tested at a final concentration of 1 µM. 
Exchange of the two methoxy of compound 1 (t1/2 = 17 min) by two methyl groups 
provides compound 12 (t1/2 = 19 min), which is also rather metabolically labile (Table 7). 
Changing the substitution pattern of the methyl functions does not influence metabolic 
stability, as it results from comparison of meta-,meta- 12,para-,meta- 13 andpara-,ortho- 16 
(t1/2 = 19 min, 15 min and 22 min, respectively).  
Compound 21(t1/2 = 20 min), bearing an additional methyl in para- position on ring A , in 
comparison to 12 does not show an improved stability (21 t1/2 = 20 min vs.12 t1/2 = 19 min). 
Compound 22, with a chlorine on ring C, shows a slightly increased half-life (t1/2 = 32 
min) in comparison to 12 (t1/2 = 19 min).  
In addition compound 41, previously described[25], and bearing a free carboxamide 
moiety was also tested for stability. In comparison to the others thiophene derivatives and 
more especially to the methylated analogue5, it is exceptionally stable (t1/2 = 117 min). It is 
not clear whether the methyl group of the N-CH3 amide is the metabolic reactive site or 
whether its absence stabilizes another site in the molecule. 
Replacement of the thiophene by a furane (compound 31, t1/2 = 92 min) or by a benzene 
(compound 35, t1/2120 min) results in strong improvement of metabolic stability. On the 
contrary, exchange of the thiophene by a thiazole leads to very labile compound (30, t1/2 = 5 
min). From these results, it is likely that the thiophene plays a major role in the metabolic 
fate in the 2,5-thiophene class of compounds. 
The strategy of lowering the cLogP of compound 12 (cLogP = 4.77), in order to improve 
the metabolic stability, led to the pyrazole27 (cLogP = 2.46) and the pyridine 25 (cLogP = 
3.38). As expected the most hydrophilic compound 27 (t1/2 = 82 min), is more stable than 
compounds25 (t1/2 = 21 min), and12 (t1/2 = 19 min). 
3.5. Metabolites Identification. 
Three compounds (1, 2 and 12) were investigated regarding their metabolic fate and tested 
in the human S9 fraction using a similar procedure as already described for determination of 
the metabolic stability. Inhibitors were incubated at a concentration of 10 µM inhibitors 
without phase ΙΙ cofactors for three hours (no phase II metabolism is expected).After 
extraction the samples were analyzed using a high resolution LC-MS (LTQ/Orbitrap). 
Potential metabolites were identified by searching for expected biotransformations(Table 8). 
The results are presented as area percentage relative to the remaining parent compound. In 
some cases two different peaks were found for one biotransformation, due to its occurrence 
at two different sites of the molecule. 
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Table 8. List of expected metabolites and their amounts, expressed as area percentage of the 
remaining parent compound. 
Mass 
Difference 
Formula Description 
Percentage of metabolite relative to 
parent compound
a
 
1 2 12 
0 - Parent 100 100 100 
+2 -CH2+O Demethylation + Hydroxylation nf 4 6 
+16 +O 
Hydroxylation, N, S oxidation, 
epoxydation 
12 
14 
5 
20 
4 
+30 +O2-H2 CH3 to CO2H nf nf 5 
+32 +O2 Dihydroxylation 2 nf 7 
-14 -CH2 Demethylation 
27 
9 
7 10 
-28 -C2H4 Didemethylation 2 nf nf 
nf: not found 
aArea percentage is calculated based on the assumption that each metabolite is equally responsive as parent. 
For the most prominent metabolites, we propose a structure based on comparison of the 
fragmentation pattern of the parent compound and the ones of the metabolites (Figure 1). 
The spectrum of 1 (Fig. 1a) contains strong signals at m/z 136 and 164, representing the 
substituted aniline ring without or with the amide function, respectively. It also contains the 
signal m/z 217 representing the left part of the molecule after cleavage of the amide 
function. This fragmentation is observed in all the tested 2,5-thiophene amide inhibitors and 
their metabolites. The main metabolite of compound 1 is a demethylated product that 
accounts for 27 % of the remaining parent compound (Table 8). The spectrum of 
thisdemethylation product (Fig. 1b) still contains the signals m/z 136 and 164, indicating 
that no demethylation occurred either on the C ring or on the amide. A new signal at m/z 
203, coming from the left part of the molecule, indicates that the cleavage of the methoxy 
occurred on the A ring. In addition a second demethylation product was also observed 
representing 9 % of the remaining parent compound as well as an+O product (12%, Table 
8). Other biotransformations result in negligible amounts (Table 8). The exact structure of 
these metabolites was not identified. 
In case of 2 (Fig. 1c and 1d) the metabolic demethylation (7 % of the remaining parent 
compound) was less intense  compared to the methoxy compound 1, whereas the +16 
biotransformation (Table 8) results in two different products, accounting for 14 % and 5 % 
of the remaining parent compound. Comparing the fragmentation pattern of 2 (Fig. 1c) and 
its main oxidation product (Fig.1d) it can be concluded that the oxygen addition occurs on 
the thiophene phenyl A ring part of the molecule highlighted with the dotted line (Fig. 1d). 
The structure of the metabolite was not elucidated. Also in this case, the other 
biotransformationswere negligible. 
For compound 12, the main metabolic product derives from an oxidation (Table 8). Two 
different peaks for the +16 biotransformation can be observed (Table 8), one representing 
20 % of the remaining parent compound and the other 4 %. Demethylation (10 %), and 
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oxidation of the -CH3 into carboxylic acid (5 %) are also present. For 12, the demethylation 
alone can only occur at the amide function. The transformation demethylation+ 
hydroxylation and the di-hydroxylation were also detected for this compound (Table 8). 
Comparing the fragmentation pattern of 12 (Fig. 1e) and its main oxidation product (Fig. 
1f), it can be concluded that the oxygen incorporation occurs on the thiophene phenyl part 
of the molecule highlighted with the dotted line. Comparing the fragmentation pattern of the 
-CH3 to -CO2H biotransformation in the same way (Fig. 1g), it becomes apparent that the 
carboxylic acid group is on the A ring. 
 
Results 
 
41 
 
 
Fig. 1. MS2 spectra of a) 1; b) 1 major demethylation product; c) 2; d) 2 major oxidation 
product; e) 12; d) 12 oxidation product; g) 12 CH3 to CO2H with proposed structures. 
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Since we were interested in the identification of the exact hydroxylation site for 12 and 
since the fragmentation pattern using only the MS/MS data was not conclusive, we 
synthesized the most probable metabolites. They are represented in Figure 2. 
 
Fig. 2. Potential oxidized metabolites of compound 12. 
Compound 36-40are derived from compound 12 with addition of one hydroxy group in 
different positions (Figure 2). The mass +16 (Table 8) observed in our experiment could in 
theory come from an S-oxidation of the thiophene. The S-oxide thiophene is known to be 
chemically highlyunstable[48] and after synthesis it was rapidly degraded (data not shown). 
In addition since the procedures for metabolitesynthesis and identification require the 
samples to be exposed to light at room temperature, able to even accelerate the S-oxide 
degradation[48], it was concluded that the biotransformation product observed is unlikely to 
be the thiophene S-oxide. 
The other 5 potential metabolites, depicted in Figure 2, were synthesized and co-injected in 
the LC-MS/MS together with a solution of the metabolites of 12 (Figure 3). 
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Fig. 3. Ion chromatogram of 12 major oxidation product and its co-injection with the 
synthesized potential metabolite. On the top of the peaks, the retention times are shown. 
From the top to the bottom are displayed the six chromatograms of the a) hydroxylation 
products after incubation with the S9 fraction; b) co-injected with 40; c) co-injected with 36; 
d) co-injected with 38; e) co-injected with 37; f) co-injected with 39. 
The chromatograms of the hydroxylated metabolites of 12 alone (Fig. 3a) and the one of 
the co-injection with compound 40 (Fig. 3b) are identical with a main peak observed with a 
retention time of 5.82 minutes and a minor peak at 6.07 minutes. The co-injection of any 
other potential metabolite synthesized (36-39) produces spectra with additional peaks 
having different retention time in comparison to the original spectrum: 36 (Fig. 3c), 38 (Fig. 
3d), 37 (Fig. 3e) and 39 (Fig. 3f) produce new peaks at 6.25 min, 6.63 min, 6.27 min and 
8.03 min, respectively (Fig. 3). This experiment demonstrates the identity of the 
hydroxylated metabolite of12 with the hydroxy methylcompound40. 
To confirm that 40 is the main metabolite of 12 we compared the fragmentation pattern of 
the metabolite and the synthesized compound (Figure 4). 
 
Fig. 4. a) Fragmentation pattern of the pure 40; b) fragmentation pattern of 12 major 
hydroxylated product. 
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As displayed in Figure 4a and 4b, the two fragmentation pattern perfectly match. Prominent 
signals at m/z 120, 148, 173 and 217 are present in both spectra. Interestingly, the signal at 
m/z 173 is observed only in the MS2 spectra of 40 and in none of the fragmentation spectra 
produced for the other potential metabolites (data not shown). This signal is likely to 
represent the fragment depicted in Figure 5, derived from the loss of the hydroxy group on 
the methylene. Since the other potential metabolites all bear an OH directly linked to an 
aromatic ring (Fig. 2), they might lack the signal at m/z 173 because the fragmentation at an 
aromatic OH needs more energy to be produced. Since this same signal is present in the 
fragmentation spectrum of the hydroxylated metabolite of compound 2 (Fig. 1d) and given 
the high structural similarity with 12, we could speculate that the hydroxylation reaction 
occurs at the methyl on the A ring of compound 2 as observed for12. 
 
Fig. 5. Proposed structure for signal at m/z 173. 
The main metabolic pathway for compound 12 is depicted in Figure 6. The different 
metabolites of 12 are expressed both as percentage of the total found metabolites and as 
percentage of the remaining parent compound in brackets. 39% of the metabolites derives 
from the hydroxylation of the methyl on the A ring (compound 40) and its following 
transformation into a carboxylic acid group (compound42) accounts for 10% of the total 
biotransformations. The cleavage of the methyl on the amide function (compound 
43)represents 19% of all the metabolites and the combination of hydroxylation and 
demethylation(compound 44) accounts for 12% of the detected biotransformation products. 
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Fig. 6. Proposed pathway for the phase І metabolism of 12 in human S9 fraction. 
4. DISCUSSION 
The main goal of this study was the optimization of the metabolic stability of our in house 
17β-HSD2 inhibitors, together with a satisfying understanding of their main routes of 
metabolism. The new 17β-HSD2 inhibitors were designed trying to keep potency and 
selectivity over 17β-HSD1 and the ERs in an acceptable range while improving their 
metabolic stability.  
4.1. Potency and selectivity 
In the design process we focused on compounds bearing methyl substituents on rings A 
and C. Compound 12 (IC50 = 52 nM) was obtained, which retains the activity of the 
dimethoxy analogue1 (IC50 = 58 nM). This result indicates that a polar moiety is not 
necessary to achieve high potency as previously believed[24], therefore suggesting that the 
compounds are notsteroidomimetics and do not have the same binding mode as the natural 
substrate E2.  
The effect of all the 9 possible substitution pattern of the methyl groups on rings A and C 
was studied. The substitution in meta or ortho position on ring A, while keeping a methyl in 
meta position on ring C (compounds 12 and 13, IC50 = 52 and 58 nM) leads to a an increase 
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in activity of a factor of nearly 20, in comparison with the compound having the two 
unsubstituted phenyl rings (48% inhibition at 1 µM) [21]. Recently Leung et al. reported 
about the effects of the addition of a methyl group to a lead compound on its biological 
activity, revealing how, from analysis of more than 2000 examples described in the 
literature, an activity improvement of a factor of 10 or more is found with an 8% frequency 
only[49]. The authors pointed out that the highest activity increase is often the resultfrom 
the combination of good fitting of the methyl group into a hydrophobic region of the protein 
target together with a possible conformational gain, derived from anortho methyl 
substitution at a phenyl ring. The increase in inhibitory potency observed in our class of 
inhibitors might come from the burial of the methyl group in meta position on ring A in a 
hydrophobic pocket of the enzyme, since any conformational restrain induced byortho 
substitution at this ring (compounds17 and20, 14% and 27% inhibition at 1 µM, 
respectively) is detrimental for activity. 
By introducing two methyl groups in para and meta position on ring A, the most potent 
compound of this class (21, IC50 = 33 nM) was obtained, indicating additive effects of the 
two methyl groups. It also reveals the presence of a likely hydrophobic cavity around ring 
A. 
Exchange of the A ring of compound 12 by different heterocycles like methyl pyridine 
leads to a significant decrease of activity. This might be due to an unfavorable electrostatic 
potential of the ring, compared to the phenyl (Table 3) or to the presence of the polar 
nitrogen, which does not fit well into the enzyme, confirming the presence of a lipophilic 
cavity.  Compound 27, bearing a 1-methyl-1H-pyrazole, is even less potent (Table 3) 
confirming that polar groups on the A ring are not compatible with a strong binding to the 
protein target. 
The replacement of the central thiophene ring by a furane is also detrimental for activity 
(31, 14% of inhibition at 1 µM). A small study on the effects of different substituents the A 
ring resulted in compound 34 as best inhibitor of this series (38% of 17β-HSD2 inhibition at 
1 µM and 46% of 17β-HSD1 inhibition at 1 µM), indicating the inadequateness of this 
central ring. The furane ring indeed seems to reverse the activity in favor of 17β-HSD1 
inhibition, since 31 and 34 are slightly more active on 17β-HSD1 and much less active on 
17β-HSD2, in comparison to compound 12 (table 4). 
4.2. Metabolic stability 
Compounds 1, 2 and 3 taken as leads for the study of metabolic stability were found to be 
rather unstable (t1/2 = 17 min, 38 min and 4 min, respectively). An important goal of this 
work was the improvement of the metabolic stability of this class of compounds. To achieve 
this goal two different techniques were applied: 1. modification of the potential reactive site 
of the inhibitors, 2. lowering theircLogP.  
In order to understand the reason for the instability of 1, 2 and 3 and in order to identify 
the metabolically reactive sites in these molecules, a small set of compounds was 
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synthesized and tested. As the methoxy groups seemed to be labile in presence of hepatic 
enzymes, they were exchanged by methyl groups, in principle slightly more stable. 
However, this strategy did not improve the stability of the inhibitors, as seen for compounds 
12,13, 22, 21 and22 with half-life in the same range as previous molecules (t1/2 around 20 
min). While replacement of the methoxygroup by methyl could preserve inhibitory potency, 
it did not influence metabolic stability. This can be explained looking at the primary 
metabolite of 1 and 12: the methoxy group of 1 as well as the methyl group of 12 on ring 
Aare soon oxidized, thus leading to ether cleavage and CH2OH formation, respectively. The 
rate of this reaction, which might be catalyzed by the same enzyme, appears to be in the 
same order of magnitude for both molecule and the metabolic stability is clearly not 
influenced by the nature of the substituents on the two compounds.  
Given the high structural similarity of compounds 1 and 12 with others 2,5-thiophene 
amide inhibitors and considering the instability of the tested compounds of this class, it is 
very likely that the oxidation observed for 1 and 12 is the main metabolic route for the other 
compounds as well.  
Compounds bearing hydroxy groups display half-lifes either similar or lower than 
inhibitors without hydroxy groups (Table 1) and are likely to be also affected by metabolic 
phase ΙΙ reactions.  
This metabolite identification study clearly indicates that the central thiophene of 
compound 12 does not constitute a metabolic reactive site and is not susceptible to any 
biotransformation. Therefore it is striking that the exchange of the thiophene either by a 
furaneor by benzene ring leads to more stable compounds like 31 and 35 (t1/2 = 92 min and 
>120 min, respectively). This means that it is possible to modulate the metabolic rate of 
compound 12 by modification of the central ring, although it does not constitute a metabolic 
labile site. 
The stability of compound 31 (cLogP = 3.86) might be explained by the decrease in 
cLogPaccomplished by the furane ring in comparison to the thiophene derivative12 (cLogP 
= 4.77). This result is also confirmed by the 1-methyl-1H-pyrazole compound27 (cLogP = 
2.46) which shows a half-life in human liver S9 fraction of 82 minutes. Exchange of the 
thiophene by a benzene ring does not significantly modify the cLogP for 35 (cLogP = 4.93). 
The improvement in the t1/2 of this compound might be causedby a decreased affinity for the 
metabolizing enzyme, due to a higher steric hindrance. 
4.3. CONCLUSION 
In the drug discovery process it is important to take into account the metabolic properties 
of lead compounds as early as possible. The design of metabolically stable molecules, 
which maintain the pharmacological activity, is a challenging task. In this work we 
identified the metabolic liability of a series of 2,5-thiophene amide inhibitors. We have also 
detailed the specific metabolic pathway of compound 12 and profiled the metabolic fate of 1 
and 2, leading to an overall comprehension of the metabolic liabilities of the 2,5-thiophene 
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amide class of inhibitors. Using two different strategies we discovered three new inhibitors 
with a highly improved metabolic stability: 27 (t1/2 = 82 min), 31 (t1/2 = 92 min) and 35 (t1/2 
= >120 min). The inhibitory potency and selectivity profiles of the synthesized compounds 
were also evaluated. 
Among the three most stable inhibitors, 35 also retains a good activity and selectivity (IC50 
= 1126 nM, s.f. = 10) and shows no affinity for the estrogen receptors. The relative 
structural simplicity of compound 35 still leaves room for an appropriate molecular 
optimization. 
 EXPERIMENTAL SECTION 
5.1. Chemical Methods. Chemical names follow IUPAC nomenclature. Starting materials 
were purchased from Aldrich, Acros, Combi-Blocks, Enamine or Fluka and were used 
without purification. 
Column chromatography was performed on silica gel (70-200 μm) and reaction progress 
was monitored by TLC on Alugram SIL G/UV254 (Macherey-Nagel). Visualization was 
accomplished with UV light. 
1
H NMR and 
13
C NMR spectra were measured on a Bruker AM500 spectrometer (at 500 
MHz and 125 MHz, respectively) at 300 K and on Bruker Fourier 300 (at 300 MHz and 75 
MHz, respectively) at 300K. Chemical shifts are reported in δ (parts per million: ppm), by 
reference to the hydrogenated residues of deuteriated solvent as internal standard: 2.05 ppm 
(1H NMR) and 29.8 and 206.3 ppm (
13
C NMR) for CD3COCD3, 7.26 ppm (
1
H NMR) and 
77.0 ppm (
13
C NMR) for CDCl3. Signals are described as br (broad), s (singlet), d (doublet), 
t (triplet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of 
triplets) and m (multiplet). All coupling constants (J) are given in Hertz (Hz).  
Melting points (mp) were measured in open capillaries on a Stuart Scientific SMP3 
apparatus and are uncorrected. 
Mass spectrometry was performed on a TSQ® Quantum (ThermoFisher, Dreieich, 
Germany). The triple quadrupole mass spectrometer was equipped with an electrospray 
interface (ESI). The purity of the compounds was assessed by LC/MS. The Surveyor®-LC-
system consisted of a pump, an auto sampler, and a PDA detector. The system was operated 
by the standard software Xcalibur®. A RP C18 NUCLEODUR® 100-5 (3 mm) column 
(Macherey-Nagel GmbH, Dühren, Germany) was used as stationary phase. All solvents 
were HPLC grade. In a gradient run the percentage of acetonitrile (containing 0.1 % 
trifluoroacetic acid) was increased from an initial concentration of 0 % at 0 min to 100 % at 
15 min and kept at 100 % for 5 min. The injection volume was 15 µL and flow rate was set 
to 800 µL/min. MS analysis was carried out at a needle voltage of 3000 V and a capillary 
temperature of 350 °C. Mass spectra were acquired in positive mode from 100 to 1000 m/z 
and UV spectra were recorded at the wave length of 254 nm and in some cases at 360 nm.  
All microwave irradiation experiments were carried out in a 507 CEM-Discover 
microwave apparatus. 
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All tested compounds exhibited ≥ 95% chemical purity as measured by LC/MS, after 
dissolving them in methanol. 
The following compounds were prepared according to previously described procedures: 5-
bromo-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide 12a[25], lithium 5-(3-
methylphenyl)-1,3-thiazole-2-carboxylate 30a[42]. 
 
5.1.1. Method A, general procedure for amide formation:  
A mixture of bromo-N-heteroarylcarboxylic acid (2 mmol), thionyl chloride (4 mmol) and 
DMF (5 drops) in toluene (10 mL) was refluxed at 110°C for 4 hours. The reaction mixture 
was cooled to room temperature; the solvent and the excess of thionyl chloride were 
removed under reduced pressure. The corresponding N-methylamine (2 mmol) and Et3N (2 
mmol) in CH2Cl2 (10 mL) was added at 0°C under N2 atmosphere to the acyl chloride. After 
30 minutes at 0°C, the ice bath was removed and the solution was warmed up and stirred at 
room temperature overnight. The reaction mixture was extracted twice with CH2Cl2 (2 × 15 
mL); the organic layer was dried over MgSO4, filtered and the solution was concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
using n-hexane and EtOAc as eluent or by trituration in a mixture of diethyl ether / 
petroleum ether to afford the desired compound. 
 
5.1.2. Method B, general procedure for Suzuki-Miyaura coupling:  
In a sealed tube the previously prepared bromo-N-heteroarylcarboxamide derivative (1 
eq.) was introduced followed by the corresponding boronic acid (1.5 eq.), cesium carbonate 
(3 eq.), tetrakis(triphenylphosphine)palladium (0.02 eq.) and a mixture of DME/EtOH/H2O 
(1:1:1, v:v:v, 3 mL) as solvent. The reactor was flushed with N2 and submitted to 
microwave irradiation (150°C, 150 W) for 20 minutes. After cooling to room temperature, a 
mixture of EtOAc/H2O (1:1, v:v, 2 mL) was added to stop the reaction. The aqueous layer 
was extracted with EtOAc (3 × 10 mL). The organic layer was washed once with brine and 
once with water, dried over MgSO4, filtered and the solution was concentrated under 
reduced pressure. The residue was purified by column chromatography using n-hexane and 
EtOAc as eluent to afford the desired compound. 
 
5.1.3. Detailed Synthesis Procedures of the Most Interesting Compounds.5.1.3.1.N-
Methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide (12).The title compound was 
prepared by reaction of 5-bromo-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide 
12a (150 mg, 0.48 mmol), m-tolylboronic acid (86 mg, 0.63 mmol), cesium carbonate (469 
mg, 1.44 mmol) and tetrakis(triphenylphosphine) palladium (11 mg, 0.02 eq) according to 
method B. The residue was purified by silica gel column chromatography (n-hexane/ethyl 
acetate 80:20) to afford the desired product as yellow solid (117 mg, 76 %). C20H19NOS; 
MW 321; mp: 98 – 101°C; MS (ESI) 322 [M+H]+; 1H NMR (CDCl3, 500 MHz) 2.36 (s, 
3H), 2.39 (s, 3H), 3.47 (s, 3H), 6.68 (d, J = 4.1 Hz, 1H), 6.97 (d, J = 4.1 Hz, 1H), 7.09 – 
7.12 (m, 3H), 7.21 – 7.25 (m, 2H), 7.28 – 7.29 (m, 1H), 7.31-7.34 (m, 2H); 13C NMR 
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(CDCl3, 125 MHz)δ 21.3, 21.4, 39.4, 122.7, 123.2, 125.0, 126.7, 128.5, 128.9, 129.2, 129.7, 
133.4, 133.5, 136.3, 138.6, 140.0, 143.8, 149.7, 163.1; IR (cm
-1
) 3048, 2921, 1599, 1584. 
5.1.3.2.N-Methyl-N-(3-methylphenyl)-5-(4-methylphenyl)thiophene-2-carboxamide 
(13). The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (100 mg, 0.32 mmol), p-tolyl boronic acid (65 
mg, 0.48 mmol), cesium carbonate (313 mg, 0.96 mmol) and tetrakis(triphenylphosphine) 
palladium (8 mg, 0.02 eq) according to method B. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 80:20) to afford the desired product as 
yellow solid (63 mg, 61 %). C20H19NOS; MW 321; mp: 95 – 98°C; MS (ESI) 322 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) 2.32 (s, 3H), 2.36 (s, 3H), 3.37 (s, 3H), 6.49 (d, J = 3.9 
Hz, 1H), 7.07 (d, J = 3.9 Hz, 1H), 7.14 – 7.16 (m, 1H), 7.19 – 7.22 (m, 3H), 7.24 – 7.26 (m, 
1H), 7.35 (t, J = 7.8 Hz, 1H), 7.46 (dt, J = 2.0,  8.3 Hz, 2H); 
13
C NMR (CD3COCD3, 125 
MHz)δ 21.2, 21.3, 39.1, 123.4, 126.1, 126.6, 129.6, 129.7, 130.5, 130.6, 131.8, 133.3, 
138.6, 139.3, 140.8, 145.5, 149.3, 162.5; IR (cm
-1
) 3050, 2921, 1599, 1585. 
 
5.1.3.3.5-(3,4-Dimethylphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-
carboxamide (21).The title compound was prepared by reaction of 5-bromo-N-methyl-N-
(3-methylphenyl)thiophene-2-carboxamide 12a (150 mg, 0.48 mmol), 3,4-dimethylphenyl 
boronic acid (94.5 mg, 0.63 mmol), cesium carbonate (469 mg, 1.44 mmol) and 
tetrakis(triphenylphosphine) palladium (11 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as colorless solid (55 mg, 34 %). C21H21NOS; MW 335; mp: 138 – 
140°C; MS (ESI) 336 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz) 2.26 (s, 3H), 2.27 (s, 3H), 2.38 
(s, 3H), 3.45 (s, 3H), 6.57 (d, J = 4.0 Hz, 1H), 6.92 (d, J = 4.0 Hz, 1H), 7.08 – 7.11 (m, 3H), 
7.20 – 7.21 (m, 1H), 7.23 (dd, J = 2.1, 7.8 Hz, 1H), 7.28 – 7.33 (m, 2H); 13C NMR (CDCl3, 
125 MHz)δ 19.5, 19.7, 21.3, 39.1, 122.2, 123.4, 125.0, 127.2, 128.5, 128.9, 129.6, 130.1, 
131.2, 132.8, 136.6, 137.0, 137.1, 139.8, 144.1, 149.4, 162.6; IR (cm
-1
) 3029, 2918, 1612, 
1602. 
 
5.1.3.4.N-Methyl-N-(3-methylphenyl)-5-(1-methyl-1H-pyrazol-4-yl)thiophene-2-
carboxamide (27). The title compound was prepared by reaction of 5-bromo-N-methyl-N-
(3-methylphenyl)thiophene-2-carboxamide 12a (150 mg, 0.48 mmol), 1-methyl-1H-
pyrazole-4-boronic acid (96 mg, 0.63 mmol), cesium carbonate (626 mg, 1.92 mmol) and 
tetrakis(triphenylphosphine) palladium (11 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to afford 
the desired product as yellow solid (70 mg, 53 %). C17H17N3OS; MW 311; mp: 132 – 
134°C; MS (ESI) 312 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)2.37 (s, 3H), 3.43 (s, 3H), 3.89 
(s, 3H), 6.49 (d, J = 4.0 Hz, 1H), 6.70 (d, J = 4.0 Hz, 1H), 7.06 – 7.10 (m, 2H), 7.19 – 7.21 
(m, 1H), 7.30 (t, J = 7.7 Hz, 1H), 7.47 (s, 1H), 7.57 (d, J = 1.0 Hz, 1H); 
13
C NMR (CDCl3, 
125 MHz)δ 21.6, 29.6, 39.0, 116.4, 122.0, 125.0, 127.4, 128.5, 128.9, 129.5, 132.7, 135.4, 
137.0, 140.0, 140.2, 144.1, 162.4; IR (cm
-1
) 3075, 2923, 2854, 1616, 1601, 1582. 
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5.1.3.5.N-Methyl-N,5-bis(3-methylphenyl)-1,3-thiazole-2-carboxamide (30). To a 
solution of lithium 5-(3-methylphenyl)-1,3-thiazole-2-carboxylate 30a (100 mg, 0.44 mmol) 
in CH2Cl2 (15 mL) was added drop wise oxalyl chloride (80 µL, 0.88 mmol) followed by 
few drops of DMF at 0°C under N2 atmosphere. The reaction mixture was stirred at 0°C for 
10 min and then at room temperature for 3 h. The solvent was removed under reduced 
pressure (bath temperature of rotavapor at 20°C). This residue was diluted in dry CH2Cl2 
(10 mL) and N,3-dimethylaniline (0.06 mL, 0.44 mmol) was added followed by 
triethylamine (0.10 µL, 0.44 mmol). The solution was stirred overnight at room temperature 
under N2 atmosphere. The solvent was removed under reduced pressure (bath temperature 
of rotavapor at 20°C). A mixture of Na2CO3 2N (15 mL) and EtOAc (15 mL) were added. 
The aqueous layer was extracted with EtOAc (15 mL). The organic layer was washed twice 
with Na2CO3 2N (15 mL), once with water (15 mL), dried over MgSO4, filtered and the 
solution was concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 70:30) to afford the desired product as pale 
brown solid (51 mg, 36 %). C19H18N2OS; MW 322; mp: 79 – 80°C; MS (ESI) 323 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz) 2.32 (s, 3H), 2.36 (s, 3H), 3.54 (br s, 3H), 7.07 – 7.09 (m, 1H), 
7.10 – 7.12 (m, 1H), 7.15 (br s, 1H), 7.20 – 7.26 (m, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.44 – 
7.46 (m, 2H), 7.49 (br s, 1H), 7.93 (br s, 1H); 
13
C NMR (CDCl3, 125 MHz) 21.3, 39.6, 
124.9, 125.0, 128.3, 128.4, 128.6, 130.0, 130.1, 130.6, 131.5, 139.69, 139.70, 139.9, 144.2, 
145.4, 161.2 . IR (cm
-1
) 3096, 2922, 1624, 1606, 1585. 
 
5.1.3.6.N-Methyl-N,5-bis(3-methylphenyl)furan-2-carboxamide (31). The title 
compound was prepared by reaction of 31a (150 mg, 0.51 mmol), m-tolylboronic acid (104 
mg, 0.77 mmol), cesium carbonate (499 mg, 1.53 mmol) and tetrakis(triphenylphosphine) 
palladium (12 mg, 0.02 eq) according to method B. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 70:30) to afford the desired product as 
orange oil (100 mg, 64 %). C20H19NO2; MW 305; MS (ESI) 306 [M+H]
+
; 
1
H NMR 
(CD3COCD3, 500 MHz) 2.30 (s, 3H), 2.38 (s, 3H), 3.37 (s, 3H), 6.67 (d, J = 3.7 Hz, 1H), 
6.74 (d, J = 3.7 Hz, 1H), 7.00 – 7.01 (m, 1H), 7.07 – 7.12 (m, 2H), 7.16 – 7.22 (m, 3H), 7.24 
– 7.27 (m, 1H), 7.35 (t, J = 7.8 Hz, 1H); 13C NMR (CD3COCD3, 125 MHz)δ 21.3, 38.7, 
107.1, 119.4, 122.3, 125.3, 125.4, 128.8, 129.0, 129.5, 129.9, 130.2, 130.7, 139.2, 140.3, 
145.9, 148.2, 155.8, 159.1. 
 
5.1.3.7.N,3'-Dimethyl-N-(m-tolyl)-[1,1'-biphenyl]-4-carboxamide (35). The title 
compound was prepared by reaction of35a (120 mg, 0.39 mmol), m-tolylboronic acid(69 
mg, 0.51 mmol), cesium carbonate (381 mg, 1.17 mmol) and tetrakis(triphenylphosphine) 
palladium (9 mg, 0.02 eq) according to method B. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 80:20) to afford the desired product as 
yellow oil (105 mg, 85 %). C22H21NO; MW 315; MS (ESI) 316 [M+H]
+
; 
1
H NMR 
(CD3COCD3, 300 MHz) 2.24 (s, 3H), 2.37 (s, 3H), 3.42 (s, 3H), 6.93 – 6.96 (d, J = 9Hz, 
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1H), 6.98 – 7.00 (d, J = 7Hz, 1H), 7.07 (s, 1H), 7.11 – 7.18 (m, 2H), 7.30 (t, J = 8 Hz, 1H), 
7.37 – 7.42 (m, 4H), 7.47 – 7.50 (m, 2H);  13C NMR (CD3COCD3, 75 MHz) 21.2, 21.4, 
38.5, 124.8, 125.1, 126.8, 127.9, 128.4, 128.44, 129.3, 129.6, 129.7, 130.1, 136.5, 139.3, 
139.9, 140.8, 142.7, 146.2, 170.2. IR (cm
-1
) 3037, 2920, 2862, 1740, 1639, 1603. 
 
5.1.3.8.5-[3-(Hydroxymethyl)phenyl]-N-methyl-N-(3-methylphenyl)thiophene-2-
carboxamide (40). To a solution of 5-(3-formylphenyl)-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 40a (76 mg, 0.23 mmol) in a mixture of dry MeOH 
(3 mL) and dry dioxane (3 mL) was added at 0°C sodium borohydride (87 mg, 0.46 mmol). 
After 2 hours at 0°C, water was added to quench the reaction. The aqueous layer was 
extracted three times with EtOAc (3 × 5 mL). The organic layer was washed once with 
saturated solution of NaHCO3 and once with water, dried over MgSO4, filtered and the 
solution was concentrated under reduced pressure. The residue was purified by preparative 
HPLC (using acetonitrile/water from 10% to 95% of acetonitrile) to afford the desired 
product as colorless oil (14 mg, 18 %). C20H19NO2S; MW 337; MS (ESI) 338 [M+H]
+
; 
1
H 
NMR (CDCl3, 300 MHz)  2.36 (s, 3H), 3.43 (s, 3H), 4.70 (s, 2H), 6.57 (d, J = 4.0 Hz, 1H), 
6.96 (d, J = 4.0 Hz, 1H), 7.04 – 7.06 (m, 1H), 7.06 – 7.10 (m, 1H), 7.17 – 7.22 (m, 1H), 7.27 
– 7.36 (m, 3H), 7.40 (dt, J = 1.8, 7.2 Hz, 1H), 7.49 – 7.51 (m, 1H); 13C NMR (CDCl3, 75 
MHz)
132.9, 133.9, 137.4, 139.9, 141.7, 144.1, 148.7, 162.6. IR (cm
-1
) : 3397, 3027, 2921, 2865, 
1598, 1582. 
 
5.3. logP Determination:The logP values were calculated from ACD/Labs Percepta 2012 
Release program. The logarithm of partition constant P (log P) was calculated using the 
“GALAS” method (Global Adjusted Locally According to Similarity). The program 
predicts clog P by comparing the molecule with structurally similar molecules where 
experimental data are known. 
 
5.4. Biological Methods. [2,4,6,7-
3
H]-E2 and [2,4,6,7-
3
H]-E1 were purchased from 
Perkin-Elmer, Boston. Quickszint Flow 302 scintillator fluid was bought from Zinsser 
Analytic, Frankfurt. Other chemicals were purchased from Sigma, Roth or Merck. 
 
5.4.1. 17β-HSD1 and 17β-HSD2 enzyme preparation.Cytosolic (17β-HSD1) and 
microsomal (17β-HSD2) fractions were obtained from human placenta according to 
previously described procedures[38, 39, 50]. Fresh tissue was homogenized and the 
enzymes were separated by fractional centrifugation at 1000g, 10,000g and 150,000g. The 
pellet fraction containing the microsomal 17β-HSD2 was used for the determination of 17β-
HSD2 inhibition, while 17β-HSD1 was obtained after precipitation with ammonium sulfate 
from the cytosolic fraction for use of testing of 17β-HSD1 inhibition. Aliquots containing 
17β-HSD1 or 17β-HSD2 were stored frozen. 
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5.4.2 Inhibition of 17β-HSD2 in cell-free assay. Inhibitory activities were evaluated by an 
established method with minor modifications[37, 51, 52]. Briefly, the enzyme preparation 
was incubated with NAD
+
 [1500 µM] in the presence of potential inhibitors at 37 °C in a 
phosphate buffer (50 mM) supplemented with 20% of glycerol and EDTA 1mM. Inhibitor 
stock solutions were prepared in DMSO. Final concentration of DMSO was adjusted to 1% 
in all samples. The enzymatic reaction was started by addition of a mixture of unlabelled- 
and [
3
H]-E2 (final concentration: 500 nM, 0.11 µCi). After 20 min, the incubation was 
stopped with HgCl2 and the mixture was extracted with ether. After evaporation, the steroids 
were dissolved in acetonitrile/water (45:55). E1 and E2 were separated using 
acetonitrile/water (45:55) as mobile phase in a C18 RP chromatography column (Nucleodur 
C18, 3µm, Macherey-Nagel, Düren) connected to a HPLC-system (Agilent 1100 Series, 
Agilent Technologies, Waldbronn). Detection and quantification of the steroids were 
performed using a radioflow detector (Berthold Technologies, Bad Wildbad). The 
conversion rate was calculated according to the following equation: %conversion = 
(%E1/(%E1+%E2))×100. Each value was calculated from at least three independent 
experiments. 
 
5.4.3. Inhibition of 17β-HSD1 in cell-free assay.The 17β-HSD1 inhibition assay was 
performed similarly to the 17β-HSD2 test. The microsomal fraction was incubated with 
NADH [500 µM], test compound and a mixture of unlabelled- and [
3
H]-E1 (final 
concentration: 500 nM, 0.15 µCi) for 10 min at 37°C. Further treatment of the samples and 
HPLC separation was carried out as mentioned above for 17β-HSD2. 
 
5.4.4. Estrogen receptor affinity in a Cellular Free Assay.The binding affinity of selected 
compounds to ERα and ERβ was determined according to the recommendations of the US 
Environmental Protection Agency (EPA) by their Endocrine Disruptor Screening Program 
(EDSP) [44] using recombinant human proteins. Briefly, 1 nM of ERα and 4 nM of ERβ, 
respectively, were incubated with [
3
H]-E2 (3 nM for ERα and 10 nM for ERβ) and test 
compound for 16-20 h at 4°C.  
The potential inhibitors were dissolved in DMSO (5% final concentration). Evaluation of 
non-specific-binding was performed with unlabeled E2 at concentrations 100-fold of [
3
H]-
E2 (300 nM for ERα and 1000 nM for ERβ). After incubation, ligand-receptor complexes 
were selectively bound to hydroxyapatite (83.5 g/LinTE-buffer). The bound complex was 
washed three times and resuspended in ethanol. For radiodetection, scintillator cocktail 
(Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were measured in a 
liquid scintillation counter (1450 LSC & Luminescence Counter, Perkin Elmer). 
From these results the percentage of [
3
H]-E2 displacement by the compounds was 
calculated. The plot of % displacement versus compound concentration resulted in 
sigmoidal binding curves. The compound concentrations to displace 50% of the receptor 
bound [
3
H]-E2 were determined. Unlabeled E2 IC50 values were determined in each 
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experiment and used as reference. The E2 IC50 values accepted, were 3±20% nM for ERα 
and 10±20% nM for ERβ. 
Relative Binding Affinity was determined by applying the following equation: RBA[%] = 
(IC50(E2)/IC50(compound)) ∙ 100[44]. This results in an RBA value of 100% for E2.  
After the assay was established and validated, a modification was made to increase 
throughput. Compounds were tested at concentrations of 1000 ∙ IC50(E2). Compounds with 
less than 50% displacement of [3H]-E2 at a concentration of 1000 ∙IC50(E2) were classified 
as RBA <0.1%. 
 
5.4.5. Metabolic Stability in a Cell Free Assay. Compounds 3, 5, 7-9, 12, 13, 16, 21, 22, 
25, 27, 30, 31, 35 and 41 were tested according to established method[45-47].For evaluation 
of phase I and II metabolic stability 1 µM compound was incubated with 1 mg/ml pooled 
mammalian liver S9 fraction (BD Gentest), 2 mM NADPH regenerating system, 1 mM 
UDPGA and 0.1 mM PAPS at 37°C for 0, 5, 15 and 60 minutes at a final volume of 100 µL. 
The incubation was stopped by precipitation of S9 enzymes with 2 volumes of cold 
acetonitrile containing internal standard. Concentration of the remaining test compound at 
the different time points was analyzed by LC-MS/MS and used to determine half-life (t1/2). 
Compounds 1, 2. 4, 6, 10 and 11 were tested following a similar procedure with the 
following changes: 3 µM compound was incubated with 1 mg/ml pooled mammalian liver 
S9 fraction (IVT, Xenotech or TCS cellworks), 1mM NADPH regenerating system, 
0.75mM UDPGA and 0.05mM PAPS at 37°C for 0, 5, 15 and 45 minutes.  
5.4.6. Metabolite identification in a Cell Free Assay. Compounds 1, 2 and 12 were 
incubated at a final concentration of 10 µM with 1 mg/ml pooled mammalian liver S9 
fraction(BD Gentest) and 2 mM NADPH regenerating system for three hours(final volume 
3 mL). The water phase was extracted with dichloromethane (3 × mL), which was 
evaporated to dryness at room temperature. The residue was resuspended in 500 µL 
methanol. Separation of 2 µL sample was accomplished on a Dionex Ultimate 3000 RSLC 
system using a BEH C18 50 ×2.1 mm, 1.7 µM dp column (Waters, Germany). Separation 
was achieved by a linear gradient from (A) H2O + 0.1% formic acid (FA) to (B) ACN + 
0.1% FA at a flow rate of 600 µL/min and 45 °C. The gradient was initiated by a 0.33 min 
isocratic step at 5% B, followed by an increase to 95% B in 9 min to end up with a 1 min 
step at 95% B before reequilibration under the initial conditions. The flow entered the 
LTQ/Orbitrap (Thermo Scientific, Germany) using the NanomateAdvionNanospray ion 
source (NSI). The Mass Spectrometer was set with the following parameters: scan range 
200-2000 m/z in positive ionization mode; 200 °C Capillary Temperature; 1,7 kV Voltage at 
NSI; Fourier Transform Mass Spectrometry (FTMS) Resolution of 30000; MS/MS analysis 
was data-dependent and triggered by the most abundant ions.. 
Data Acquisition was performed with Xcalibur version 1.0.2.65 (Thermo Electron, San 
Jose, Ca, USA). Five-decimal monoisopic masses of 1, 2 and 15 and their predicted 
metabolites, calculated from CambidgeSoftChem& Bio Draw 11.0 using the ChemDrawPro 
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1.0 program, were used for the parent data and to filter data in Qual Browser (Thermo 
Electron, San Jose, Ca, USA) with a mass tolerance threshold of 5 ppm. 
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2.1.1 Supporting Information 
Table of contents 
a) Chemical synthesis and spectroscopic data of all compounds 
b) NMR spectra of representative compounds 
c) References 
a) Chemical Methods. Chemical names follow IUPAC nomenclature. Starting materials 
were purchased from Aldrich, Acros, Combi-Blocks, Enamine or Fluka and were used 
without purification. 
Column chromatography was performed on silica gel (70-200 μm) and reaction progress 
was monitored by TLC on Alugram SIL G/UV254 (Macherey-Nagel). Visualization was 
accomplished with UV light. 
1
H NMR and 
13
C NMR spectra were measured on a Bruker AM500 spectrometer (at 500 
MHz and 125 MHz, respectively) at 300 K and on Bruker Fourier 300 (at 300 MHz and 75 
MHz, respectively) at 300K. Chemical shifts are reported in δ (parts per million: ppm), by 
reference to the hydrogenated residues of deuteriated solvent as internal standard: 2.05 ppm 
(
1
H NMR) and 29.8 and 206.3 ppm (
13
C NMR) for CD3COCD3, 7.26 ppm (
1
H NMR) and 
77.0 ppm (
13
C NMR) for CDCl3. Signals are described as br (broad), s (singlet), d (doublet), 
t (triplet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of 
triplets) and m (multiplet). All coupling constants (J) are given in Hertz (Hz).  
Melting points (mp) were measured in open capillaries on a Stuart Scientific SMP3 
apparatus and are uncorrected. 
Mass spectrometry was performed on a TSQ® Quantum (ThermoFisher, Dreieich, 
Germany). The triple quadrupole mass spectrometer was equipped with an electrospray 
interface (ESI). The purity of the compounds was assessed by LC/MS. The Surveyor®-LC-
system consisted of a pump, an auto sampler, and a PDA detector. The system was operated 
by the standard software Xcalibur®. A RP C18 NUCLEODUR® 100-5 (3 mm) column 
(Macherey-Nagel GmbH, Dühren, Germany) was used as stationary phase. All solvents 
were HPLC grade. In a gradient run the percentage of acetonitrile (containing 0.1 % 
trifluoroacetic acid) was increased from an initial concentration of 0 % at 0 min to 100 % at 
15 min and kept at 100 % for 5 min. The injection volume was 15 µL and flow rate was set 
to 800 µL/min. MS analysis was carried out at a needle voltage of 3000 V and a capillary 
temperature of 350 °C. Mass spectra were acquired in positive mode from 100 to 1000 m/z 
and UV spectra were recorded at the wave length of 254 nm and in some cases at 360 nm.  
All microwave irradiation experiments were carried out in a 507 CEM-Discover microwave 
apparatus. 
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All tested compounds exhibited ≥ 95% chemical purity as measured by LC/MS , after 
dissolving them in methanol. 
The following compounds were prepared according to previously described procedures:5-
bromo-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide 12a[1], lithium 5-(3-
methylphenyl)-1,3-thiazole-2-carboxylate 30a[2].
 
 
Method A, general procedure for amide formation:  
A mixture of bromo-N-heteroarylcarboxylic acid (2 mmol), thionyl chloride (4 mmol) and 
DMF (5 drops) in toluene (10 mL) was refluxed at 110°C for 4 hours. The reaction mixture 
was cooled to room temperature; the solvent and the excess of thionyl chloride were 
removed under reduced pressure. The corresponding N-methylamine (2 mmol) and Et3N (2 
mmol) in CH2Cl2 (10 mL) was added at 0°C under N2 atmosphere to the acyl chloride. After 
30 minutes at 0°C, the ice bath was removed and the solution was warmed up and stirred at 
room temperature overnight. The reaction mixture was extracted twice with CH2Cl2 (2 × 15 
mL); the organic layer was dried over MgSO4, filtered and the solution was concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
using n-hexane and EtOAc as eluent or by trituration in a mixture of diethyl ether / 
petroleum ether to afford the desired compound. 
 
Method B, general procedure for Suzuki-Miyaura coupling: 
In a sealed tube the previously prepared bromo-N-heteroarylcarboxamide derivative (1 eq.) 
was introduced followed by the corresponding boronic acid (1.5 eq.), cesium carbonate (3 
eq.), tetrakis(triphenylphosphine)palladium (0.02 eq.) and a mixture of DME/EtOH/H2O 
(1:1:1, v:v:v, 3 mL) as solvent. The reactor was flushed with N2 and submitted to 
microwave irradiation (150°C, 150 W) for 20 minutes. After cooling to room temperature, a 
mixture of EtOAc/H2O (1:1, v:v, 2 mL) was added to stop the reaction. The aqueous layer 
was extracted with EtOAc (3 × 10 mL). The organic layer was washed once with brine and 
once with water, dried over MgSO4, filtered and the solution was concentrated under 
reduced pressure. The residue was purified by column chromatography using n-hexane and 
EtOAc as eluent to afford the desired compound. 
 
5-Bromo-N-methyl-N-(2-methylphenyl)thiophene-2-carboxamide (15a) 
The title compound was prepared by reaction of 5-bromo-thiophene-2-carboxylic acid36c 
(700 mg, 3.4 mmol), thionyl chloride (0.5 mL, 6.8 mmol) and N,2-dimethylaniline, HCl 
(536 mg, 3.4 mmol) according to method A. The residue was purified by silica gel column 
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chromatography (n-hexane/EtOAc 90:10) to afford the desired product as yellow solid (820 
mg, 78 %).C13H12BrNOS; MW 310; mp: 59 – 62°C; MS (ESI) 310, 312[M+H]
+
; 
1
H NMR 
(CD3COCD3, 500 MHz)δ2.19 (s, 3H), 3.29 (s, 3H), 6.51 (d, J = 4.1 Hz, 1H), 6.93 (d, J = 4.1 
Hz, 1H), 7.33 – 7.42 (m, 4H); 13C NMR (CD3COCD3, 125 MHz)δ 17.4, 37.7, 118. 6, 128.8, 
130.0, 130.2, 131.1, 132.6, 133.1, 137.5, 140.8, 143.0, 161.1; IR (cm
-1
) 3087, 2920, 1643, 
1616, 1596. 
 
5-Bromo-N-methyl-N-(4-methylphenyl)thiophene-2-carboxamide (18a) 
The title compound was prepared by reaction of 5-bromo-thiophene-2-carboxylic acid36c 
(700 mg, 3.4 mmol), thionyl chloride (0.5 mL, 6.8 mmol) and N,4-dimethylaniline (412 mg, 
3.4 mmol) according to method A. The residue was purified by crystallization in n-hexane, 
to afford the desired product as colorless solid (580 mg, 55 %).C13H12BrNOS; MW 310; 
mp: 87 – 88°C; MS (ESI) 310, 312 [M+H]+; 1H NMR (CDCl3, 500 MHz)δ2.41 (s, 3H), 3.38 
(s, 3H), 6.59 (d, J = 4.1 Hz, 1H), 6.76 (d, J = 4.1 Hz, 1H), 7.12 (dt, J = 2.4, 8.3 Hz, 2H), 
7.22 – 7.23 (m, 2H); 13C NMR (CD3COCD3, 125 MHz)δ 21.4, 39.2, 118.9, 128.0, 129.8, 
130.7, 132.6, 138.9, 139.4, 141.0, 161.6.IR (cm
-1
) 3054, 3030, 2921, 1629. 
 
5-Bromo-N-(3-chlorophenyl)-N-methylthiophene-2-carboxamide (22a) 
The title compound was prepared by reaction of 5-bromo-furan-2-carboxylic acid 36c(520 
mg, 2.5 mmol), thionyl chloride (0. 36 mL, 5 mmol) and N-methyl-3-chloroaniline(354 mg, 
2.5 mmol) according to method A. The residue was purified by silica gel column 
chromatography (n-hexane/EtOAc 90:10) to afford the desired product as brown solid (600 
mg, 72 %). C12H9BrClNOS, MW 329; mp: 114– 116°C; MS (ESI) 330, 332, 333 [M+H]
+  
; 
1
H NMR (CDCl3, 500 MHz)δ3.40 (s, 3H), 6.61 (d, J = 4.0 Hz, 1H), 6.79 (d, J = 4.0 Hz, 
1H), 7.13 (dt, J = 1.5 Hz, 7.5 Hz, 1H), 7.27 (t, J = 1.9 Hz, 1H), 7.35 (t, J = 8.1 Hz, 1H), 7.39 
(dt, J = 1.5 Hz, 8.2 Hz, 1H); 
13
C NMR (CDCl3, 125 MHz)δ39.2, 119.2, 126.6, 128.5, 128.9, 
130.0, 131.0, 133.0, 135.5, 138.9, 144.9, 161.5. 
 
5-Bromo-N-methyl-N-(3-methylphenyl)furan-2-carboxamide (31a) 
The title compound was prepared by reaction of 5-bromo-furan-2-carboxylic acid 31b(1000 
mg, 5.2 mmol), thionyl chloride (0.76 mL, 10.4 mmol) and N,3-dimethylaniline (634 mg, 
5.2 mmol) according to method A. The residue was purified by silica gel column 
chromatography (n-hexane/EtOAc 80:20) to afford the desired product as yellow solid 
(1226 mg, 80 %).C13H12BrNO2; MW 294; mp: 84 – 86°C; MS (ESI) 294, 296[M+H]
+
; 
1
H 
NMR (CD3COCD3, 500 MHz)δ2.35 (s, 3H), 3.33 (s, 3H), 5.87 (d, J = 3.5 Hz, 1H), 6.36 (d, 
J = 3.5 Hz, 1H), 7.08 – 7.10 (m, 1H), 7.15 – 7.16 (m, 1H), 7.21 – 7.24 (m, 1H), 7.33 (t, J = 
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7.8 Hz, 1H); 
13
C NMR (CD3COCD3, 125 MHz)δ 21.2, 38.3, 113.8, 118.9, 125.0, 125.3, 
128.8, 129.3, 130.2, 140.5, 144.9, 150.5, 158.1. IR (cm
-1
) 3122, 2925, 1639, 1462. 
 
4-Bromo-N-methyl-N-(m-tolyl)benzamide (35a) 
To a solution of N,3-dimethylaniline35c (200 mg, 1.65 mmol) in CH2Cl2 were added the 4-
bromobenzoyl chloride35b (724 mg, 330 mmol) and Et3N (168 mg, 1.65 mmol) under N2 
atmosphere. The reaction was stirred at room temperature overnight. The reaction mixture 
was extracted twice with CH2Cl2 (2 × 15 mL). The organic layer was dried over MgSO4, 
filtered and the solution was concentrated under reduced pressure. The residue was purified 
on silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford the desired 
product as a colorless solid (500 mg, 100 %). C15H14BrNO; MW 304; mp : 90 – 92 °C; MS 
(ESI) 304, 306 [M+H]
+
; 
1
H NMR (CD3COCD3, 300 MHz)δ2.24 (s, 3H), 3.39 (s, 3H), 6.92 
(d, J = 8Hz, 1H), 6.99 – 7.05 (m, 2H), 7.14 (t, J = 8Hz, 1H), 7.23 – 7.26 (m, 2H), 7.37 – 
7.40 (m, 2H); 
13
C NMR (CD3COCD3, 75 MHz)δ21.2, 38.4, 123.9, 125.2, 128.1, 128.5, 
129.8, 131.4, 131.6, 137.0, 140.0, 145.8, 169.4; IR (cm
-1
) 3086, 3058, 2923, 1638. 
 
5-bromo-4-methoxy-N-methyl-N-(m-tolyl)thiophene-2-carboxamide (38b) 
The title compound was prepared by reaction of 5-bromo-4-methoxythiophene-2-carboxylic 
acid38c (245 mg, 1.0 mmol), thionyl chloride (0.15 mL, 2.0 mmol) and N,3-dimethylaniline 
(125 mg, 1.0 mmol) according to method A. The residue was crystallized in water and 
ethanol, to afford the desired product as yellow solid (349 mg, 100%).C14H14BrNO2S; MW 
340; mp: 70 – 71°C; MS (ESI) 340, 342 [M+H]+; 1H NMR (CDCl3, 500 MHz)δ2.38 (s, 3H), 
3.39 (s, 3H), 3.66 (s, 3H), 6.61 (s, 1H), 7.05– 7.08 (m, 2H), 7.23– 7.25 (m, 1H), 7.33 (t, J = 
7.6 Hz, 1H); 
13
C NMR (CDCl3, 125 MHz)δ21.4, 39.3, 58.9, 98.4, 121.2, 125.5, 129.1, 
129.7, 129.9, 134.9, 140.4, 143.3, 154.3, 161.3. IR (cm
-1
) 3047, 2934, 2848, 1623, 1604, 
1587. 
N-methyl-N,5-bis(2-methylphenyl)thiophene-2-carboxamide (17) 
The title compound was prepared by reaction of 15a (100 mg, 0.32 mmol), o-tolylboronic 
acid (50 mg, 0.37 mmol), cesium carbonate (313 mg, 0.96 mmol) and 
tetrakis(triphenylphosphine) palladium (8 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as beige oil (40 mg, 39 %). C20H19NOS; MW 321; MS (ESI) 322 
[M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz)δ 2.23 (s, 3H), 2.29 (s, 3H), 3.32 (s, 3H), 6.67 (d, 
J = 3.9 Hz, 1H), 6.86 (d, J = 3.9 Hz, 1H), 7.18 – 7.21 (m, 1H), 7.23 – 7.27 (m, 3H), 7.32 – 
7.39 (m, 4H); 
13
C NMR (CD3COCD3, 125 MHz)δ 17.5, 21.1, 37.7, 126.9, 127.1, 128.6, 
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129.3, 129.8, 130.0, 130.7, 131.8, 132.4, 132.5, 134.1, 136.6, 137.4, 138.8, 143.7, 148.8, 
162.2.IR (cm
-1
) 3073, 3049, 2923, 1618. 
 
N-Methyl-N-(2-methylphenyl)-5-(3-methylphenyl)thiophene-2-carboxamide (15) 
The title compound was prepared by reaction of15a (100 mg, 0.32 mmol), m-tolylboronic 
acid (50 mg, 0.37 mmol), cesium carbonate (313 mg, 0.96 mmol) and 
tetrakis(triphenylphosphine) palladium (8 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as white solid (51 mg, 50%). C20H19NOS; MW 321; mp: 99 – 100°C; 
MS (ESI) 322 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.24 (s, 3H), 2.34 (s, 3H), 3.38 (s, 
3H), 6.63 (d, J = 4.0 Hz, 1H) 6.95 (d, J = 4.0 Hz, 1H), 7.08 – 7.10 (m, 1H), 7.19 – 7.37 (m, 
7H); 
13
C NMR (CDCl3, 125 MHz)δ 17.6, 21.5, 37.9, 122.9, 123.2, 126.8, 127.8, 128.9, 
129.0, 129.1, 129.2, 131.8, 132.8, 133.6, 136.6, 136.8, 138.7, 142.7, 149.6, 162.5. IR (cm
-1
) 
3089, 2921, 1615, 1595. 
 
N-Methyl-N-(2-methylphenyl)-5-(4-methylphenyl)thiophene-2-carboxamide (16) 
The title compound was prepared by reaction of15a (100 mg, 0.32 mmol), p-tolylboronic 
acid (50 mg, 0.37 mmol), cesium carbonate (313 mg, 0.96 mmol) and 
tetrakis(triphenylphosphine) palladium (8 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as white solid (60 mg, 58 %). C20H19NOS; MW 321; mp: 128 – 129°C; 
MS (ESI) 322 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.24 (s, 3H), 2.33 (s, 3H), 3.38 (s, 
3H), 6.63 (d, J = 4.0 Hz, 1H), 6.92 (d, J = 4.0 Hz, 1H), 7.12 – 7.14 (m, 2H), 7.23 (dd, J = 
1.5, 7.6 Hz, 1H), 7.27 – 7.37 (m, 5H); 13C NMR (CDCl3, 125 MHz)δ 17.6, 21.3, 37.9, 
122.4, 126.0, 127.8, 129.0, 129.1, 129.7, 131.0, 131.8, 132.9, 136.4, 136.6, 138.4, 142.7, 
149.7, 162.6;IR (cm
-1
) 3095, 2919, 1614, 1596. 
 
N-Methyl-5-(2-methylphenyl)-N-(3-methylphenyl)thiophene-2-carboxamide (14) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (100 mg, 0.32 mmol), o-tolylboronic acid (65 
mg, 0.48 mmol), cesium carbonate (313 mg, 0.96 mmol) and tetrakis(triphenylphosphine) 
palladium (8 mg, 0.02 eq) according to method B. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 80:20) to afford the desired product as 
yellow solid (60 mg, 58 %). C20H19NOS; MW 321; mp: 88 – 91°C; MS (ESI) 322 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz)δ 2.30 (s, 3H), 2.36 (s, 3H), 3.38 (s, 3H), 6.66 (d, J = 3.9 
Hz, 1H), 6.85 (d, J = 3.9 Hz, 1H), 7.16 – 7.18 (m, 1H), 7.19 – 7.29 (m, 6H), 7.36 (t, J = 7.7 
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Hz, 1H); 
13
C NMR (CD3COCD3, 125 MHz)δ 21.1, 21.2, 39.0, 126.1, 126.96, 127.03, 
129.26, 129.61, 129.65, 130.4, 130.8, 131.8, 132.6, 134.1, 136.6, 139.2, 140.7, 145.3, 148.5, 
162.4;IR (cm
-1
) 3050, 2921, 2855, 1614, 1586. 
 
N-Methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide (12) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a(150 mg, 0.48 mmol), m-tolylboronic acid (86 
mg, 0.63 mmol), cesium carbonate (469 mg, 1.44 mmol) and tetrakis(triphenylphosphine) 
palladium (11 mg, 0.02 eq) according to method B. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 80:20) to afford the desired product as 
yellow solid (117 mg, 76 %). C20H19NOS; MW 321; mp: 98 – 101°C; MS (ESI) 322 
[M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.36 (s, 3H), 2.39 (s, 3H), 3.47 (s, 3H), 6.68 (d, J = 
4.1 Hz, 1H), 6.97 (d, J = 4.1 Hz, 1H), 7.09 – 7.12 (m, 3H), 7.21 – 7.25 (m, 2H), 7.28 – 7.29 
(m, 1H), 7.31-7.34 (m, 2H); 
13
C NMR (CDCl3, 125 MHz)δ 21.3, 21.4, 39.4, 122.7, 123.2, 
125.0, 126.7, 128.5, 128.9, 129.2, 129.7, 133.4, 133.5, 136.3, 138.6, 140.0, 143.8, 149.7, 
163.1; IR (cm
-1
) 3048, 2921, 1599, 1584. 
 
N-Methyl-N-(3-methylphenyl)-5-(4-methylphenyl)thiophene-2-carboxamide (13) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (100 mg, 0.32 mmol), p-tolylboronic acid (65 
mg, 0.48 mmol), cesium carbonate (313 mg, 0.96 mmol) and tetrakis(triphenylphosphine) 
palladium (8 mg, 0.02 eq) according to method B. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 80:20) to afford the desired product as 
yellow solid (63 mg, 61 %). C20H19NOS; MW 321; mp: 95 – 98°C; MS (ESI) 322 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz)δ 2.32 (s, 3H), 2.36 (s, 3H), 3.37 (s, 3H), 6.49 (d, J = 3.9 
Hz, 1H), 7.07 (d, J = 3.9 Hz, 1H), 7.14 – 7.16 (m, 1H), 7.19 – 7.22 (m, 3H), 7.24 – 7.26 (m, 
1H), 7.35 (t, J = 7.8 Hz, 1H), 7.46 (dt, J = 2.0,  8.3 Hz, 2H); 
13
C NMR (CD3COCD3, 125 
MHz)δ 21.2, 21.3, 39.1, 123.4, 126.1, 126.6, 129.6, 129.7, 130.5, 130.6, 131.8, 133.3, 
138.6, 139.3, 140.8, 145.5, 149.3, 162.5;IR (cm
-1
) 3050, 2921, 1599, 1585. 
 
N-Methyl-5-(2-methylphenyl)-N-(4-methylphenyl)thiophene-2-carboxamide (20) 
The title compound was prepared by reaction of 18a (70 mg, 0.23 mmol), o-tolylboronic 
acid (37 mg, 0.27 mmol), cesium carbonate (221 mg, 0.68 mmol) and 
tetrakis(triphenylphosphine) palladium (5mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as white solid (40 mg, 54 %). C20H19NOS; MW 321; mp: 116 – 117°C; 
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MS (ESI) 322 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.31 (s, 3H), 2.40 (s, 3H), 3.43 (s, 
3H), 6.75 (d, J = 3.9 Hz, 1H), 6.76 (d, J = 3.9 Hz, 1H), 7.16 – 7.19 (m, 3H), 7.21 – 7.23 (m, 
4H), 7.26 – 7.28 (m, 1H); 13C NMR (CDCl3, 125 MHz)δ 21.2, 21.3, 39.3, 126.0, 126.2, 
128.0, 128.4, 130.3, 130.5, 130.9, 132.4, 133.6, 136.2, 137.6, 138.4, 141.7, 148.5, 162.8;IR 
(cm
-1
) 3081, 2922, 1604. 
 
N-Methyl-5-(3-methylphenyl)-N-(4-methylphenyl)thiophene-2-carboxamide (18) 
The title compound was prepared by reaction of18a (70 mg, 0.23 mmol), m-tolylboronic 
acid (37 mg, 0.27 mmol), cesium carbonate (221 mg, 0.68 mmol) and 
tetrakis(triphenylphosphine) palladium (5 mg, 0.02 eq) according to method B. The residue 
was purified by crystallization in n-hexane to afford the desired product as colorless needles 
(30 mg, 41 %). C20H19NOS; MW 321; mp: 111 – 112°C; MS (ESI) 322 [M+H]
+
; 
1
H NMR 
(CDCl3, 500 MHz)δ 2.35 (s, 3H), 2.41 (s, 3H), 3.43 (s, 3H), 6.59 (d, J = 4.0 Hz, 1H), 6.95 
(d,  J = 4.0 Hz, 1H), 7.09 – 7.10 (m, 1H), 7.16 (dt, J = 2.0, 8.3 Hz, 2H), 7.21 – 7.24 (m, 3H), 
7.28 – 7.31 (m, 2H); 13C NMR (CDCl3, 125 MHz)δ 21.3 21.5, 39.3, 122.8, 123.3, 126.9, 
127.9, 128.9, 129.2, 130.5, 132.9, 133.7, 137.3, 138.3, 138.7, 141.9, 149.3, 162.8;IR (cm
-1
) 
3081, 2919, 1602. 
 
N-Methyl-N,5-bis(4-methylphenyl)thiophene-2-carboxamide (19) 
The title compound was prepared by reaction of 18a (70 mg, 0.23 mmol), p-tolylboronic 
acid (37 mg, 0.27 mmol), cesium carbonate (221 mg, 0.68 mmol) and 
tetrakis(triphenylphosphine) palladium (5 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as pale brown solid (43 mg, 58 %). C20H19NOS; MW 321; mp: 118 – 
119°C; MS (ESI) 322 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.34 (s, 3H), 2.41 (s, 3H), 
3.43 (s, 3H), 6.59 (d, J = 4.0 Hz, 1H), 6.92 (d, J = 4.0 Hz, 1H), 7.13 – 7.17 (m, 4H), 7.21 – 
7.23 (m, 2H), 7.38 (dt, J = 1.8, 8.2 Hz, 2H); 
13
C NMR (CDCl3, 125 MHz)δ 21.3, 39.3, 
122.4, 126.0, 127.9, 129.7, 130.5, 131.0, 133.0, 136.9, 138.3, 138.4, 141.8, 149.3, 162.8; IR 
(cm
-1
) 3029, 2917, 1898, 1611. 
 
5-(3,4-Dimethylphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide (21) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (150 mg, 0.48 mmol), 3,4-dimethylphenyl 
boronic acid (94.5 mg, 0.63 mmol), cesium carbonate (469 mg, 1.44 mmol) and 
tetrakis(triphenylphosphine) palladium (11 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
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the desired product as colorless solid (55 mg, 34 %). C21H21NOS; MW 335; mp: 138 – 
140°C; MS (ESI) 336 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.26 (s, 3H), 2.27 (s, 3H), 
2.38 (s, 3H), 3.45 (s, 3H), 6.57 (d, J = 4.0 Hz, 1H), 6.92 (d, J = 4.0 Hz, 1H), 7.08 – 7.11 (m, 
3H), 7.20 – 7.21 (m, 1H), 7.23 (dd, J = 2.1, 7.8 Hz, 1H), 7.28 – 7.33 (m, 2H); 13C NMR 
(CDCl3, 125 MHz)δ 19.5, 19.7, 21.3, 39.1, 122.2, 123.4, 125.0, 127.2, 128.5, 128.9, 129.6, 
130.1, 131.2, 132.8, 136.6, 137.0, 137.1, 139.8, 144.1, 149.4, 162.6;IR (cm
-1
)  3029, 2918, 
1612, 1602. 
 
5-(4-methoxy-3-methylphenyl)-N-methyl-N-(m-tolyl)thiophene-2-carboxamide (36a) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (150 mg, 0.48 mmol), (4-methoxy-3-
methylphenyl)boronic acid (92 mg, 0.55 mmol), cesium carbonate (469 mg, 1.44 mmol) and 
tetrakis(triphenylphosphine) palladium (11 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as grey solid (70 mg, 42 %). C21H21NO2S; MW 351; mp: 127 – 128°C; 
MS (ESI) 352 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ2.21 (s, 3H), 2.37 (s, 3H), 3.43 (s, 
3H), 3.83 (s, 3H), 6.53 (d, J = 3.9 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 4 Hz, 1H), 
7.07– 7.10 (m, 2H), 7.18– 7.20 (m, 1H), 7.27– 7.31 (m, 3H); 13C NMR (CDCl3, 125 
MHz)δ16.4, 21.4, 39.3, 55.6, 110.3, 121.8, 124.8, 125.2, 126.1, 127.3, 128.6, 128.7, 129.0, 
129.7, 133.0, 136.3, 140.0, 144.4, 149.5, 158.2, 162.8; IR (cm
-1
)  3088, 2922, 2841, 1598, 
1536. 
 
5-(3-methoxy-5-methylphenyl)-N-methyl-N-(m-tolyl)thiophene-2-carboxamide(37a) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (200 mg, 0.64 mmol), (5-methoxy-3-
methylphenyl)boronic acid (123 mg, 0.74 mmol), cesium carbonate (626 mg, 1.92 mmol) 
and tetrakis(triphenylphosphine) palladium (15 mg, 0.02 eq) according to method B. The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to 
afford the desired product as yellow oil (184 mg, 82 %). C21H21NO2S; MW 351; MS (ESI) 
352 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.32 (s, 3H),  2.37 (s, 3H), 3.44 (s, 3H), 3.79 (s, 
3H), 6.54 (d, J = 4 Hz, 1H), 6.65 – 6.66 (m, 1H), 6.83 – 6.84 (m, 1H), 6.91 – 6.92 (m, 1H), 
6.93 (d, J = 4 Hz, 1H), 7.06 – 7.10 (m, 2H), 7.18 – 7.20 (m, 1H), 7.30 (t, J = 8 Hz, 1H) 13C 
NMR (CDCl3, 125 MHz)δ121.3, 21.5, 39.1, 55.2, 108.7, 114.6, 119.4, 122.8, 124.9, 128.4, 
128.9, 129.5, 132.6, 134.6, 137.2, 139.8, 140.0, 144.1, 148.9, 159.9, 162.5. 
 
5-(3-Chlorophenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide (23) 
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The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (80 mg, 0.26 mmol), 3-chlorophenyl boronic 
acid (52.4 mg, 0.34 mmol), cesium carbonate (254 mg, 0.78 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as colorless solid (41 mg, 46 %). C19H16ClNOS; MW 342; mp: 143 – 
145°C; MS (ESI) 343, 345 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.39 (s, 3H), 3.45 (s, 
3H), 6.60 (d, J = 4.1 Hz, 1H), 6.97 (d, J = 4.1 Hz, 1H), 7.07 – 7.10 (m, 2H), 7.21 – 7.23 (m, 
1H), 7.24 – 7.29 (m, 2H), 7.32 (t, J = 7.8 Hz, 1H), 7.37 (dt, J = 1.9, 7.0 Hz, 1H), 7.47 – 7.48 
(m, 1H); 
13
C NMR (CDCl3, 125 MHz)δ 21.4, 39.3, 123.6, 124.3, 125.1, 126.0, 128.3, 128.6, 
129.2, 129.8, 130.3, 133.0, 134.9, 135.5, 138.3, 140.1, 144.1, 147.2, 162.4; IR (cm
-1
) 
 
N-Methyl-N-(3-methylphenyl)-5-(5-methylpyridin-3-yl)thiophene-2-carboxamide (26) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (80 mg, 0.26 mmol), 5-methyl-3-pyridine 
boronic acid (43 mg, 0.31 mmol), cesium carbonate (254 mg, 0.78 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 60:40) to afford 
the desired product as colorless solid (45 mg, 54 %). C19H18N2OS; MW 322; mp: 167 – 
170°C; MS (ESI) 323 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.34 (s, 3H), 2.37 (s, 3H), 
3.43 (s, 3H), 6.62 (d, J = 4.1 Hz, 1H), 6.99 (d, J = 4.1 Hz, 1H), 7.05 – 7.09 (m, 2H), 7.19 – 
7.21 (m, 1H), 7.30 (t, J = 7.8 Hz, 1H), 7.56 (br s, 1H), 8.34 (br s, 1H), 8.54 (br s, 1H); 
13
C 
NMR (CDCl3, 125 MHz)δ 18.5, 21.4, 39.2, 123.8, 125.1, 128.6, 129.2, 129.4, 129.8, 133.0, 
133.4, 133.8, 138.6, 140.1, 144.0, 144.2, 145.1, 149.7, 162.3; IR (cm
-1
) 3076, 2923, 1617, 
1601. 
 
N-Methyl-5-(2-methylpyridin-4-yl)-N-(m-tolyl)thiophene-2-carboxamide (25) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (80 mg, 0.26 mmol), (2-methylpyridin-4-
yl)boronic acid (43 mg, 0.31 mmol), cesium carbonate (254 mg, 0.78 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 60:40) to afford 
the desired product as colorless solid (50 mg, 60 %). C19H18N2OS; MW 322; mp: 131 – 
133°C; MS (ESI) 323 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ2.37 (s, 3H), 2.55 (s, 3H), 3.44 
(s, 3H), 6.59 (d, J = 4.0 Hz, 1H), 7.05 – 7.08 (m, 2H), 7.11 (d, J = 4.0 Hz, 1H), 7.15 – 7.16 
(m, 1H), 7.20 – 7.22 (m, 2H), 7.30 (t, J = 7.65 Hz, 1H), 8.43 (d, J = 5.1 Hz, 1H); 13C NMR 
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(CDCl3, 125 MHz)δ21.4, 24.5, 39.3, 117.3, 119.6, 124.8, 125.1, 128.5, 129.3, 129.8, 132.8, 
139.6, 140.2, 141.2, 144.0, 145.6, 149.7, 159.2, 162.2; IR (cm
-1
) 3090, 2924, 1614, 1600. 
 
N-Methyl-N-(3-methylphenyl)-5-(1-methyl-1H-pyrazol-4-yl)thiophene-2-carboxamide 
(27) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide 12a (150 mg, 0.48 mmol), 1-methyl-1H-pyrazole-
4-boronic acid (96 mg, 0.63 mmol), cesium carbonate (626 mg, 1.92 mmol) and 
tetrakis(triphenylphosphine) palladium (11 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to afford 
the desired product as yellow solid (70 mg, 53 %). C17H17N3OS; MW 311; mp: 132 – 
134°C; MS (ESI) 312 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.37 (s, 3H), 3.43 (s, 3H), 
3.89 (s, 3H), 6.49 (d, J = 4.0 Hz, 1H), 6.70 (d, J = 4.0 Hz, 1H), 7.06 – 7.10 (m, 2H), 7.19 – 
7.21 (m, 1H), 7.30 (t, J = 7.7 Hz, 1H), 7.47 (s, 1H), 7.57 (d, J = 1.0 Hz, 1H); 
13
C NMR 
(CDCl3, 125 MHz)δ 21.6, 29.6, 39.0, 116.4, 122.0, 125.0, 127.4, 128.5, 128.9, 129.5, 132.7, 
135.4, 137.0, 140.0, 140.2, 144.1, 162.4; IR (cm
-1
) 3075, 2923, 2854, 1616, 1601, 1582. 
 
N-(3-Chlorophenyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide (22) 
The title compound was prepared by reaction of 22a (80 mg, 0.24 mmol), m-tolylboronic 
acid (43 mg, 0.32 mmol), cesium carbonate (236 mg, 0.73 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as yellow solid (49 mg, 59 %). C19H16ClNOS; MW 342; mp: 89 – 92°C; 
MS (ESI) 342, 344 [M]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.36 (s, 3H), 3.45 (s, 3H), 6.70 (d, J 
= 3.9 Hz, 1H), 6.99 (d, J = 3.9 Hz, 1H), 7.11 – 7.12 (m, 1H), 7.17 (dt, J = 2.0, 7.0 Hz, 1H), 
7.24 (t, J = 7.6 Hz, 1H), 7.29 – 7.32 (m, 3H), 7.34 – 7.37 (m, 2H); 13C NMR (CDCl3, 125 
MHz)δ 21.5, 39.2, 122.9, 123.4, 126.5, 126.9, 128.3, 128.4, 129.0, 129.4, 130.9, 133.2, 
133.5, 135.3, 136.4, 138.8, 145.7, 149.8, 162.8. IR (cm
-1
) 
 
N-Methyl-N,5-bis(3-methylphenyl)-1,3-thiazole-2-carboxamide (30) 
To a solution of lithium 5-(3-methylphenyl)-1,3-thiazole-2-carboxylate 30a (100 mg, 0.44 
mmol) in CH2Cl2 (15 mL) was added drop wise oxalyl chloride (80 µL, 0.88 mmol) 
followed by few drops of DMF at 0°C under N2 atmosphere. The reaction mixture was 
stirred at 0°C for 10 min and then at room temperature for 3 h. The solvent was removed 
under reduced pressure (bath temperature of rotavapor at 20°C). This residue was diluted in 
dry CH2Cl2 (10 mL) and N,3-dimethylaniline (0.06 mL, 0.44 mmol) was added followed by 
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triethylamine (0.10 µL, 0.44 mmol). The solution was stirred overnight at room temperature 
under N2 atmosphere. The solvent was removed under reduced pressure (bath temperature 
of rotavapor at 20°C). A mixture of Na2CO3 2N (15 mL) and EtOAc (15 mL) were added. 
The aqueous layer was extracted with EtOAc (15 mL). The organic layer was washed twice 
with Na2CO3 2N (15 mL), once with water (15 mL), dried over MgSO4, filtered and the 
solution was concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography (n-hexane/ethyl acetate 70:30) to afford the desired product as pale 
brown solid (51 mg, 36 %). C19H18N2OS; MW 322; mp: 79 – 80°C; MS (ESI) 323 [M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ 2.32 (s, 3H), 2.36 (s, 3H), 3.54 (br s, 3H), 7.07 – 7.09 (m, 
1H), 7.10 – 7.12 (m, 1H), 7.15 (br s, 1H), 7.20 – 7.26 (m, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.44 
– 7.46 (m, 2H), 7.49 (br s, 1H), 7.93 (br s, 1H); 13C NMR (CDCl3, 125 MHz)δ 21.3, 39.6, 
124.9, 125.0, 128.3, 128.4, 128.6, 130.0, 130.1, 130.6, 131.5, 139.69, 139.70, 139.9, 144.2, 
145.4, 161.2. IR (cm
-1
) 3096, 2922, 1624, 1606, 1585. 
 
N-Methyl-N,5-bis(3-methylphenyl)furan-2-carboxamide (31) 
The title compound was prepared by reaction of 31a (150 mg, 0.51 mmol), m-tolylboronic 
acid (104 mg, 0.77 mmol), cesium carbonate (499 mg, 1.53 mmol) and 
tetrakis(triphenylphosphine) palladium (12 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to afford 
the desired product as orange oil (100 mg, 64 %). C20H19NO2; MW 305; MS (ESI) 306 
[M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz)δ 2.30 (s, 3H), 2.38 (s, 3H), 3.37 (s, 3H), 6.67 (d, 
J = 3.7 Hz, 1H), 6.74 (d, J = 3.7 Hz, 1H), 7.00 – 7.01 (m, 1H), 7.07 – 7.12 (m, 2H), 7.16 – 
7.22 (m, 3H), 7.24 – 7.27 (m, 1H), 7.35 (t, J = 7.8 Hz, 1H); 13C NMR (CD3COCD3, 125 
MHz)δ 21.3, 38.7, 107.1, 119.4, 122.3, 125.3, 125.4, 128.8, 129.0, 129.5, 129.9, 130.2, 
130.7, 139.2, 140.3, 145.9, 148.2, 155.8, 159.1. 
 
5-(3-Methoxyphenyl)-N-methyl-N-(3-methylphenyl)furan-2-carboxamide (32) 
The title compound was prepared by reaction of 31a (200 mg, 0.68 mmol), m-
methoxyphenylboronic acid (155 mg, 1.02 mmol), cesium carbonate (665 mg, 2.04 mmol) 
and tetrakis(triphenylphosphine) palladium (16 mg, 0.02 eq) according to method B. The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to 
afford the desired product as colorless oil (200 mg, 94 %). C20H19NO3; MW 321; MS (ESI) 
322 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz)δ 2.37 (s, 3H), 3.37 (s, 3H), 3.80 (s, 3H), 
6.61 (d, J = 3.7 Hz, 1H), 6.78 (d, J = 3.7 Hz, 1H), 6.83 – 6.86 (m, 2H), 6.93 – 6.95 (m, 1H), 
7.09 – 7.12 (m, 1H), 7.20 – 7.26 (m, 3H), 7.33 (t, J = 7.8 Hz, 1H); 13C NMR (CD3COCD3, 
125 MHz)δ 21.2, 38.5, 55.7, 107.5, 110.2, 114.9, 117.5, 119.2, 125.1, 128.7, 129.0, 130.1, 
130.6, 132.0, 140.3, 145.7, 148.3, 155.5, 159.1, 161.0. 
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5-(2-Fluoro-3-methoxyphenyl)-N-methyl-N-(3-methylphenyl)furan-2-carboxamide (33) 
The title compound was prepared by reaction of 31a (200 mg, 0.68 mmol), 2-fluoro-3-
methoxyphenyl boronic acid (173 mg, 1.02 mmol), cesium carbonate (665 mg, 204 mmol) 
and tetrakis(triphenylphosphine) palladium (16 mg, 0.02 eq) according to method B. The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to 
afford the desired product as colorless solid (80 mg, 35 %). C20H18FNO3; MW 339; mp: 99 
– 101°C; MS (ESI) 340 [M+H]+; 1H NMR (CD3COCD3, 500 MHz)δ 2.37 (s, 3H), 3.38 (s, 
3H), 3.88 (s, 3H), 6.60 – 6.64 (m, 2H), 6.74 (t, J = 3.8 Hz, 1H), 7.04 – 7.09 (m, 2H), 7.10 – 
7.12 (m, 1H), 7.21 – 7.24 (m, 2H), 7.34 (t, J = 7.8 Hz, 1H); 13C NMR (CD3COCD3, 125 
MHz)δ 25.5, 42.9, 61.0, 116.2, 116.3, 118.1, 118.4, 122.3, 123.48, 123.53, 123.6, 129.41, 
129.44, 129.5, 133.1, 133.3, 134.5, 144.7, 149.9, 152.46, 152.47, 153.0, 153.3, 153.4, 
153.76, 153.78, 155.0, 163.2. IR (cm
-1
) 3064, 2924, 1719, 1627, 1604, 1586. 
 
5-(3,4-Dimethylphenyl)-N-methyl-N-(m-tolyl)furan-2-carboxamide (34) 
The title compound was prepared by reaction of 31a (150 mg, 0.51 mmol), (3,4-
dimethylphenyl)boronic acid(115 mg, 0.77 mmol), cesium carbonate (499 mg, 1.53 mmol) 
and tetrakis(triphenylphosphine) palladium (12 mg, 0.02 eq) according to method B. The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to 
afford the desired product as a colorless oil (118 mg, 72 %). C21H21NO2; MW 319; MS 
(ESI) 320 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz)δ2.22 (s, 3H), 2.23 (s, 3H), 2.38 (s, 
3H), 3.44 (s, 3H), 6.44 (d, J = 3.6 Hz, 1H), 6.61 (d, J = 3.6 Hz, 1H), 6.96 (brs, 1H), 7.03 – 
7.05 (m, 3H), 7.10 (s, 1H), 7.19 – 7.20 (m, 1H), 7.30 (t, J = 7.7 Hz, 1H);  13C NMR 
(CD3COCD3, 125 MHz)δ19.6, 19.7, 21.3, 38.7, 105.5, 119.3, 121.9, 124.4, 125.4, 127.5, 
127.9, 128.3, 129.4, 129.8, 136.8, 137.1, 139.5, 144.6, 146.4, 155.7, 159.2. 
 
N,3'-Dimethyl-N-(m-tolyl)-[1,1'-biphenyl]-4-carboxamide (35) 
The title compound was prepared by reaction of 35a (120 mg, 0.39 mmol), m-tolylboronic 
acid(69 mg, 0.51 mmol), cesium carbonate (381 mg, 1.17 mmol) and 
tetrakis(triphenylphosphine) palladium (9 mg, 0.02 eq) according to method B. The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as yellow oil (105 mg, 85 %). C22H21NO; MW 315; MS (ESI) 316 
[M+H]
+
; 
1
H NMR (CD3COCD3, 300 MHz)δ2.24 (s, 3H), 2.37 (s, 3H), 3.42 (s, 3H), 6.95 (d, 
J = 9Hz, 1H), 6.99 (d, J = 7Hz, 1H), 7.07 (s, 1H), 7.11 – 7.18 (m, 2H), 7.30 (t,J = 8 Hz, 
1H), 7.37 – 7.42 (m, 4H), 7.47 – 7.50 (m, 2H);  13C NMR (CD3COCD3, 75 MHz)δ21.3, 
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21.5, 38.6, 124.8, 125.2, 126.9, 128.0, 128.4, 128.5, 129.4, 129.6, 129.7, 130.2, 136.5, 
139.4, 140.0, 140.8, 142.7, 146.2, 170.2.IR (cm
-1
) 3037, 2920, 2862, 1740, 1639, 1603. 
 
4-methoxy-N-methyl-N,5-di-m-tolylthiophene-2-carboxamide (38a) 
The title compound was prepared by reaction of 5-bromo-4-methoxy-N-methyl-N-(m-
tolyl)thiophene-2-carboxamide 38b (150 mg, 0.44 mmol), m-tolylboronic acid (72 mg, 0.53 
mmol), cesium carbonate (430 mg, 1.32 mmol) and tetrakis(triphenylphosphine) palladium 
(10 mg, 0.02 eq) according to method B. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 80:20) to afford the desired product as a yellow oil 
(40 mg, 26 %). C21H21NO2S; MW 351; MS (ESI) 352 [M+H]
+
; 
1
H NMR (CDCl3, 500 
MHz)δ2.34 (s, 3H), 2.39 (s, 3H), 3.47 (s, 3H), 3.65 (s, 3H), 6.73 (s, 1H), 7.04–7.06 (m, 1H), 
7.11– 7.13 (m, 2H), 7.21 (t, J = 7.6 Hz, 1H), 7.24– 7.25 (m, 1H), 7.33– 7.40 (m, 3H); 13C 
NMR (CDCl3, 125 MHz)δ21.4, 21.6, 36.7, 58.5, 123.0, 124.6, 125.2, 127.8, 128.1, 128.4, 
128.6, 128.7, 129.6, 129.9, 131.1, 132.3, 138.3, 140.3, 143.4, 152.6, 163.2; IR (cm
1
)  2922, 
2857, 1778, 1623, 1601, 1582. 
 
4-hydroxy-N-methyl-N,5-di-m-tolylthiophene-2-carboxamide (38) 
A solution of 4-methoxy-N-methyl-N,5-di-m-tolylthiophene-2-carboxamide 38a(29 mg, 
0.08mmol) and boron trifluoride methyl sulfide complex BF3.SMe2 (50 µL, 0.48mmol) in 
CH2Cl2 (3 mL) was stirred at room temperature overnight. Methanol (3 mL) was added to 
quench the reaction and the solution was stirred at room temperature for 30 minutes. The 
residual solvent was removed under reduced pressure at 25°C. The residue was triturated 
with cold water and stirred at room temperature for 2 hours. The precipitate formed was 
filtered off and washed once with water and twice with Et2O to afford the desired product as 
colorless solid (27 mg, 100 %). C20H19NO2S; mp: 156 – 157°C; MW 337; MS (ESI) 338 
[M+H]
+
; 
1
H NMR (CDCl3, 500 MHz)δ2.35 (s, 3H), 2.37 (s, 3H), 3.39 (s, 3H), 6.65 (s, 1H), 
7.05 – 7.08 (m, 3H), 7.18 – 7.20 (m, 1H), 7.24 (t, J = 7.70 Hz, 1H), 7.29 (t, J = 7.7 Hz, 1H), 
7.36 – 7.38 (m, 1H), 7.40 (brs, 1H); 13C NMR (CDCl3, 125 MHz)δ21.3, 21.5, 39.3, 124.4, 
125.0, 125.2, 126.5, 127.9, 128.1, 128.5, 128.7, 129.2, 129.6, 132.0, 132.3, 138.5, 139.9, 
143.5, 148.4, 162.2. IR (cm
-1
) : 3142, 3098, 2924, 1559. 
 
5-(4-hydroxy-3-methylphenyl)-N-methyl-N-(m-tolyl)thiophene-2-carboxamide (36) 
A solution of 5-(4-methoxy-3-methylphenyl)-N-methyl-N-(m-tolyl)thiophene-2-
carboxamide 36a(65 mg, 0.18 mmol) and boron trifluoride methyl sulfide complex 
BF3.SMe2 (120 µL, 1.11 mmol) in CH2Cl2 (3 mL) was stirred at room temperature 
overnight. Methanol (3 mL) was added to quench the reaction and the solution was stirred at 
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room temperature for 30 minutes. The residual solvent was removed under reduced pressure 
at 25°C. The residue was triturated with cold water and stirred at room temperature for 2 
hours. The precipitate formed was filtered off and washed once with water and twice with 
Et2O to afford the desired product as colorless solid (55 mg, 90 %).C20H19NO2S; mp: 169 – 
170°C; MW 337; MS (ESI) 338 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz)δ 2.21 (s, 3H), 
2.36 (s, 3H), 3.36 (s, 3H), 6.43 (d, J = 4.1 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 3.8 
Hz, 1H), 7.14-7.16 (m, 1H), 7.21 – 7.26 (m, 3H), 7.36 – 7.37 (m, 2H), 8.50 (s, 1H); 13C 
NMR (CD3COCD3, 125 MHz)δ 16.1, 21.2, 39.1, 116.0, 122.2, 125.4, 125.92, 125.96, 126.0, 
129.2, 129.4, 129.5, 130.4, 133.2, 137.4, 140.7, 145.6, 150.0, 156.9, 162.6. IR (cm
-1
) : 3174, 
2924, 1592, 1578. 
 
5-(3-hydroxy-5-methylphenyl)-N-methyl-N-(m-tolyl)thiophene-2-carboxamide (37) 
A solution of 5-(3-methoxy-5-methylphenyl)-N-methyl-N-(m-tolyl)thiophene-2-
carboxamide37a(95 mg, 0.27 mmol) and boron trifluoride methyl sulfide complex 
BF3.SMe2 (170 µL, 1.62 mmol) in CH2Cl2 (3 mL) was stirred at room temperature 
overnight. Methanol (3 mL) was added to quench the reaction and the solution was stirred at 
room temperature for 30 minutes. The residual solvent was removed under reduced pressure 
at 25°C. The residue was triturated with cold water and stirred at room temperature for 2 
hours. The precipitate formed was filtered off and washed once with water and twice with 
Et2O to afford the desired product as colorless solid (87 mg, 96 %).C20H19NO2S; mp: 173 – 
174°C; MW 337; MS (ESI) 338 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) 2.28 (s, 3H),  
2.36 (s, 3H), 3.46 (s, 3H), 6.39 (d, J = 4 Hz, 1H), 6.67 (brs, 1H), 6.86 (brs, 1H), 6.91 (d, J = 
4 Hz, 1H), 7.02 – 7.08 (m, 3H), 7.19 – 7.21 (m, 1H), 7.30 (t, J = 8 Hz, 1H); 13C NMR 
(CD3COCD3, 125 MHz)δ 21.3, 21.4, 39.5, 110.6, 116.5, 118.5, 123.0, 124.7, 128.2, 129.1, 
129.6, 132.8, 134.5, 136.7. 140.0, 140.1, 144.0, 149.6, 156.9, 163.2. 
 
Ethyl 3-hydroxy-5-(3-methylphenyl)thiophene-2-carboxylate (39d) 
Through a solution of ethyl 3-(3-methylphenyl)-3-oxopropanoate39e (1 g, 4.9mmol) and 
ethyl thioglycolate39f (1.06 mL, 9.7 mmol) was bubbled dry HCl(g) at room temperature 
for 5 hours. Water was added to quench the reaction. The aqueous layer was extracted three 
times with Et2O (3 × 15 mL). The organic layer was washed once with water, dried over 
MgSO4, filtered and the solution was concentrated under reduced pressure. To the residue 
was added drop wise a solution of sodium ethanolate (prepared from 900 mg of sodium 
metal). The reaction mixture was stirred for about 2 hours and then stopped with cold water. 
The basic pH was adjusted to neutral pH with a solution of HCl 1N. The aqueous layer was 
extracted three times with EtOAc (3 × 15 mL). The organic layer was washed once with 
water, dried over MgSO4, filtered and the solution was concentrated under reduced pressure. 
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The residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 
80:20 to 0:100) to afford the desired product as beige solid (267 mg, 21 %). C14H14O3S; 
MW 262; mp: 49 – 51 °C; MS (ESI) 263 [M+H]+; 1H NMR (CD3COCD3, 500 MHz)δ1.36 
(t, J = 7.2 Hz, 3H), 2.38 (s, 3H), 4.37 (q, J = 7.2 Hz, 2H), 7.15 (s, 1H), 7.23 – 7.26 (m, 1H), 
7.33 (t, J = 7.7 Hz, 1H), 7.50 – 7.53 (m, 1H), 7.54 – 7.56 (m, 1H), 9.70 (br s, 1H); 13C NMR 
(CD3COCD3, 125 MHz)δ14.6, 21.3, 61.8, 103.6, 116.0, 123.8, 127.2, 130.0, 131.1, 133.8, 
139.8, 150.1, 165.4, 166.6. 
 
Ethyl 3-methoxy-5-(3-methylphenyl)thiophene-2-carboxylate (39c) 
A mixture of ethyl 3-hydroxy-5-(3-methylphenyl)thiophene-2-carboxylate39d (265 mg, 
1.0mmol), potassium carbonate (207 mg, 1.5 mmol), methyl iodide (93 µL, 1.5 mmol) in 
dry acetonitrile (5 mL) was heated at reflux under N2 atmosphere for 48 hours. The residual 
solvent was removed under reduced pressure and water was added to the residue. The 
organic layer was extracted three times with EtOAc (3 × 10 mL). The organic layer was 
dried over MgSO4, filtered and the solution was concentrated under reduced pressure. The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to 
afford the desired product as yellow oil (170 mg, 62 %). C15H16O3S; MW 276; MS (ESI) 
277 [M+H]
+
; 
1
H NMR (CD3COCD3, 300 MHz)δ1.31 (t, J = 7.1 Hz, 3H), 2.38 (s, 3H), 4.01 
(s, 3H), 4.26 (q, J = 7.1 Hz, 2H), 7.20 – 7.24 (m, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.44 (s, 1H), 
7.50 – 7.55 (m, 1H), 7.56 – 7.58 (m, 1H); 13C NMR (CD3COCD3, 75 MHz)δ14.3, 20.8, 
58.8, 60.1, 108.5, 113.4, 123.0, 126.5, 129.4, 130.2, 133.6, 139.2, 147.9, 161.2, 162.5. 
 
3-Methoxy-5-(3-methylphenyl)thiophene-2-carboxylic acid (39b) 
A solution of ethyl 3-methoxy-5-(3-methylphenyl)thiophene-2-carboxylate 39c (165 mg, 
0.6 mmol) and potassium hydroxide (500 mg, 8.9 mmol) in a mixture of H2O/THF (10 mL, 
1:1, v:v) was heated at reflux for 4 hours. After cooling, the solution was extracted once 
with EtOAc (1 × 10 mL). The aqueous layer was acidified to pH = 2 at 0°C. The precipitate 
formed was filtered off and washed three times with water and two times with Et2O to 
afford the desired product as pale brown solid (67 mg, 45 %). C13H12O3S; MW 248; MS 
(ESI) 249 [M+H]
+
; 
1
H NMR (CD3COCD3, 300 MHz)δ2.39 (s, 3H), 4.06 (s, 3H), 7.21 – 7.26 
(m, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.49 (s, 1H), 7.52 – 7.57 (m, 1H), 7.58 – 7.60 (m, 1H), 
10.55 (br s, 1H); 
13
C NMR (CD3COCD3, 75 MHz)δ20.4, 58.6, 108.7, 113.0, 122.7, 126.1, 
129.1, 129.9, 133.3, 138.9, 147.9, 161.4, 161.7. 
 
3-Methoxy-N-methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide (39a) 
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The title compound was prepared by reaction of 3-methoxy-5-(3-methylphenyl)thiophene-2-
carboxylic acid 39b (67 mg, 0.27 mmol), thionyl chloride (78 µL, 1.1 mmol) and 3-
methylaniline (34 µL, 0.27 mmol) according to method A. The residue was purified by 
silica gel column chromatography (n-hexane/EtOAc 70:30) to afford the desired product as 
yellow oil (84 mg, 88 %). C21H21NO2S; MW 351; MS (ESI) 352 [M+H]
+
; 
1
H NMR 
(CD3COCD3, 300 MHz)δ2.46 (s, 3H), 2.52 (s, 3H),3.53 (s, 3H), 3.62 (s, 3H), 7.12 – 6.14 
(m, 1H), 7.17 – 7.19 (m, 1H), 7.06 – 7.09 (m, 1H), 7.24 (s, 1H), 7.30 – 7.35 (m, 2H), 7.45 (t, 
J = 7.7 Hz, 1H), 7.56 – 7.59 (m, 1H), 7.62 (s, 1H); 13C NMR (CD3COCD3, 75 MHz)δ21.3, 
21.4, 38.3, 58.6, 113.1, 123.2, 124.2, 126.7, 127.5, 127.9, 129.1, 129.9, 130.1, 134.6, 139.1, 
139.7, 145.5, 146.2, 147.0, 156.3, 163.8.IR (cm
-1
): 2925, 2856, 1622, 1602, 1586. 
 
3-Hydroxy-N-methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide (39) 
A solution of 3-methoxy-N-methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide 39a 
(83 mg, 0.24 mmol) and boron trifluoride methyl sulfide complex BF3.SMe2 (150 µL, 1.42 
mmol) in CH2Cl2 (3 mL) was stirred at room temperature overnight. Methanol (3 mL) was 
added to quench the reaction and the solution was stirred at room temperature for 30 
minutes. The residual solvent was removed under reduced pressure at 25°C. The residue 
was triturated with cold water and stirred at room temperature for 2 hours. The precipitate 
formed was filtered off and washed once with water and twice with Et2O to afford the 
desired product as beige solid (59 mg, 72 %). C20H19NO2S; mp: 171 – 173°C; MW 337; MS 
(ESI) 338 [M+H]
+
; 
1
H NMR (CD3COCD3, 300 MHz)δ2.33 (s, 3H), 2.47 (s, 3H), 3.61 (s, 
3H), 7.04 (s, 1H), 7.23 – 7.31 (m, 3H), 7.33 – 7.36 (m, 1H), 7.48 – 7.53 (m, 2H),7.54 – 7.60 
(m, 2H); 
13
C NMR (CD3COCD3, 75 MHz)δ20.34, 20.35, 39.3, 115.18, 115.20, 123.0, 125.3, 
126.4, 128.8, 129.1, 130.6, 130.9, 131.4, 132.3, 139.0, 139.8, 141.1, 155.7, 169.6.IR (cm
-1
) : 
3049, 2924, 2854, 1569, 1540, 1505. 
 
5-(3-Formylphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide (40a) 
The title compound was prepared by reaction of 5-bromo-N-methyl-N-(3-
methylphenyl)thiophene-2-carboxamide12a(620 mg, 2.0mmol), m-formylphenylboronic 
acid(450 mg, 3.0mmol), cesium carbonate (1.955 g, 6mmol) and 
tetrakis(triphenylphosphine) palladium (46 mg, 0.02 eq) according to method B. The residue 
was purified by recrystallization in EtOH/water to afford the desired product as pale brown 
solid (250 mg, 37 %). C20H17NO2S; MW 335; MS (ESI) 336 [M+H]
+
; 
1
H NMR (CDCl3, 500 
MHz)δ2.38 (s, 3H), 3.45 (s, 3H), 6.60 (d, J = 4.1 Hz, 1H), 7.05 (d, J = 3.9 Hz, 1H), 7.06 – 
7.11 (m, 2H), 7.20 – 7.23 (m, 1H), 7.31 (t, J = 7.7 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 7.74 
(ddd, J = 1.2, 1.9, 7.9 Hz, 1H), 7.78 (dt, J = 1.8, 7.6 Hz, 1H), 7.98 (t, J = 1.6 Hz, 1H), 10.01 
(s, 1H); 
 13
C NMR (CDCl3, 125 MHz) δ 21.3, 39.1, 123.7, 125.0, 126.7, 128.4, 129.1, 129.2, 
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129.6, 129.7, 131.6, 132.8, 134.7, 136.9, 138.4, 140.0, 144.0, 146.9, 162.2, 191.8. IR (cm
-1
) 
: 3083, 3055, 2922, 2840, 1694, 1601, 1584.  
 
5-[3-(Hydroxymethyl)phenyl]-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide 
(40) 
To a solution of 5-(3-formylphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-
carboxamide 40a (76 mg, 0.23 mmol) in a mixture of dry MeOH (3 mL) and dry dioxane (3 
mL) was added at 0°C sodium borohydride (87 mg, 0.46 mmol). After 2 hours at 0°C, water 
was added to quench the reaction. The aqueous layer was extracted three times with EtOAc 
(3 × 5 mL). The organic layer was washed once with saturated solution of NaHCO3 and 
once with water, dried over MgSO4, filtered and the solution was concentrated under 
reduced pressure. The residue was purified by preparative HPLC (using acetonitrile/water 
from 10% to 95% of acetonitrile) to afford the desired product as colorless oil (14 mg, 18 
%). C20H19NO2S; MW 337; MS (ESI) 338 [M+H]
+
; 
1
H NMR (CDCl3, 300 MHz)δ 2.38 (s, 
3H), 3.44 (s, 3H), 4.71 (s, 2H), 6.58 (d, J = 4.0 Hz, 1H), 6.97 (d, J = 4.0 Hz, 1H), 7.06 – 
7.09 (m, 2H), 7.19 – 7.22 (m, 1H), 7.28 – 7.36 (m, 3H), 7.41 (dt, J = 1.8, 7.2 Hz, 1H), 7.49 
– 7.51 (m, 1H); 13C NMR (CDCl3, 75 MHz)δ21.3, 39.1, 65.0, 122.9, 124.5, 125.0, 125.2, 
126.8, 128.5, 129.0, 129.1, 129.6, 132.9, 133.9, 137.4, 139.9, 141.7, 144.1, 148.7, 162.5.IR 
(cm
-1
) : 3397, 3027, 2921, 2865, 1598, 1582. 
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b) NMR spectra of representative compounds 
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Compound 13: 
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Compound 21: 
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Compound 31: 
 
0602emg155.001.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
3.363.323.211.001.061.032.123.271.101.11
7
.3
5
7
.3
3
7
.2
1
7
.2
0
7
.1
9
7
.1
8
6
.7
4
6
.7
4
6
.6
7
6
.6
6
3
.3
7
2
.3
8 2
.3
0
0602emg155.001.001.1r.esp
7.45 7.40 7.35 7.30 7.25 7.20 7.15 7.10 7.05 7.00 6.95 6.90 6.85 6.80 6.75 6.70 6.65 6.60
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1.001.061.032.123.271.101.11
7
.3
6
7
.3
5
7
.3
3
7
.2
6
7
.2
6
7
.2
2
7
.2
2
7
.2
1
7
.2
1
7
.2
1
7
.2
0
7
.1
9
7
.1
9
7
.1
8
7
.1
8
7
.1
0
7
.0
9
7
.0
9
7
.0
9
7
.0
9
7
.0
1
7
.0
1
7
.0
1
7
.0
1
7
.0
0
6
.7
4
6
.7
4
6
.6
7
6
.6
6
Results 
 
83 
 
0602emg155.002.001.1r.esp
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1
5
9
.0
9
1
5
5
.8
0
1
4
8
.2
3
1
4
5
.8
7
1
4
0
.3
2
1
3
9
.2
2
1
3
0
.7
1
1
3
0
.2
2
1
2
9
.9
2
1
2
9
.5
0
1
2
9
.0
2
1
2
8
.8
3
1
2
5
.4
0
1
2
5
.2
9
1
2
2
.3
0
1
1
9
.4
0
1
0
7
.1
3
3
8
.6
6 2
1
.3
3
Compound 35: 
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Compound 39a: 
EP281.001.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
2.962.912.852.880.920.970.961.971.000.980.97
7
.6
2
7
.4
5 7
.3
3
7
.3
0
7
.2
4
7
.1
9
7
.1
2
3
.6
2
3
.5
3
2
.5
2
2
.4
6
Results 
 
87 
 
EP281.001.001.1r.esp
7.70 7.65 7.60 7.55 7.50 7.45 7.40 7.35 7.30 7.25 7.20 7.15 7.10 7.05
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
0.920.970.961.971.000.980.97
7
.6
2
7
.5
9 7
.5
6
7
.4
7
7
.4
5
7
.4
2
7
.3
5 7
.3
3
7
.3
3
7
.3
1 7
.3
0
7
.2
4
7
.1
9
7
.1
7
7
.1
4
7
.1
2
EP281.002.001.1r.esp
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1
6
3
.7
4
1
5
6
.3
1
1
4
6
.1
6
1
4
5
.5
1
1
3
9
.6
6
1
3
9
.1
3
1
3
4
.6
0
1
3
0
.0
6
1
2
9
.9
1
1
2
9
.1
1
1
2
7
.8
4
1
2
7
.5
4
1
2
6
.6
6
1
2
4
.2
2
1
2
3
.2
3
1
1
6
.0
5
1
1
3
.0
9
5
8
.5
6
3
8
.2
7
2
1
.3
4
 
 
 
 
 
 
 
 
Results 
 
88 
 
 
Compound 40: 
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Abstract 
Design and synthesis of a new class of inhibitors for the treatment of osteoporosis and its 
comparative h17β-HSD2 and m17β-HSD2 SAR study are described. 17a is the first 
compound to show strong inhibition of both h17β-HSD2 and m17β-HSD2, intracellular 
activity, metabolic stability, selectivity toward h17β-HSD1, m17β-HSD1 and estrogen 
receptors α and β as well as appropriate physicochemical properties for oral bioavailability. 
These properties make it eligible for pre-clinical animal studies, prior to human studies. 
Introduction 
Osteoporosis is a common, age-related disease, characterized by a systemic impairment of 
bone mass and microarchitecture, increasing bone fragility and risk of fractures[1]. It has 
been shown that the drop in 17β-estradiol (E2) and testosterone (T) levels, occurring with 
ageing, is the main factor driving the onset and progression of this disease[2]. 17β-
Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyzes the conversion of the highly 
active E2 and T into the weakly potent 17-ketosteroids estrone (E1) and Δ4-androstene-
3,17-dione (Δ4-AD), respectively[3]. It is expressed in osteoblastic cells [4], therefore its 
inhibition can lead to the desired increase of E2 and T levels in the bone tissue and may thus 
be a novel approach for the treatment of osteoporosis. 
Some steroidal[5-7] and non steroidal[8, 9] 17β-HSD2 inhibitors are already described. In 
our group we also developed and reported about several classes of non-steroidal 17β-HSD2 
inhibitors[10-14], with a strong inhibition of human 17β-hydroxysteroid dehydrogenase 
type 2 (h17β-HSD2) and a good selectivity toward h17β-HSD1. Since h17β-HSD1 is the 
biological counterpart of h17β-HSD2, catalyzing the opposite conversion, selectivity toward 
this enzyme is an important feature to take into consideration. Potent and selective h17β-
HSD1inhibitors have also been described for the treatment of estrogen-dependent 
diseases[15, 16]. 
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Given that the most commonly used animal model for osteoporosis studies are established 
in rodents[17, 18], we aimed at the development of new inhibitors displaying a good 
inhibition of mouse 17β-hydroxysteroid dehydrogenase type 2 (m17β-HSD2) and a 
reasonable selectivity toward m17β-HSD1. In order to have a compound suitable for animal 
testing and following human studies, the designed inhibitors should also display h17β-
HSD2 inhibitory activity and selectivity toward h17β-HSD1. Other characteristics to be 
implemented are preferably low affinity to the estrogen receptors (ERs) α and βin order 
tomaximize the E2 local effect and to minimize systemic adverse effects as well as 
metabolic stability. 
Since the 3D-structure for both human and mouse 17β-HSD2 is up to date not available a 
ligand based approach was chosen for the design of new inhibitors. A set of h17β-HSD2 
inhibitors was selected and tested for m17β-HSD2 inhibitory activity in order to get insight 
in the SAR and tracking the lead for the rational design of new inhibitors. 
RESULTS AND DISCUSSION 
h17β-HSD2, h17β-HSD1, m17β-HSD2 and m17β-HSD1 cell-free assays were performed 
similarly, by incubating enzyme, tritiated substrate, cofactor and inhibitor, according to 
described procedures[19-22]. 
As starting point 25 previously described h17β-HSD2 inhibitors (Fig. 1), belonging to the 
2,5-thiophene amide, 1,3-phenyl amide and 1,4-phenyl amide class[12-14], were tested for 
m17β-HSD2 inhibition, in order to elaborate a comparative SAR and to develop an 
optimization strategy. 
 
Fig 1. Previously described h17β-HSD2 inhibitors, tested form17β-HSD2 inhibition. 
IC50 or percent of inhibition values for both h17β-HSD2 and m17β-HSD2 are given (Table 
1, compounds 1a-2g, 3a, 4a-4f) to facilitate comparison. 
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Table 1. Inhibition of Human and Mouse 17β-HSD2 by 2,5-Thiophene Amide, 1,3-
Phenyl Amide and 1,4-Phenyl Amide Derivatives in a Cell-Free Assay.  
 IC50 (nM)
a
 or % inh. at 1 µM
a, d
 
Cmpd R1 R2 h17β-HSD2
b 
m17β-HSD2c 
1a 3-OMe 3-OMe 68 29% 
1b 3-Me 3-Me 52 42% 
1c 3-Me 3-OMe 58 30% 
1d 2-OMe 3-OMe 490 19% 
1e 3-OH 3-OH 33% n.i. 
1f 2-OH 3-OH 410 18% 
1g 3-N(Me)2 3-OMe 170 40% 
1h 3-F 3-OMe 510 n.i. 
1i 4-CN 3-OMe 48% n.i. 
1j 2-F, 3-OMe 3-OMe 62 26% 
1k 2-F, 3-OMe 3-Me 62 45% 
2a 2-F, 3-OMe 3-OH 61 65% 
2b 3-OMe 3-OMe 370 16% 
2c 3-OH 3-OH 390 26% 
2d 4-OH 3-OH 330 35% 
2e 3-Me 3-OH 160 45% 
2f 3-F 3-OH 330 37% 
2g 4-CN 3-OH n.i. n.i. 
3a 3-Me 3-Me 1100 50% 
4a 3-OMe 3-OMe 520 25% 
4b 4-OMe 3-OMe 1200 11% 
4c 3-OH 3-OH 35% n.i. 
4d 3-OMe 3-OMe 11% n.i. 
4e 3-OH 3-OH 640 29% 
4f 4-OH 3-OH 480 22% 
aMean value of at least two determinations, standard deviation less than 20%. bHuman placental microsomal fraction, substrate E2 
[500 nM], cofactor NAD+ [1500 µM]. cMouse liver microsomal fraction, substrate E2 [500 nM], cofactor NAD+ [1500 µM]. dn.i.: no 
inhibition, i.e., inhibition ≤10%. 
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In the 2,5-thiophene amide class (compounds 1a-2g), h17β-HSD2 inhibitors[13, 14], a 
broad range of inhibitory activities was detected, depending on the substitution pattern; the 
most active compounds show IC50 values around 60 nM (Table 1). Conversely, the 
inhibitory activity towards m17β-HSD2 was only marginally affected by these changes 
(inhibitory activity around 30% at 1 µM). Only compound 2a shows a more pronounced 
m17β-HSD2 inhibition combined with good inhibition of the human enzyme (65% at 1 µM 
and IC50 = 61 nM). Unfortunately, compound 2a turned out to be metabolically very 
unstable, with a half-life of only 4 minutes in the human liver S9 fraction[13]. In a further 
screening, all the tested 2,5-thiophene amide displayed a high metabolic instability [13]. 
It is striking that neither the nature of substituents on ring A and C or their substitution 
pattern does appear to exert an effect on m17β-HSD2 inhibition, whereas it is decisive for 
the h17β-HSD2 one. This result suggests that the inhibitors in this class are likely to have 
different binding modes in the two enzyme isoforms. 
Exchange of the central thiophene by a 1,3-disubstituted phenyl led to compounds 4a-4c for 
n = 0 and 4d-4f for n = 1, with weak inhibitory activity towards both the human and the 
mouse enzyme (Table 1). 
In contrast, compound 3a (Table 1), bearing a 1,4-disubstituted phenyl moiety as central 
ring, shows moderate inhibition of both h17β-HSD2 and m17β-HSD2 and also revealed 
exceptional metabolic stability in the human liver S9 fraction, with a half-life time>120 
minutes[13]. It was therefore taken as starting point for the design of a small library of 
inhibitors where the substitution pattern and the physicochemical nature of substituents on 
the A and C rings was varied (Fig. 2). Compounds 25a and 25 were also synthesized to 
investigate the effect of the methylene linker between the amide function and the C ring. 
 
Fig. 2.Chemical Structures of the Designed Compounds 
The synthesis of the 1,4-phenyl derivatives 5a-23a, 25a, 7and 25, depicted in Fig. 3, was 
accomplished following a two- or three-step reaction pathway. 
First, amidation was carried out by reaction of the commercially available 4-bromobenzoyl 
chloride 5d with substituted anilines 5c or with the1-(3-methoxyphenyl)-N-
methylmethanamine25cusing standard conditions (method A: triethylamine, 
dichloromethane, from 0 °C to room temperature, overnight) affording the brominated 
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intermediates 5b, 6b and 11b in almost quantitative yields. Subsequently, Suzuki coupling 
(Method B) using tetrakis(triphenylphosphine)palladium and cesium carbonate in a mixture 
of DME/EtOH/H2O (1:1:1,3 mL) as solvent and microwave irradiation (150°C, 150 W for 
20 minutes), provided the biphenyl derivatives 5a-21a and 25a, and the 1,3-benzodioxole 
derivatives 22a and 23a in good yields. Compounds 7a and 25a were submitted to ether 
cleavage using boron trifluoride-dimethyl sulfide complex, yielding the hydroxylated 
molecules 7 and 25. 
 
 
 
Fig. 3. Synthesis of 1,4-Phenyl Derivatives 5a-23a, 25a, 7, 25. 
Reagents and conditions: (i) Et3N, CH2Cl2, room temperature, overnight; (ii) 
DME/EtOH/H2O (1:1:1), Cs2CO3, Pd(PPh3)4, microwave irradiation (150°C, 150W, 20 
min); (iii) BF3·SMe2, CH2Cl2, room temperature, overnight. 
The synthesis of the retroamide24a, displayed in Fig. 4, follows a two-step procedure. First 
the commercially available 3-methoxybenzoyl chloride 24c was reacted with 4-bromo-N-
methyl aniline 24d according to method A and afforded the brominated intermediate 24b 
with 70% yield. Subsequently, Suzuki coupling following method B afforded compound 
24a in 68% yield. 
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Fig. 4. Synthesis of 1,4-Phenyl Retroamide Derivative 24a. 
Reagents and conditions: (i) Et3N, CH2Cl2, room temperature, overnight; (ii) DME/EtOH/H2O 
(1:1:1), Cs2CO3, Pd(PPh3)4, microwave irradiation (150°C, 150W, 20 min). 
Compounds 5a-25a, 7 and 25 were tested for h17β-HSD2, m17β-HSD2 and h17β-HSD1 
inhibition (Table 2, results expressed as percentage of inhibition or IC50 value). 
Compounds 18a and 24a were not tested for inhibition of m17β-HSD2, due to their low 
inhibitory activity towards the human enzyme. Among the different synthesized 1,4-
biphenyl amides without methylene linker (n=0, Table 2, compounds 5a-21a), the best 
h17β-HSD2 inhibitory activity and selectivity toward h17β-HSD1 was achieved for 
compounds 6a, 7a and 17a (Table 2, IC50 values between 260 and 330nM, s.f. between 20 
and 44), showing that a 3-OMe-group on ring C in combination with either a 3-OMe- or a 3-
Me-group on ring A leads to a maximum in potency and selectivity in this series of 
compounds. 
The presence of a methyl group in 4-position of ring A is tolerated by the h17β-HSD2 
(compound 17a, IC50 = 310nM) and increases the selectivity toward h17β-HSD1 (17a: s.f. 
44; 6a: s.f. 25). In contrast, compound 16a bearing a 3,4-dimethoxy substituted A ring 
displays a slight decrease in h17β-HSD2 inhibitory activity if compared to the 
corresponding compound 7a with only one methoxygroup on that ring. The rigidification of 
the two methoxy substituents by the synthesis of a 1,3-benzodioxole ring (compounds 22a 
and 23a) could not overcome the drop in potency.Compounds 6a, 7a and 17a displayed the 
strongest m17β-HSD2 inhibitory activity (IC50 = 260, 290 and 140 nM, respectively). 
In general, the introduction of methyl- or methoxy-groups, especially in the 3-positions of 
rings A and B, had a positive impact on inhibitory activity, which is similar for both 17β-
HSD2 isoforms (Table 2). Therefore, inhibitors belonging to the 1,4-phenyl class are likely 
to bind in a conserved area common to both enzymes, in contrast to the 2,5-thiophene amide 
class. As 17β-HSD2 belongs to the SDR superfamily, characterized by the conserved 
Rossmann fold and catalytic triad[23], it is possible that these inhibitors bind in or very 
close to this region. Furthermore, since compounds 6a and 17a lack the two oxygen 
functions to mimic the E2 interactions with the enzyme, they are likely to bind to the active 
site in an alternative mode, significantly influenced by the methyl substitution patterns. 
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Table 2. Inhibition of h17β-HSD2, m17β-HSD2 and h17β-HSD1 by Biphenyl Amide 
Derivatives with Different Substitution Patterns on the A and C Rings in Cell-Free 
System. 
 IC50 (nM)
a
or % inh. at 1 µM
a, c
  IC50 (nM)
a
or % inh. at 1 µM
a, c
 
Cmpd R1 R2 h17β-HSD2
b
 h17β-HSD1c s. f.d,f m17β-HSD2f,g 
3a 3-Me 3-Me 1100 11500 10 50% 
5a 3-OMe 3-Me 44% n.i. n.d. 56% 
6a 3-Me 3-OMe 260 6400 25 260 
7a 3-OMe 3-OMe 330 6400 20 290 
8a -H 3-OMe 51% 22% n.d. 48% 
9a 2-OMe 3-OMe 50% n.i. n.d. 33% 
10a 4-OMe 3-OMe 710 27000 38 66% 
11a 3-OMe 4-OMe 27% n.i. n.d. 58% 
12a 4-OMe 4-OMe 19% n.i. n.d. 62% 
7 3-OH 3-OH 36% 15% n.d. 42% 
13a 3-F 3-OMe 1000 8000 8 57% 
14a 3-Cl 3-OMe 950 12600 13 73% 
15a 3-N(Me)2 3-OMe 650 5000 8 67% 
16a 3-OMe,4-OMe 3-OMe 520 85500 164 52% 
17a 3-Me,4-Me 3-OMe 300 13300 44 140 
18a 3-F,4-F 3-OMe 31% n.i. n.d. n.d. 
19a 2-F, 3-OMe 3-OMe 64% 35% n.d. 67% 
20a 2-F, 3-Me 3-OMe 460 11300 24 48% 
21a 2-F, 3-Me 3-Me 330 3710 11 56% 
22a - 3-OMe 51% n.i. n.d. 56% 
23a - 3-Me 560 10900 20 70% 
24a - - 11% n.i. n.d. n.d. 
25a 2-F, 3Me 3-OMe 310 87000 283 43% 
25 2-F, 3-Me 3-OH 260 31000 118 190 
aMean value of at least two determinations, standard deviation less than 20% except for 11a (hHSD2): 26%, 7(hHSD1):25%,. 
bHuman placental, microsomal fraction, substrate E2[500 nM], cofactor NAD+[1500 µM]. cHuman placental, cytosolic fraction, 
substrate E1[ 500 nM], cofactor NADH[500 µM]. ds.f. (selectivity factor)=IC50(17β-HSD1)/IC50(17β-HSD2). 
en.i.: no inhibition 
(inhibition of <10%).fn.d.: not determined. gMouse liver microsomal fraction, substrate E2 [500 nM], cofactor NAD+ [1500 µM]. 
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Compounds with a methylene linker 25a and 25 (Table 2), showed h17β-HSD2 inhibitory 
activity in the same order of magnitude as the corresponding derivative 20a lacking the 
methylene group, but displayed improved selectivities over h17β-HSD1. In contrast to what 
was observed for human 17β-HSD2, compounds 25a and 25 showed a significant difference 
in terms of m17β-HSD2 inhibition, indicating that the hydroxy group of compound 25 might 
function as H-bond donor in the interaction with the enzyme. 
The 1,4-phenyl amides are likely to be competitive inhibitors, as derivatives with a similar 
structure were found to inhibit the enzyme following this mode of action. 
The most potent m17β-HSD2 inhibitors 6a-8a, 10a, 14a, 15a, 17a, 19a, 21a, 23a and 25 
were also tested for their m17β-HSD1 inhibitory activity. None of the tested compounds 
showed any inhibition of m17β-HSD1 at a concentration of 1 µM, indicating a strong 
selectivity toward this enzyme. 
The inhibitory activity of compounds 6a, 17a and 25 was also evaluated in the human 
mammary cell line MDA-MB-231 containing endogenous 17β-HSD2 (Table 3). The 
compounds were tested at 250 nM and 1250 nM, representing approximately the 
IC50observed in the cell-free assay, and its 5-fold value. As displayed in Table 3, all three 
compounds showed an inhibition between 60% and 67%at the lower concentration and 
approximately 90% inhibition at the higher concentratio indicating that the inhibitors can 
permeate the membrane and are able to inhibit the enzyme in a concentration dependent 
manner. 
Table 3.Human 17β-HSD2 Cellular Inhibition of Compounds 6a, 17a and 25. 
Cmpd % inh
b
 HSD2
a
 at 250 nM % inh
b
 HSD2
a
 at 1250 nM 
6a            60            87 
17a            66            90 
25            67            88 
aMDA-MB-231 cell line, substrate E2[200 nM]. bMean value of two determinations, standard deviation less than 15%. 
Compounds 6a, 7a, 17a, 21a, 25a and 25 were tested for their affinity toward the ERs α and 
β according to described methods[24] (assay details are available in the Supporting 
Information).Even when applied in a 1000-fold excess relative to E2, no inhibitor was able 
to displace more than 20% of the steroid from the corresponding receptor, indicating a very 
low binding affinity to the ERs. 
The metabolic stabilities of the most active compounds6a,17a and 25 were evaluated using 
human liver microsomes (S9 fraction). In addition, compounds 5a, 14a, 20a and 25a were 
also tested in order to investigate whether structure modifications might exert an effect on 
metabolic stability (Table 4, assay details are available in the Supporting Information). All 
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compounds, except 25, revealed a very high stability, which was not influenced by the 
nature of the substituents. Compound 25, exhibiting a short half-life, bears a hydroxy group, 
potentially susceptible to phase ΙΙ metabolism. Interestingly, all the tested inhibitors from 
the 1,4-phenyl amide class, for n= 0, demonstrated high metabolic stability, which 
seemingly constitutes a positive feature of the whole class. As species differences for the 
metabolism of drugs that are not or only partly metabolized are usually small [25], sufficient 
metabolical stability in species other than human can be anticipated. 
Table 4. Half-life in Human Liver Microsomes S9 Fraction of Representative 
Compounds 3a, 5a, 6a, 14a, 17a, 20a, 25a and 25. 
Cmpd R1 R2 Inhibitor
c
 t1/2(min)
a,b
 
3a 3-Me 3-Me >120 
5a 3-OMe 3-Me 116 
6a 3-Me 3-OMe 106 
14a 3-Cl 3-OMe 82 
17a 3-Me,4-Me 3-OMe 107 
20a 2-F, 3-Me 3-OMe 104 
25a 2-F, 3-Me 3-OMe 103 
25 2-F, 3-Me 3-OH 6 
aMean of at least two determinations, standard deviation less than 25%. b1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 
2 mM NADPH regenerating system, 1 mM UDPGA and 0.1 mM PAPS at 37°C for 0, 5, 15 and 60 minutes. cInhibitor tested at a 
final concentration of 1 µM. 
CONCLUSION 
The aim of this work was the design of a compound, which should be suitable for 
application in both an animal model of osteoporosis and in humans. We report here the 
discovery of compound 17a, which is the first to show an appropriate profile for this 
purpose, with strong inhibition of both human and mouse 17β-HSD2 and selectivity toward 
the respective type 1 enzymes and the ERs. It also displayed good cellular inhibitory 
activity, high metabolic stability and good physicochemical parameters (MW= 345 and 
cLogP = 4.75)predictor for good oral bio-availability[26]. A comparative SAR study for 
h17β-HSD2 and m17β-HSD2 is also described for the 1,4-phenyl and the 2,5-thiophene 
classes of inhibitors, revealing that only compounds belonging to the first series similarly 
inhibit the two enzymes, probably through a similar binding mode. The species specific 
characterization of the thiophene and the phenyl derivatives pointed out the superiority of 
the latter class of inhibitors, which is able to equally inhibit the two isoenzymes and 
additionally displays a high metabolic stability. In vivo assays in a mouse osteoporosis 
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model will be carried out soon and the results reported in due course in a specialized journal 
dealing with bone diseases. 
Materials and Methods 
Chemical Methods 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from 
Aldrich, Acros, Combi-Blocks or Fluorochem and were used without purification.Column 
chromatography was performed on silica gel (70-200 μm) and reaction progress was 
monitored by TLC on Alugram SIL G/UV254 (Macherey-Nagel). Visualization was 
accomplished with UV light.
1
H NMR and 
13
C NMR spectra were measured on a Bruker 
AM500 spectrometer (at 500 MHz and 125 MHz, respectively) at 300 K and on Bruker 
Fourier 300 (at 300 MHz and 75 MHz, respectively) at 300K. Chemical shifts are reported 
in δ(parts per million: ppm), by reference to the hydrogenated residues of deuteriated 
solvent as internal standard: 2.05 ppm (
1
H NMR) and 29.8 and 206.3 ppm (
13
C NMR) for 
CD3COCD3, 7.26 ppm (
1
H NMR) and 77.0 ppm (
13
C NMR) for CDCl3. Signals are 
described as br (broad), s (singlet), d (doublet), t (triplet), dd (doublet of doublets), ddd 
(doublet of doublet of doublets), dt (doublet of triplets) and m (multiplet). All coupling 
constants (J) are given in Hertz (Hz).  
Melting points (mp) were measured in open capillaries on a Stuart Scientific SMP3 
apparatus and are uncorrected. 
Mass spectrometry was performed on a TSQ Quantum (ThermoFisher, Dreieich, Germany). 
The triple quadrupole mass spectrometer was equipped with an electrospray interface (ESI). 
The Surveyor-LC-system consisted of a pump, an auto sampler, and a PDA detector. The 
system was operated by the standard software Xcalibur. A RP C18 NUCLEODUR 100-5 (3 
mm) column (Macherey-Nagel GmbH, Dühren, Germany) was used as stationary phase. All 
solvents were HPLC grade. In a gradient run(acetonitrile/water) the percentage of 
acetonitrile (containing 0.1 % trifluoroacetic acid) was increased from an initial 
concentration of 0 % at 0 min to 100 % at 15 min and kept at 100 % for 5 min. The injection 
volume was 15 µL and flow rate was set to 800 µL/min. MS analysis was carried out at a 
needle voltage of 3000 V and a capillary temperature of 350 °C. Mass spectra were acquired 
in positive mode from 100 to 1000 m/z and UV spectra were recorded at the wave length of 
254 nm and in some cases at 360 nm.  
All microwave irradiation experiments were carried out in a 507 CEM-Discover microwave 
apparatus. 
All tested compounds exhibited ≥ 95% chemical purity as measured by LC/MS. 
The following compounds were prepared according to previously described procedures: 4-
bromo-N-methyl-N-(m-tolyl)benzamide7a[13]. 
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Method A, general procedure for amide formation 
To a solution of bromobenzoylchloride (2 mmol) was added the corresponding N-
methylaniline (2 mmol) followed by Et3N (2 mmol) in CH2Cl2 (10 mL) at 0°C. After a few 
minutes, the ice bath was removed and the reaction mixture was warmed up to room 
temperature and stirred at room temperature overnight. The reaction mixture was extracted 
twice with CH2Cl2 (2 × 15 mL). The organic layer was dried over MgSO4, filtered and the 
solution was concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography using hexanes and EtOAc as eluent or by trituration in a mixture of 
diethyl ether / petroleum ether to afford the desired compound. 
Method B, general procedure for Suzuki-Miyaura coupling 
In a sealed tube the previously prepared bromo-N-heteroarylcarboxamide derivative (1 eq.) 
was introduced, followed by the corresponding boronic acid (1.5 eq.), cesium carbonate (3 
eq.), tetrakis(triphenylphosphine)palladium (0.02 eq.) and a mixture of DME/EtOH/H2O 
(1:1:1, v:v:v, 3 mL) as solvent. The reactor was flushed with N2 and submitted to 
microwave irradiation (150°C, 150 W) for 20 minutes. After cooling to room temperature, a 
mixture of EtOAc/H2O (1:1, v:v, 2 mL) was added to stop the reaction. The aqueous layer 
was extracted with EtOAc (3 × 10 mL). The organic layer was washed once with brine and 
once with water, dried over MgSO4, filtered and the solution was concentrated under 
reduced pressure. The residue was purified by column chromatography using hexanes and 
EtOAc as eluent to afford the desired compound. 
Detailed synthesis procedures of the compounds 
4-Bromo-N-(4-methoxyphenyl)-N-methylbenzamide(11b)The title compound was 
prepared by reaction of 4-bromobenzoyl chloride(5c)(1272 mg, 5.8mmol) and 4-methoxy-
N-methylaniline(11d) (400 mg, 2.9mmol) according to method A. The residue was purified 
by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product 
as yellow solid (932 mg, 99%). C15H14BrNO2; MW 320; mp: 61 – 62°C; MS (ESI) 320, 322 
[M]
+
; IR (cm
-1
) 1635, 2840, 2850, 2917;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 3.36 (s, 
3H), 3.74 (s, 3H), 6.82 (d, J = 9.0 Hz, 2H), 7.09 (d, J = 9.0 Hz, 2H), 7.23 (d, J = 8.0 Hz, 
2H), 7.38 (d, J = 8.0 Hz, 2H); 
13
C NMR (C2D6CO, 125 MHz) δ (ppm) 38.5, 55.7, 115.2, 
123.7, 129.3, 131.4, 131.6, 137.1, 138.6, 159.1, 169.5. 
4-Bromo-N-(3-methoxyphenyl)-N-methylbenzamide (6b)The title compound was 
prepared by reaction of 4-bromobenzoyl chloride(5c) (1272 mg, 5.8mmol) and 3-methoxy-
N-methylaniline(6d) (400 mg, 2.9mmol) according to method A. The residue was purified 
by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product 
as yellow solid (935 mg, quantitative). C15H14BrNO2; MW 320; mp: 98 – 100°C; MS (ESI) 
320, 322 [M]
+
; IR (cm
-1
) 1638, 2840, 2945, 3012;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 
3.40 (s, 3H), 3.71 (s, 3H), 6.70 – 6.72 (m, 1H), 6.74 – 6.78 (m, 2), 7.17 (t,J = 8.0 Hz, 1H), 
7.26 – 7.28 (m, 2H), 7.39 – 7.41 (m, 2H); 13C NMR (C2D6CO, 125 MHz) δ (ppm) 38.2, 
55.7, 113.2, 113.8, 120.2, 123.9, 130.7, 131.3, 131.6, 137.0, 147.0, 161.2, 169.4. 
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4-Bromo-N-methyl-N-(m-tolyl)benzamide (5b)The title compound was prepared by 
reaction of 4-bromobenzoyl chloride(5c) (724 mg, 3.3mmol) and N-methyl-m-toluidine(5d) 
(200 mg, 1.6mmol) according to method A. The residue was purified by silica gel column 
chromatography (hexanes/EtOAc80:20) to afford the desired product as white solid (500 
mg, 99%). C15H14BrNO; MW 304; mp: 90 – 92 °C; MS (ESI) 304, 306 [M]
+
; IR (cm
-1
) 
1586, 1638, 2853, 2923, 3058;
1
H NMR (C2D6CO, 300 MHz) δ (ppm) 2.24 (s, 3H), 3.39 (s, 
3H), 6.90 – 6.93 (d, J = 8.0Hz, 1H), 6.99 – 7.05 (m, 2H), 7.14 (t,J = 8.0 Hz, 1H), 7.23 – 
7.26 (m, 2H), 7.37 – 7.40 (m, 2H); 13C NMR (C2D6CO, 75 MHz) δ (ppm) 21.2, 38.4, 123.9, 
125.2, 128.1, 128.5, 129.8, 131.4, 131.6, 137.0, 140.0, 145.8, 169.4. 
4-Bromo-N-(3-methoxybenzyl)-N-methylbenzamide (25b)The title compound was 
prepared by reaction of 4-bromobenzoyl chloride(5c) (579 mg, 2.6mmol) and 3-methoxy-N-
methylbenzylamine(25d) (200 mg, 1.3mmol) according to method A. The residue was 
purified by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired 
product as yellow oil(430 mg, 97%).C16H16BrNO2; MW 334; MS (ESI) 334, 336 [M]
+
; IR 
(cm
-1
) 1630, 2834, 2923;
1
H NMR (C2D6CO, 500 MHz) δ(ppm) 2.91 (s, 3H), 3.79 (s, 3H), 
4.52 – 4.70 (m, 2H), 6.76-6.80 (m, 1H), 6.86 (dd, J = 8.8 Hz, 5Hz, 1H), 6.95 (s, 1H), 7.28 (t, 
J = 8.0 Hz, 1H), 7.44 (d, J = 7.6 Hz, 2H), 7.62 (s, 2H); 
13
C NMR (C2D6CO, 125 MHz) 
δ(ppm) 37.2, 51.0, 55.5, 113.3, 113.6, 114.4, 119.7, 121.0, 123.9, 129.9, 130.5, 132.3, 
137.0, 161.1. 
N-(4-bromophenyl)-3-methoxy-N-methylbenzamide (24b)The title compound was 
prepared by reaction of 3-methoxybenzoyl chloride(24c) (336 mg, 2.0mmol) and 4-bromo-
N-methylaniline(24d) (367 mg, 2.0mmol) according to method A. The residue was purified 
by silica gel column chromatography (hexanes/EtOAc80:20) to afford the desired product 
as white solid (440 mg, 70%). C15H14BrNO2; MW 320; mp: 97 – 100°C; MS (ESI) 320, 322 
[M]
+
; IR (cm
-1
) 1634, 2834, 2929, 3009;
1
H NMR (C2D6CO, 300 MHz) δ(ppm) 3.41 (s, 3H), 
3.69 (s, 3H), 6.84 – 6.88 (m, 3H), 7.12 – 7.17 (m, 3H), 7.44 – 7.47 (m, 2H); 13C NMR 
(C2D6CO, 75 MHz) δ(ppm) 38.3, 55.6, 114.8, 116.3, 120.1, 121.7, 129.8, 130.0, 133.1, 
138.8, 145.7, 160.1, 170.3. 
N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (8a)The title compound 
was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-methylbenzamide(6b)(80 
mg, 0.25mmol), phenylboronic acid (40 mg, 0.33mmol), cesium carbonate (244 mg, 
0.75mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 6 mg) in DME/EtOH/H2O 
(1/1/1/, 3 mL) according to method B. The residue was purified by silica gel column 
chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow solid (77 
mg, 97%). C21H19NO2; MW 317; mp: 102 – 104°C; MS (ESI) 318 [M+H]
+
; IR (cm
-1
) 1588, 
1636, 2831, 2917, 2960, 3040;
1
H NMR (C2D6CO, 300 MHz) δ (ppm) 3.44 (s, 3H), 3.70 (s, 
3H), 6.72 – 6.77 (m, 2H), 6.80 (t,J= 2 Hz, 1H), 7.17 (t,J = 8 Hz, 1H), 7.33 – 3.37 (s, 1H), 
7.41 – 7.46 (m, 4H), 7.51 – 7.54 (m, 2H), 7.60 – 7.63 (m, 2H); 13C NMR (C2D6CO, 75 
Results 
 
102 
 
MHz) δ (ppm) 38.4, 55.7, 113.0, 113.8, 120.1, 126.9, 127.7, 128.6, 129.8, 130.1, 130.6, 
136.7, 140.8, 142.6, 147.4, 161.2, 170.2. 
2'-Methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (9a)The 
title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (112 mg, 0.35mmol), 2-methoxyphenylboronic acid (70 mg, 
0.46mmol), cesium carbonate (342 mg, 1.05mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 8 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as colorless 
oil (113 mg, 93%). C22H21NO3; MW 347; MS (ESI) 348 [M+H]
+
; IR (cm
-1
) 1597, 1640, 
2837, 2939;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 3.44 (s, 3H), 3.69 (s, 3H), 3.77 (s, 3H), 
6.73 – 6.78 (m, 3H), 6.99 (dt, J = 1.0, 7.3 Hz, 1H), 7.07 (dd, J = 1.0, 8.3 Hz, 1H), 7.18 (dt, J 
= 1.0, 7.5 Hz, 1H), 7.24 (dd, J = 2.0, 7.5 Hz, 1H), 7.30 – 7.34 (m, 1H), 7.35 – 7.39 (m, 4H); 
13
C NMR (C2D6CO, 125 MHz) δ (ppm) 38.4, 55.6, 55.9, 112.5, 113.0, 113.7, 120.0, 121.7, 
129.1, 129.5, 130.0, 130.4, 130.6, 131.3, 136.0, 140.7, 147.4, 157.5, 161.1, 170.4. 
3'-Methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (7a)The 
title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (81 mg, 0.25mmol), 3-methoxyphenylboronic acid (46 mg, 
0.3mmol), cesium carbonate (247 mg, 0.75mmol) and tetrakistriphenylphosphine palladium 
(0.02 eq., 6 mg) according to method B. The residue was purified by silica gel column 
chromatography (hexanes/EtOAc70:30) to afford the desired product as white solid (74 mg, 
85%). C22H21NO3; MW 347; mp: 131– 134°C; MS (ESI) 348 [M+H]
+
; IR (cm
-1
) 1582, 
1635, 2837, 2941, 2963;
1
H NMR (C2D6CO, 500 MHz) δ(ppm) 3.43 (s, 3H), 3.70 (s, 3H), 
3.84 (s, 3H), 6.73 – 6.76 (m, 2H), 6.80 – 6.81 (m, 1H), 6.92(ddd, J = 1.0, 2.0, 8.0 Hz, 1H), 
7.14 – 7.19 (m, 3H), 7.32 – 7.35 (m, 1H), 7.41 – 7.42 (m, 2H), 7.51 – 7.53 (m, 2H); 13C 
NMR (C2D6CO, 125 MHz) δ(ppm) 38.4, 55.6, 55.7, 113.0, 113.1, 113.8, 114.3, 120.0, 
120.1, 126.9, 130.0, 130.6, 130.8, 136.8, 142.2, 142.5, 147.37, 147.38, 161.2, 170.2. 
3'-Hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (7)To a 
solution of 3'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide 
(7a)(100 mg, 0.29mmol) in CH2Cl2 (10 mL) was added trifluorobromine dimethyl sulphide 
complex BF3.SMe2 (0.36 mL, 3.46 mM) at room temperature. The reaction mixture was 
stirred overnight. The reaction was quenched with MeOH (10 mL). The solvent was 
removed under reduced pressure at 25°C. Water was added to dissolve inorganic salts and 
the precipitate was filtered off and triturated with diethyl ether to afford the desired product 
as white solid (80 mg, 87%). C20H17NO3; MW 319; mp: 168 – 171°C; MS (ESI) 
320[M+H]
+
; IR (cm
-1
) 1589, 3191;
1
H NMR (C2D6CO, 300 MHz) δ(ppm) 3.42 (s, 3H), 6.64 
– 6.68 (m, 3H), 6.82 – 6.86 (m, 1H), 7.07 – 7.12 (m, 3H), 7.26 (t, J = 8.0 Hz, 1H), 7.39 – 
7.44 (m, 2H), 7.47 – 7.49 (m, 2H), 8.42 (s, 1H), 8.48 (s, 1H); 13C NMR (C2D6CO, 75 MHz) 
δ(ppm) 38.4, 114.4, 114.6, 115.0, 115.6, 119.0, 119.1, 126.8, 130.1, 130.7, 130.8, 136.6, 
142.3, 142.7, 147.4, 158.8, 158.9, 170.1. 
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4'-Methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (10a)The 
title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (123 mg, 0.38mmol), 4-methoxyphenylboronic acid (75 mg, 
0.49mmol), cesium carbonate (371 mg, 1.14mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 9 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc80:20) to afford the desired product as white solid 
(70 mg, 53%). C22H21NO3; MW 347; mp: 128 – 130°C; MS (ESI) 348 [M+H]
+
; IR (cm
-1
) 
1601, 1625, 2840, 2935, 2963;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 
3H), 3.82(s, 3H), 6.72 – 6.75 (m, 2H), 6.78 – 6.79 (m, 1H), 6.98 (d, J = 2.3 Hz, 1H), 7.00 (d, 
J = 2.3 Hz, 1H), 7.15 – 7.18 (m, 1H), 7.37 – 7.40 (m, 2H), 7.46 – 7.48 (m, 2H), 7.55 – 7.58 
(m,2H); 
13
C NMR (C2D6CO, 125 MHz) δ (ppm) 38.4, 55.6, 55.7, 112.9, 113.8, 115.2, 
120.1, 126.3, 128.8, 130.1, 130.6, 130.1, 135.9, 142.4, 147.5, 160.7, 161.2, 170.3. 
3'-Fluoro-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (13a)The title 
compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (100 mg,0.31mmol), 3-fluorophenylboronic acid (57 mg, 0.41mmol), 
cesium carbonate (303 mg, 0.93mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 
7 mg) according to method B. The residue was purified by silica gel column 
chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow solid (91 
mg, 89%). C21H18FNO2; MW 335; mp: 97 – 100°C; MS (ESI) 336 [M+H]
+
; IR (cm
-1
) 1587, 
1637, 2834, 2923, 2960;
1
H NMR (C2D6CO, 300 MHz) δ (ppm) 3.44 (s, 3H), 3.71 (s, 3H), 
6.73 – 6.77 (m, 2H), 6.80 – 6.81 (m, 1H), 7.09 – 7.21 (m, 2H), 7.36 – 7.50 (m, 5H), 7.55 – 
7.57 (m, 2H); 
13
C NMR (C2D6CO, 75 MHz) δ (ppm) 38.4, 55.8, 113.1, 113.9, 114.3, 114.6, 
115.2, 115.4, 120.2, 123.7, 127.1, 130.2, 130.8, 131.6, 131.8, 137.4, 141.2, 143.3, 143.4, 
147.4, 161.3, 162.6, 165.8, 170.1. 
3'-Chloro-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (14a)The title 
compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (80 mg, 0.25mmol), 3-chlorophenylboronic acid (52 mg, 0.33mmol), 
cesium carbonate (244 mg, 0.75mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 
6 mg) according to method B. The residue was purified by silica gel column 
chromatography (hexanes/EtOAc70:30) to afford the desired product as colorless oil (47 
mg, 53 %). C21H18ClNO2; MW 352; MS (ESI) 352, 354 [M]
+
; IR (cm
-1
) 1594, 1639, 2837, 
2938;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 3H), 6.73 – 6.76 (m, 2H), 
6.80 – 6.81(m, 1H), 7.17 (t,J = 8 Hz, 1H), 7.38 – 7.40 (m, 1H), 7.43 – 7.47 (m, 3H), 7.54 – 
7.59 (m, 3H), 7.63 – 7.64 (m, 1H); 13C NMR (C2D6CO, 125 MHz) δ (ppm) 38.3, 55.7, 
113.1, 113.8, 120.2, 126.3, 127.0, 127.6, 128.5, 130.1, 130.7, 131.4, 135.3, 137.4, 141.0, 
142.9, 147.3, 161.2, 170.0. 
N-(3-methoxyphenyl)-N,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (6a)The title 
compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (77 mg, 0.24mmol), 3-methylphenylboronic acid (42 mg, 0.31mmol), 
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cesium carbonate (235 mg, 0.72mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 
6 mg) according to method B. The residue was purified by silica gel column 
chromatography (hexanes/EtOAc70:30) to afford the desired product as colorless oil (56 
mg, 71 %). C22H21NO2; MW 331; MS (ESI) 332 [M+H]
+
; IR (cm
-1
) 1586, 1640, 2840, 
2929;
1
H NMR (C2D6CO, 300 MHz) δ(ppm) 3.38 (s, 3H), 3.44 (s, 3H), 3.70 (s, 3H), 6.74 – 
6.76 (m, 2H), 6.79 – 6.80 (m, 1H), 7.15 – 7.20 (m, 2H), 7.31 (t,J = 8 Hz, 1H), 7.39 – 7.43 
(m, 4H), 7.49 – 7.52 (m, 2H); 13C NMR (C2D6CO, 75 MHz) δ(ppm) 21.5, 38.4, 55.7, 113.0, 
113.9, 120.2, 124.9, 126.9, 128.5, 129.4, 129.8, 130.1, 130.7, 136.6, 137.4, 140.9, 142.9, 
147.5, 161.3, 170.3. 
3'-(Dimethylamino)-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide 
(15a)The title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b)(80 mg, 0.25mmol), 3-(dimethylamino)phenylboronic acid (54 mg, 
0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 6 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil 
(49 mg, 54%). C23H24N2O2; MW 360; MS (ESI) 361 [M+H]
+
; IR (cm
-1
) 1597, 1639, 2797, 
2834, 2939;
1
H NMR (C2D6CO, 300 MHz) δ (ppm) 2.97 (s, 6H), 3.43 (s, 3H), 3.70 (s, 3H), 
6.72 – 6.76 (m, 3H), 6.79 –-6.80 (m, 1H), 6.86 – 6.93 (m, 2H), 7.17 (t,J = 8.0 Hz, 1H), 7.23 
(t, J = 8.0 Hz, 1H), 7.38 – 7.41 (m, 2H), 7.49 – 7.52 (m, 2H); 13C NMR (C2D6CO, 75 MHz) 
δ (ppm) 38.5, 40.8, 55.7, 111.8, 113.0, 113.9, 116.0, 120.2, 127.0, 130.0, 130.4, 130.7, 
136.5, 141.6, 143.9, 147.5, 152.2, 161.3, 170.4. 
N-(3-methoxyphenyl)-N,3',4'-trimethyl-[1,1'-biphenyl]-4-carboxamide (17a)The title 
compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (100 mg, 0.31mmol), 3,4-dimethylphenylboronic acid (62 mg, 
0.41mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 7 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil 
(106 mg, 99%). C23H23NO2; MW 345; MS (ESI) 346[M+H]
+
; IR (cm
-1
) 1599, 1640, 2840, 
2914, 2942;
1
H NMR (C2D6CO, 500 MHz) δ(ppm) 2.26 (s, 3H), 2.29 (s, 3H), 3.43 (s, 3H), 
3.70 (s, 3H), 6.73 – 6.75 (m, 2H), 6.79 –-6.80 (m, 1H), 7.15 – 7.19 (m, 2H), 7.32 (dd, J = 
2.0Hz, 8.0Hz, 1H), 7.38 – 7.40 (m, 3H), 7.47 – 7.49 (m, 2H); 13C NMR (C2D6CO, 125 
MHz) δ(ppm) 19.4, 19.8, 38.4, 55.6, 112.9, 113.8, 120.1, 125.0, 126.5, 128.8, 130.0, 130.6, 
131.0, 136.2, 137.0, 137.8, 138.3, 142.8, 147.4, 161.2, 170.3. 
3',4'-Difluoro-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (18a)The 
title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (100 mg, 0.31mmol), 3,4-difluorophenylboronic acid (65 mg, 
0.41mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 7 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil 
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(97 mg, 88%). C21H17F2NO2; MW 353; MS (ESI) 354[M+H]
+
; IR (cm
-1
) 1599, 1639, 2837, 
2948;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 3.43 (s, 3H), 3.70 (s, 3H), 6.73 – 6.76 (m, 2H), 
6.80 –-6.81 (m, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.35 – 7.41 (m, 1H), 7.42 – 7.44 (m, 2H), 7.45 
– 7.48 (m, 1H), 7.52 – 7.54 (m, 2H), 7.56 (dd, J = 2.0 Hz, 8.0 Hz, 1H), 7.60 (dd, J = 2.0 Hz, 
8.0 Hz, 1H); 
13
C NMR (C2D6CO, 125 MHz) δ (ppm) 38.3, 55.7, 113.0, 113.8, 116.6, 116.7, 
118.5, 118.7, 120.2, 124.3, 124.4, 126.9, 130.1, 130.7, 137.3, 140.3, 147.3, 161.2, 170.0. 
3',4'-Dimethoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide 
(16a)The title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (100 mg, 0.31mmol), 3,4-dimethoxyphenylboronic acid (75 mg, 
0.41mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 7 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as white solid 
(83 mg, 71%). C23H23NO4; MW 377; mp: 153 – 156°C; MS (ESI) 378[M+H]
+
; IR (cm
-1
) 
1604, 1635, 2843, 2938, 2969, 3003, 3068;
1
H NMR (C2D6CO, 300 MHz) δ(ppm) 3.51 (s, 
3H), 3.69 (s, 3H), 3.90 (s, 3H), 3.92 (s, 3H), 6.62 – 6.72 (m, 3H), 6.89 – 6.91 (d, J = 8.0 Hz, 
1H), 7.04 – 7.17 (m, 3H), 7.38 (s, 4H); 13C NMR (C2D6CO, 75 MHz) δ(ppm) 38.6, 55.6, 
56.1, 110.4, 111.6, 112.2, 113.0, 119.4, 119.6, 126.1, 129.4, 130.0, 133.2, 134.4, 142.2, 
146.3, 149.2, 149.3, 160.2, 170.5. 
2'-Fluoro-3'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide 
(19a)The title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (80 mg, 0.25mmol), 2-fluoro-3-methoxyphenylboronic acid (56 mg, 
0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 6 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc 90:10) to afford the desired product as brown 
solid (43 mg, 47%). C22H20FNO3; MW 365; mp: 125 – 127°C; MS (ESI) 366[M+H]
+
; IR 
(cm
-1
) 1592, 1644, 2837, 2948, 2975, 3009;
1
H NMR (C2D6CO, 300 MHz) δ(ppm) 3.44 (s, 
3H), 3.70 (s, 3H), 3.90 (s, 3H), 6.72 – 6.81 (m, 3H), 6.95 – 7.00 (m, 1H), 7.10 – 7.20 (m, 
3H), 7.39 –-7.45 (m, 4H); 13C NMR (C2D6CO, 75 MHz) δ(ppm) 38.3, 55.7, 56.6, 113.1, 
113.8, 113.9, 120.1, 122.4, 125.2, 125.3, 129.0, 129.1, 129.6, 130.6, 137.1, 137.5, 147.3, 
161.2, 170.1. 
2'-Fluoro-N-(3-methoxyphenyl)-N,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (20a)The 
title compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (72 mg, 0.22mmol), 2-fluoro-3-methylphenylboronic acid (45 mg, 
0.29mmol), cesium carbonate (215 mg, 0.66mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 5 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow 
solid (70 mg, 91%). C22H20FNO2; MW 349; mp: 91 – 94°C; MS (ESI) 350 [M+H]
+
; IR (cm
-
1
) 1599, 1635, 2840, 2920, 2963, 3055;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 2.29 (d, J = 
2.5 Hz, 3H), 3.44 (s, 3H), 3.70 (s, 3H), 6.73 – 6.77 (m, 2H), 6.79-6.80 (m, 1H), 7.13 (t, J = 
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8.0 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.25 (t, J = 8.0 Hz, 1H), 7.39 – 7.44 (m, 4H); 13C 
NMR (C2D6CO, 125 MHz) δ (ppm) 14.6, 14.7, 38.3, 55.7, 113.1, 113.8, 120.1, 125.0, 
125.1, 126.2, 126.3, 128.6, 128.7, 129.0, 129.07, 129.09, 129.6, 130.6, 131.9, 132.0, 137.0, 
137.9, 147.3, 157.9, 159.9, 170.1. 
4-(Benzo[d][1,3]dioxol-5-yl)-N-(3-methoxyphenyl)-N-methylbenzamide (22a)The title 
compound was prepared by reaction of 4-bromo-N-(3-methoxyphenyl)-N-
methylbenzamide(6b) (80 mg, 0.25mmol), benzo[d][1,3]dioxol-5-ylboronic acid (55 mg, 
0.33mmol), cesium carbonate (244 mg, 0.75mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 6 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow 
solid (68 mg, 76%). C22H19NO4; MW 361; mp: 139 – 141°C; MS (ESI) 362 [M+H]
+
; IR 
(cm
-1
) 1592, 1644, 2837, 2948, 2975, 3009;
1
H NMR (C2D6CO, 500 MHz) δ(ppm) 3.43 (s, 
3H), 3.70 (s, 3H), 6.02 (s, 2H), 6.72 – 6.73 (m, 1H), 6.74 – 6.75 (m, 1H), 6.79 –-6.80 (m, 
1H), 6.89 – 6.90 (m, 1H), 7.10 – 7.12 (m, 2H), 7.17 (t, J = 8.0 Hz, 1H), 7.37 – 7.39 (m, 2H), 
7.44 – 7.46 (m, 2H); 13C NMR (C2D6CO, 125 MHz) δ(ppm) 38.4, 55.7, 102.3, 108.0, 109.4, 
112.9, 113.8, 120.1, 121.4, 126.5, 130.0, 130.6, 135.0, 136.2, 142.4, 147.4, 148.5, 149.3 
161.2, 170.2. 
3'-Methoxy-N-(4-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (11a)The 
title compound was prepared by reaction of 4-bromo-N-(4-methoxyphenyl)-N-
methylbenzamide(11b) (100 mg, 0.31mmol), 3-methoxyphenylboronic acid (61 mg, 
0.40mmol), cesium carbonate (303 mg, 0.93mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 7 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as colorlessoil 
(106 mg, 98%). C22H21NO3; MW 347; MS (ESI) 348 [M+H]
+
; IR (cm
-1
) 1635, 2840, 
2935;
1
H NMR (C2D6CO, 300 MHz) δ (ppm) 3.40 (s, 3H), 3.75 (s, 3H), 3.85 (s, 3H), 6.82 – 
6.86 (m, 2H), 6.92 (ddd, J = 1.0 Hz, 2.6 Hz, 8.3 Hz, 1H), 7.12 – 7.19 (m, 4H), 7.32 – 7.40 
(m, 3H), 7.50 – 7.53 (m, 2H); 13C NMR (C2D6CO, 75 MHz) δ (ppm) 38.7, 55.6, 55.7, 113.1, 
114.3, 115.2, 120.0, 126.9, 129.2, 130.1, 130.8, 136.9, 139.0, 142.2, 142.3, 159.0, 161.2, 
170.2. 
4'-Methoxy-N-(4-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide (12a)The 
title compound was prepared by reaction of 4-bromo-N-(4-methoxyphenyl)-N-
methylbenzamide(11b) (78 mg, 0.24mmol), 4-methoxyphenylboronic acid (48 mg, 
0.32mmol), cesium carbonate (235 mg, 0.72mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 6 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc 90:10) to afford the desired product as yellow 
solid (73 mg, 88%). C22H21NO3; MW 347; mp: 129 – 132°C; MS (ESI) 348 [M+H]
+
; IR 
(cm
-1
) 1635, 2840, 2932, 2957;
1
H NMR (C2D6CO, 300 MHz) δ(ppm) 3.39 (s, 3H), 3.74 (s, 
3H), 3.83 (s, 3H), 6.82 – 6.82 (m, 2H), 6.98 – 7.01 (m, 2H), 7.11 – 7.14 (m, 2H), 7.34 – 
7.37 (m, 2H), 7.44 – 7.47 (m, 2H), 7.54 – 7.57 (m, 2H); 13C NMR (C2D6CO, 75 MHz) 
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δ(ppm) 38.7, 55.6, 55.7, 115.2, 126.2, 128.8, 129.2, 130.2, 133.0, 135.9, 139.1, 142.1, 
159.0, 160.6, 170.3. 
3'-Methoxy-N-methyl-N-(m-tolyl)-[1,1'-biphenyl]-4-carboxamide (5a)The title 
compound was prepared by reaction of 4-bromo-N-(3-methylphenyl)-N-methylbenzamide 
(5b) (123 mg, 0.40mmol), 3-methoxyphenylboronic acid (79 mg, 0.52mmol), cesium 
carbonate (393 mg, 1.20mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 9 mg) 
according to method B. The residue was purified by silica gel column chromatography 
(hexanes/EtOAc70:30) to afford the desired product as yellow oil (101 mg, 77%). 
C22H21NO2; MW 331; MS (ESI) 332 [M+H]
+
; IR (cm
-1
) 1582, 1601, 1639, 2834, 2935, 
3034;
1
H NMR (C2D6CO, 300 MHz) δ(ppm) 2.24 (s, 3H), 3.42 (s, 3H), 3.84 (s, 3H), 6.90 – 
7.00 (m, 3H), 7.08 (s, 1H), 7.11 – 7.18 (m, 3H), 7.33 (t, J = 8.0 Hz, 1H), 7.38 – 7.41 (m, 
2H), 7.49 – 7.52 (m, 2H); 13C NMR (C2D6CO, 75 MHz) δ(ppm) 21.2, 38.5, 55.6, 113.1, 
114.3, 120.0, 125.1, 126.9, 127.9, 128.4, 129.8, 130.1, 130.8, 136.7, 139.9, 142.3, 142.5, 
146.2, 161.2, 170.2. 
2'-Fluoro-N,3'-dimethyl-N-(m-tolyl)-[1,1'-biphenyl]-4-carboxamide (21a)The title 
compound was prepared by reaction of 4-bromo-N-(3-methylphenyl)-N-methylbenzamide 
(5b) (93 mg, 0.31mmol), 2-fluoro-3-methylphenylboronic acid (62 mg, 0.40mmol), cesium 
carbonate (303 mg, 0.93mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 7 mg) 
according to method B. The residue was purified by silica gel column chromatography 
(hexanes/EtOAc70:30) to afford the desired product as white solid (103 mg, quantitative). 
C22H20FNO; MW 333; mp: 73 – 76°C; MS (ESI) 334 [M+H]
+
; IR (cm
-1
) 1604, 1634, 2853, 
2920;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 2.24 (s, 3H), 2.28 (d, J = 2.4 Hz, 3H), 3.43 (s, 
3H), 6.94 – 6.97 (m, 1H), 6.98 – 7.01 (m, 1H), 7.07 (s, 1H), 7.11 – 7.16 (m, 2H), 7.23 –-
7.26 (m, 2H), 7.38 – 7.41 (m, 4H); 13C NMR (C2D6CO, 125 MHz) δ (ppm) 14.6, 14.7, 21.2, 
38.5, 125.05, 125.09, 125.12, 126.2, 126.3, 128.5, 128.6, 128.7, 128.99, 129.01, 129.07, 
129.09, 129.6, 129.8, 131.9, 132.0, 136.9, 137.8, 139.9, 146.1, 157.9, 159.9, 170.1. 
4-(Benzo[d][1,3]dioxol-5-yl)-N-methyl-N-(m-tolyl)benzamide(22a)The title compound 
was prepared by reaction of 4-bromo-N-(3-methylphenyl)-N-methylbenzamide (5b) (79 mg, 
0.26mmol), benzo[d][1,3]dioxol-5-ylboronic acid (56 mg, 0.34mmol), cesium carbonate 
(254 mg, 0.78mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 6 mg) according to 
method B. The residue was purified by silica gel column chromatography 
(hexanes/EtOAc70:30) to afford the desired product as yellow solid (44 mg, 49%). 
C22H19NO3; MW 345; mp: 111 – 113°C; MS (ESI) 346[M+H]
+
; IR (cm
-1
) 1602, 1634, 2788, 
2911, 2966;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 2.24 (s, 3H), 3.42 (s, 3H), 6.02 (s, 2H), 
6.89 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 7.07 – 7.11 (m, 
3H), 7.14 (t, J = 8.0 Hz, 1H), 7.35 – 7.37 (m, 2H), 7.42 – 7.44 (m, 2H); 13C NMR (C2D6CO, 
125 MHz) δ (ppm) 21.2, 38.5, 102.3, 107.9, 109.4, 121.4, 125.1, 126.5, 127.9, 128.4, 129.8, 
130.2, 135.1, 136.2, 139.9, 142.3, 146.3, 148.5, 149.3, 170.2. 
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2'-Fluoro-N-(3-methoxybenzyl)-N,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (25a)The 
title compound was prepared by reaction of 4-bromo-N-(3-methoxybenzyl)-N-
methylbenzamide (25b) (200 mg, 0.60mmol), 2-fluoro-3-methylphenylboronic acid (120 
mg, 0.78mmol), cesium carbonate (587 mg, 1.80mmol) and tetrakistriphenylphosphine 
palladium (0.02 eq., 14 mg) according to method B. The residue was purified by silica gel 
column chromatography (hexanes/EtOAc70:30) to afford the desired product as yellow oil 
(200 mg, 87%). C23H22FNO2; MW 363; MS (ESI) 364 [M+H]
+
; IR (cm
-1
) 1630, 2834, 2923, 
3034;
1
H NMR (C2D6CO, 500 MHz) δ(ppm) 2.32 (s, 3H), 2.97 (s, 3H), 3.81 (s, 3H), 4.59 – 
4.73 (m, 2H), 6.80 – 7.00 (m, 3H), 7.17 (t,J = 8 Hz, 1H), 7.27 – 7.32 (m, 2H), 7.33-7.36 (m, 
1H), 7.57 – 7.59 (m, 2H), 7.62 (s, 2H); 13C NMR (C2D6CO, 125 MHz) δ(ppm) 14.6, 14.7, 
37.3, 51.0, 55.5, 113.6, 114.4, 121.0, 125.1, 125.2, 126.2, 126.3, 128.1, 128.7, 128.8, 129.1, 
129.2, 129.7, 129.8, 130.5, 132.0, 132.1, 137.1, 138.0, 158.0, 159.9, 161.1. 
2'-Fluoro-N-(3-hydroxybenzyl)-N,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide (25)To a 
solution of 2'-fluoro-N-(3-methoxybenzyl)-N,3'-dimethyl-[1,1'-biphenyl]-4-carboxamide 
(25a) (100 mg, 0.28mmol) in CH2Cl2 (10 mL) was added trifluorobromine dimethyl 
sulphide complex BF3.SMe2 (0.18 mL, 1.68mM) at room temperature. The reaction mixture 
was stirred overnight. The reaction was quenched with MeOH (10 mL). The solvent was 
removed under reduced pressure at 25°C. Water was added to dissolve inorganic salts and 
the precipitated was filtered off and triturated with diethyl ether to afford the desired 
product as yellow solid (66 mg, 67%). C22H20FNO2; MW 349; mp: 123 – 126°C; MS (ESI) 
350 [M+H]
+
; IR (cm
-1
) 1600, 2917, 3181;
1
H NMR (C2D6CO, 500 MHz) δ (ppm) 2.32 (s, 
3H), 2.96 (s, 3H), 4.55 – 4.69 (m, 2H), 6.72 – 6.90 (m, 3H), 7.16 – 7.22 (m, 2H), 7.29 (t, J = 
8.0 Hz, 1H), 7.33 –-7.36 (m, 1H), 7.57 – 7.58 (m, 2H), 7.62 (s, 2H); 13C NMR (C2D6CO, 75 
MHz) δ (ppm) 14.6, 14.7, 115.2, 125.1, 125.2, 126.2, 126.4, 128.0, 128.7, 128.9, 129.17, 
129.21, 129.7, 129.8, 130.6, 132.0, 132.1, 137.0, 138.0, 157.3, 158.6, 160.6 
3-Methoxy-N-(3'-methoxy-[1,1'-biphenyl]-4-yl)-N-methylbenzamide(24a)The title 
compound was prepared by reaction of N-(4-bromophenyl)-3-methoxy-N-methylbenzamide 
(24b) (80 mg,0.25mmol), 3-methoxyphenylboronic acid (50 mg, 0.33mmol), cesium 
carbonate (244 mg, 0.75mmol) and tetrakistriphenylphosphine palladium (0.02 eq., 6 mg) 
according to method B. The residue was purified by silica gel column chromatography 
(hexanes/EtOAc70:30) to afford the desired product as yellow oil (59 mg, 68%). 
C22H21NO3; MW 347; MS (ESI) 348 [M+H]
+
; IR (cm
-1
) 1640, 2840, 2936;
1
H NMR 
(C2D6CO, 300 MHz) δ(ppm) 3.45 (s, 3H), 3.66 (s, 3H), 3.85 (s, 3H), 6.80 –-6.84 (m, 1H), 
6.90 – 6.94 (m, 3H), 7.09 – 7.19 (m, 3H), 7.24 – 7.27 (m, 2H), 7.34 (t, J = 8.0 Hz, 1H), 7.57 
– 7.60 (m, 2H); 13C NMR (C2D6CO, 75 MHz) δ(ppm) 38.4, 55.6, 55.7, 113.2, 114.0, 114.9, 
116.4, 120.0, 121.9, 128.3, 128.4, 129.7, 130.9, 139.0, 139.6, 142.3, 145.7, 160.1, 161.3, 
170.3. 
Biological methods 
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[2,4,6,7-
3
H]-E2 and [2,4,6,7-
3
H]-E1 were purchased from Perkin-Elmer, Boston. Quickszint 
Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. Other chemicals 
were purchased from Sigma, Roth or Merck. 
h17β-HSD1 and h17β-HSD2 enzyme preparation 
Cytosolic (h17β-HSD1) and microsomal (h17β-HSD2) fractions were obtained from human 
placenta according to previously described procedures[20, 27]. Fresh tissue was 
homogenized and the enzymes were separated from the mitochondria, cell membrane. 
Nucleus and other rests by fractional centrifugation at 1000 g, 10.000 g and 150.000 g. The 
pellet fraction containing the microsomal h17β-HSD2 was used for the determination of 
h17β-HSD2 inhibition, while h17β-HSD1 was obtained after precipitation with ammonium 
sulfate from the cytosolic fraction for use of testing of h17β-HSD1 inhibition. Aliquots 
containing h17β-HSD1 or h17β-HSD2 were stored frozen. 
m17β-HSD2 enzyme preparation and inhibition 
The microsomal fraction (m17β-HSD2) was obtained from mouse liver as described for 
h17β-HSD2. Inhibitory activities were evaluated by a method identical to the one described 
for the human enzyme. 
m17β-HSD1 enzyme preparation 
Recombinant m17β-HSD1 enzyme was produced by transfection of HEK 293 cells with a 
m17β-HSD1 expression plasmid (coding sequence of NM_010475 in pCMV6Entry vector, 
OriGene Technologies, Inc.) according to a described procedure[28]. 48 hours after 
transfection cells were homogenized by sonication (3 x 10 s) in a buffer containing 
saccharose (40 mMTris, 250 mMsaccharose, 5 mM EDTA, 7 mM DTT, 1 mM PMSF, pH 
7,5). Cell lysate was centrifuged (1000 g, 15 min, 4°C) and 20% glycerol was added to the 
supernatant before aliquots were frozen and stored at -70°C. 
Inhibition of h17β-HSD2 and m17β-HSD2 in cell-free assay 
Inhibitory activities were evaluated following an established method with minor 
modifications[29-31]. Briefly, the enzyme preparation was incubated with NAD
+
 [1500 
µM] in the presence of potential inhibitors at 37 °C in a phosphate buffer (50 mM) 
supplemented with 20% of glycerol and EDTA 1mM. Inhibitor stock solutions were 
prepared in DMSO. Final concentration of DMSO was adjusted to 1% in all samples. The 
enzymatic reaction was started by addition of a mixture of unlabelled- and [
3
H]-E2 (final 
concentration: 500 nM, 0.11 µCi). After 20 min, the incubation was stopped with HgCl2 and 
the mixture was extracted with ether. After evaporation, the steroids were dissolved in 
acetonitrile/water (45:55). E1 and E2 were separated using acetonitrile/water (45:55) as 
mobile phase in a C18 RP chromatography column (Nucleodur C18, 3µm, Macherey-Nagel, 
Düren) connected to a HPLC-system (Agilent 1100 Series, Agilent Technologies, 
Results 
 
110 
 
Waldbronn). Detection and quantification of the steroids were performed using a radioflow 
detector (Berthold Technologies, Bad Wildbad). The conversion rate was calculated 
according to the following equation: %conversion = (%E1/(%E1+%E2))×100. Each value 
was calculated from at least two independent experiments. 
Inhibition of h17β-HSD1 and m17β-HSD1 in cell-free assay 
The 17β-HSD1 inhibition assay was performed similarly to the h17β-HSD2 test. The 
human cytosolic enzyme was incubated with NADH [500 µM] while the mouse 
recombinant enzyme was reacted with NADPH [500 µM].Test compound and a mixture of 
unlabelled- and [
3
H]-E1 (final concentration: 500 nM, 0.15 µCi) were added and mixed for 
10 min at 37°C. Further treatment of the samples and HPLC separation was carried out as 
mentioned above for h17β-HSD2. 
Inhibition of h17β-HSD2 in a cellular assay 
Cellular h17β-HSD2 inhibitory activity is measured using the breast cancer cell-line 
MDA-MB-231[32] (17β-HSD1 activity negligible). [3H]-E2 (200 nM) is taken as substrate 
and is incubated with the inhibitor for 6 h at 37 °C. After ether extraction, substrate and 
product are separated by HPLC and detected with a radioflow detector. Potency is evaluated 
as percentage of inhibition (inhibitor concentrations used: 1250 nM and 250 nM). 
Estrogen receptor affinity in a cell-free assay 
The binding affinity of selected compounds to ERα and ERβ was determined according to 
the recommendations of the US Environmental Protection Agency (EPA) by their 
Endocrine Disruptor Screening Program (EDSP)[24] using recombinant human proteins. 
Briefly, 1 nM of ERα and 4 nM of ERβ, respectively, were incubated with [3H]-E2 (3 nM 
for ERα and 10 nM for ERβ) and test compound for 16-20 h at 4°C.  
The potential inhibitors were dissolved in DMSO (5% final concentration). Evaluation of 
non-specific-binding was performed with unlabeled E2 at concentrations 100-fold of [
3
H]-
E2 (300 nM for ERα and 1000 nM for ERβ). After incubation, ligand-receptor complexes 
were selectively bound to hydroxyapatite (83.5 g/LinTE-buffer). The bound complex was 
washed three times and resuspended in ethanol. For radiodetection, scintillator cocktail 
(Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were measured in a 
liquid scintillation counter (1450 LSC & Luminescence Counter, Perkin Elmer). 
From these results the percentage of [
3
H]-E2 displacement by the compounds was 
calculated. The plot of % displacement versus compound concentration resulted in 
sigmoidal binding curves. The compound concentrations necessary to displace 50% of the 
receptor bound [
3
H]-E2 were determined. Unlabeled E2 IC50 values were determined in 
each experiment and used as reference. The E2 IC50determined  were 3±20% nM for ERα 
and 10±20% nM for ERβ. 
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Relative Binding Affinity was determined by applying the following equation: RBA[%] = 
(IC50(E2)/IC50(compound)) ∙ 100[24]. This results in a RBA value of 100% for E2.  
After the assay was established and validated, a modification was made to increase 
throughput. Compounds were tested at concentrations of 1000 times the IC50(E2). 
Compounds with less than 50% displacement of [
3
H]-E2 at a concentration of 1000 
timesIC50(E2) were classified as RBA <0.1%. 
Metabolic Stability in a cell-free assay 
Compounds 7a, 8a, 16a, 19a, 22a, 27a and 27 were tested according to established 
method[33-35]For evaluation of phase I and II metabolic stability 1 µM compound was 
incubated with 1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 2 mM NADPH 
regenerating system, 1 mM UDPGA and 0.1 mM PAPS at 37°C for 0, 5, 15 and 60 minutes 
at a final volume of 100 µL. The incubation was stopped by precipitation of S9 enzymes 
with 2 volumes of cold acetonitrile containing internal standard. Concentration of the 
remaining test compound at the different time points was analyzed by LC-MS/MS and used 
to determine half-life (t1/2). 
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Paper III 
Abstract 
Four different classes of new 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) 
inhibitors were synthesized, in order to lower the cytotoxicity exhibited by the lead 
compound A, via disrupting the linearity and the aromaticity of the biphenyl moiety. 
Compounds 3, 4, 7a and 8 displayed comparable or better inhibitory activity and selectivity, 
as well as a lower cytotoxic effect, compared to the reference compound A. The best 
compound 4 (IC50 = 160 nM, selectivity factor= 168, LD50≈ 25µM) turned out as new lead 
compound for inhibition of 17β-HSD2. 
Introduction 
Osteoporosis affects more than 75 million people in the United States, Europe and Japan, 
causing almost 9 million bonefractures annualy.
1
 The current available therapies lack of 
sufficient safety and effectiveness,
2
and as consequence development of new treatments is 
needed. 
17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) is responsible for the local reduction 
of the highly biologically active estradiol (E2) and testosterone (T)into the much less active 
estrone (E1) and androstenedione (A-dione), whereas 17β-hydroxysteroid dehydrogenase 
type 1 (17β-HSD1), a target for the treatment of endometriosis,3-5 type 3 (17β-HSD3) and 
type 5 (17β-HSD5) catalyze the opposite reaction (Fig. 1).6 
The age-related decrease in the local levels of E2 and T is responsible for osteoporosis onset 
and progression.
7,8Therefore the inhibition of 17β-HSD2, which is present in the bones,9 
should rebalance the steroid levels in this tissue and represents an appealing strategy for the 
treatment of this disease. Since 17β-HSD2 and 17β-HSD1 were shown to be both expressed 
in bone tissue,
9
 17β-HSD2 inhibitors should be selective over 17β-HSD1 (Fig. 1). 
We previously reported on the discovery of compound A (Fig. 2), which showed a good 
17β-HSD2 inhibitory activity (IC50= 300 nM) and good selectivity over 17β-HSD1 (IC50= 
13.3 µM, selectivity factor= 44) as well as an improved metabolic stability in human S9 
fraction (t1/2= 107 min) compared to the other 17β-HSD2 inhibitors described so far.
10
 
However, this lead compound A was found to exert some cytotoxicity. 
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Figure 1. Blocking the reduction of estradiol and testosterone by using an inhibitor of 17β-
HSD2. 
Only 34% of the cellswere still alive were still alive after treatment with 6.25 µM of 
compound A in a MTT assay.
11
 
The 1,1´-biphenyl moiety is known for its toxicity.
12
 It might partly come from its planarity 
and the presence of two aromatic rings next to each other which might result in DNA 
intercalation by interaction with the nucleobases.
13
 
Decrease in cytotoxicity should therefore be achieved by disrupting the planarity of the 
biphenyl moiety and/or avoiding the biphenyl moiety. 
We already reported on compound B (Fig. 2) showing a 17β-HSD2 inhibitory activity 
(IC50= 510 nM)slightly weakercompared to the one of A.
14
 WhereasB and A share the 
biphenyl moiety, compound B bears,in place of a carboxamide, a sulfonamide linker. The O 
of the carbonamideA and of the sulfonamide B explores different regions of the protein and 
potentially achieves different H-bond interactions. Therefore the carboxamide of A and the 
sulfonamide of B were both taken as starting point for the design of the new inhibitors, in 
order to obtain a greater chemical diversity. 
In order to develop new 17β-HSD2 inhibitors with a better toxicity profile and a good 17β-
HSD2 inhibitory activity, we applied four strategies: (1) introduction of an ether bridge 
between the two phenyl rings, compounds 1-7; (2) exchange of the phenyl central ring by a 
cyclohexane ring, compound 8; (3) the exchange of the central ring by a piperazine ring 
linked to a sulfonyl group, compounds 9a-11a and 9-11 and (4) the exchange of the sulfonyl 
function by an acyl function, compounds 12a-14a and 12-15 (Fig. 2). 
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Fig. 2. Four different classes of inhibitors derived from the lead compounds A and B. 
The reaction steps involved in the synthesis of the target compounds 1-8 are shown in 
Scheme 1. The 4-phenoxybenzoyl chlorides were obtained from the commercially available 
corresponding 4-phenoxybenzoic acids 1a-6a and 7b by reactionwith SOCl2 and 
subsequently reacted with different anilines, according to the already described 
procedure,
15
providing compounds 1-6 and 7a. 
Compound 8 was synthesized using an identical method, starting from thecommercially 
available 4-(4-chlorophenyl)cyclohexane-1-carboxylic acid8a (Scheme 1). 
The 3-(4-phenylpiperazin-1yl)sulfonyls 9a-11a were prepared through the sulfonamide 
bond formation (Scheme 2), achieved by reaction of commercially available 1-
phenylpiperazines 9b-11b with 3-methoxybenzenesulfonyl chloride 9c, according to a 
described procedure.
14
 The following ether cleavage of 9a-11a, using BF3·SMe2 in presence 
of triethylamine, as already described,
14
 yielded the hydroxy compounds 9-11. 
The synthesis of the phenylpiperazin-1-yl methanones12-14 and 15a are depicted in Scheme 
3. The amide bond was formed, by reacting the commercially available 1-phenylpiperazines 
9b, 10b, 12b and 13b and 3-methoxybenzoyl chloride10c, using triethylamine and 
dichloromethane as solvent. Compounds 12a-14awere submitted to ether cleavage using 
boron trifluoride-dimethyl sulfide complex yielding the hydroxy compounds 12-14. 
Conditions of both reactions were previously described.
7
 
All final compounds as well as their intermediates were fully characterized (
1
H NMR, 
13
C 
NMR and LRMS) to confirm their chemical structure. The data of the representative 
compounds 4, 8, 9a and 12 are presented as examples.
16-19
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Scheme 1. Synthesis of 4-phenoxybenzamide derivatives 1-7 and 7a and 4-(4-
chlorophenyl)-N-methylcyclohexane-1-carboxamide 8. Reagents and conditions: (a) SOCl2, 
DMF cat, toluene, reflux, 4 h; (b) Et3N, CH2Cl2, room temperature, overnight; (c) 
BF3·SMe2, CH2Cl2, 0 °C to room temperature, overnight. 
 
Scheme 2. Synthesis of 3-(4-phenylpiperazin-1yl)sulfonyls 9-11. Reagents and conditions: 
(a) (Bu4)N·HSO4, NaOH 50%, CH2Cl2, room temperature, 3h; (b) BF3·SMe2, CH2Cl2, Et3N, 
0 °C to room temperature, overnight. 
 
Scheme 3. Synthesis of phenylpiperazine-1-yl methanones 12-14 and 15a. Reagents and 
conditions: (a) Et3N, CH2Cl2, room temperature, overnight; (b) BF3·SMe2, CH2Cl2, Et3N, 0 
°C to room temperature, overnight. 
 
The inhibitory activities of compounds 7a, 10a, 11a, 13a-15a and 1-15 on 17β-HSD2 and 
17β-HSD1 obtained from human placental source, were determined as previously 
described.
20
 
The 4-phenoxybenzamides 7a and 1-7, as well as the phenylcyclohexanecarboxamide8 
(Table 1) displayed a good inhibition of 17β-HSD2. Compound 4, with a bent shape and 8, 
lacking the central aromatic ring, but conserving the overall linear shape, showed an 
inhibitory activity in the same order of magnitude as compound A and significantly 
improved selectivity against 17β-HSD1, thus demonstrating that neither the linearity of the 
biphenyl moiety nor the aromaticity of the central ring are essential for inhibitory activity. 
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Table 1 
Inhibitory activities toward 17β-HSD2 and 17β-HSD1 of compounds 7a and 1-8. 
 IC50 (nM)
a
 or Inh. at 1 µM
a 
 
Cmpd R1 R2 17β-HSD2
b 
17β-HSD1
c 
s.f.
d 
A - - 75% (300nM) n.i. (13300) 44 
1 -H -Me 59% n.i. n.d. 
2 2-Me -Me 55% n.i. n.d. 
3 3-Me -Me 300 16100 54 
4 4-Me -Me 160 26300 168 
5 4-Cl -OMe 51% 13% n.d. 
6 4-NO2 -OMe 43% n.i. n.d. 
7a 4-OMe -OMe 310 9600 31 
7 4-OH -OH 43% n.i. n.d. 
8 - - 290 60100 209 
aMean value of at least two determinations, standard deviation less than 20%. bHuman placental, microsomal fraction, substrate 
E2[500 nM], cofactor NAD+[1500 µM]. cHuman placental, cytosolic fraction, substrate E1[ 500 nM], cofactor NADH[500 µM]. 
dn.d.: not determined. 
The phenylpiperazin-1-yl sulfonyls 9a-11a and 9-11 (Table 2) displayed poor inhibition of 
the 17β-HSD2 enzyme,when compared to compoundsAand B. Compound 10, which can be 
directly compared to B, is a much weaker inhibitor of 17β-HSD2. Compound 11is the best 
in the series. The improvement in activity between 10 and 11 comes from the introduction 
of the fluorine in ortho to the OH group. The Flikely positively influences the hydrogen 
bond on the OH group next to it.In comparison to compound B, the sulfonyl derivatives 
bear a much more hydrophilic central ring, which might explain the loss of activity. They 
also beara sulfonamide function condensed in the piperazine ring, whichrenders 
themolecules shorter than B. This feature might lead to a loss of important interactions with 
the enzyme, thus further explaining the lower inhibitory activity. 
Table 2 
Inhibitory activities toward 17β-HSD2 and 17β-HSD1 of compounds 9a-11a and 9-11. 
 Inh. at 1 µM
a 
Cmpd R1 R2 17β-HSD2
b 
17β-HSD1
c 
B -  66% 22% 
9a 3-Me -OMe 16% n.i.  
9 3-Me -OH 27% n.i. 
10a 3-OMe -OMe n.i n.i. 
10 3-OH -OH 25% n.i. 
11a 4-F, 3-OMe -OMe 15% n.i.  
11 4-F, 3-OH -OH 48% n.i.  
aMean value of at least two determinations, standard deviation less than 20%. bHuman placental, microsomal fraction, substrate 
E2[500 nM], cofactor NAD+[1500 µM]. cHuman placental, cytosolic fraction, substrate E1[ 500 nM], cofactor NADH[500 µM]. 
The phenylpiperazin-1-yl methanones 12a-15a and 12-14 (Table 3) displayed no or very 
low 17β-HSD2 inhibitory activity, indicating that the acyl group does not bring any 
advantage in comparison with the sulfonyl group. 
Table 3 
Inhibitory activities toward 17β-HSD2 and 17β-HSD1 of compounds 12a-15a and 12-14. 
 Inh. at 1 µM
a 
Cmpd R1 R2 17β-HSD2
b 
17β-HSD1
c 
12a -H -OMe 14% n.i.  
12 -H -OH 27% n.i. 
13a 3-Me -OMe n.i n.i. 
13 3-Me -OH 16% n.i. 
14a 4-Me -OMe 16% n.i.  
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14 4-Me -OH n.i. n.i.  
15a 3-OMe -OMe n.i. n.i. 
aMean value of at least two determinations, standard deviation less than 20%. bHuman placental, microsomal fraction, substrate 
E2[500 nM], cofactor NAD+[1500 µM]. cHuman placental, cytosolic fraction, substrate E1[ 500 nM], cofactor NADH[500 µM]. 
Cell viability in HEK293 cells was determined for the best compounds 3, 4, 7a and 8, using 
an MTT assay according to a described procedure.
11
 The results are displayed in Fig. 3. 
 
Fig. 3. Cytotoxicity of selected compounds is displayed in the order of increasing 17β-
HSD2 inhibitory activity. Incubation was carried out at the indicated inhibitor 
concentrations for 66 hours at 37 °C. 100%-values were determined without inhibitor. 
In comparison to compound A (LD50 less than 6.25 µM), all four compounds showed a 
better safety profile, with a LD50 around 25 µM for 3, 4 and 7a and above 12.5 µM for 
compound 8. Compound 4 displays improved 17β-HSD2 inhibitory activity and much better 
selectivity against 17β-HSD1 as well as significantly decrease in cytotoxicity, when 
compared to compound A. These results confirm compound 4 as new lead compound for 
inhibition of 17β-HSD2. 
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M.; Marchais-Oberwinkler S.; Hartmann R. W. PlosOne, 2015, 10(7): e0134754. 
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11. Kruchten, P.; Werth, R.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Frotscher, M.; 
Hartmann, R.W. J. Steroid. Biochem. Mol. Biol. 2009, 114, 200. 
12. http://www.epa.gov/chemfact/biphe-sd.pdf 
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15. Gargano, E. M.; Perspicace, E.; Hanke, N.; Carotti, A.; Marchais-Oberwinkler, S.; 
Hartmann, R. W. Eur. J. Med. Chem. 2014, 87, 203. 
16. Data for N-methyl-N-(m-tolyl)-4-(p-tolyloxy)benzamide(compound 4): yellow oil; 
C22H21NO2;
1
H-NMR‒300 MHz (Acetone-d6, δ, ppm) 2.25 (s, 3H), 2.30 (s, 3H), 3.39 
(s, 3H), 6.71-6.76 (m, 2H), 6.84-6.92 (m, 3H), 6.98-7.01 (m, 2H), 7.12-7.20 (m, 3H), 
7.27-7.32 (m, 2H);
13C NMR‒75 MHz (Acetone-d6, δ, ppm) 20.8, 21.3, 38.6, 117.5, 
120.4, 125.1, 127.9, 128.5, 129.8, 131.4, 131.7, 132.0, 134.5, 139.9, 146.5, 154.9, 
159.8, 169.9; LRMS (m/z) calcd. for C22H22NO2 [M+H]
+
 332.16, found 332.18. 
17. Data for 4-(4-chlorophenyl)-N-(3-methoxyphenyl)-N-methylcyclohexane-1-
carboxamide(compound 8): yellow solid; m.p.= 108-109 °C; C21H24ClNO2; . 
1
H-
NMR‒500 MHz (Acetone-d6, δ, ppm) 1.18-1.25 (m, 2H), 1.62-1.71 (m, 2H), 1.77-
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1.82(m, 4H), 2.38 (brs, 1H), 2.48-2.54 (m, 1H), 3.18 (s, 3H), 3.84 (s, 3H), 6.89-6.97 
(m, 2H), 6.96-6.98 (m, 1H), 7.17 (d, J= 9 Hz, 2H), 7.23-7.25 (m, 2H), 7.39 (t, J= 8 
Hz, 1H);
13C NMR‒125 MHz (Acetone-d6, δ, ppm) 30.5, 34.0, 37.4, 41.4, 43.9, 55.9, 
114.0, 114.2, 120.4, 129.1, 129.4, 131.3, 131.9, 146.8, 147.1, 161.7, 175.5; LRMS 
(m/z) calcd. for C21H25ClNO2 [M+H]
+
 358.16, found 358.21. 
18. Data for 1-((3-methoxyphenyl)sulfonyl)-4-(m-tolyl)piperazine (compound 9a): white 
solid; m.p.= 129-130 °C; C18H22N2O3S; 
1
H-NMR‒300 MHz (Acetone-d6, δ, ppm) 
2.24 (s, 3H), 3.11-3.14 (m, 4H), 3.22-3.25 (m, 4H), 3.91 (s, 3H), 6.63-6.66 (m, 1H), 
6.70-6.76 (m, 2H), 7.08 (t, J= 8 Hz, 1H), 7.25-7.30 (m, 2H), 7.36-7.40 (m, 1H), 7.58 
(t, J= 8 Hz, 1H);
13C NMR‒75 MHz 21.7, 47.1, 49.7, 56.1, 113.7, 114.6, 118.2, 119.7, 
120.7, 121.8, 129.7, 131.2, 137.9, 139.3, 151.9, 161.0; LRMS (m/z) calcd. 
forC18H23N2O3S [M+H]
+
 346.14, found 346.89. 
19. Data for (3-hydroxyphenyl)(4-phenylpiperazin-1-yl)methanone (compound 12): 
white solid; m.p.= 174-175 °C;C17H18N2O2; 
1
H-NMR‒300 MHz (Acetone-d6, δ, 
ppm) 4.00.4.14 (m, 8H), 6.94-6.97 (m, 1H), 6.95-7.02 (m, 3H), 7.30 (t, J= 8 Hz, 1H), 
7.56-7.68 (m, 3H), 7.83-7.86 (m, 1H), 8.64 (brs, 1H); 
13C NMR‒75 MHz (Acetone-
d6, δ, ppm) 56.5, 115.1, 118.0, 119.1, 122.0, 130.6, 131.0, 131.4, 137.1, 142.9, 158.4, 
170.4;LRMS (m/z) calcd. for C17H19N2O2 [M+H]
+
 283.14, found 283.20. 
20. Kruchten, P.; Werth, S.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R.W. 
Mol. Cell. Endocrinol. 2009,301, 154. 
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2.5 Monograph: Inhibition of 17β-Hydroxysteroid Dehydrogenase Type 1 for 
the Treatment of NSCLC: Discovery of Potent, Selective and Metabolically 
Stable Compounds for an in vivo Proof of Concept Study 
The following people contributed to the experimental work of this monograph: Vilma 
Dollaku (synthesis of compound 5a and 7b); Arcangela Mazzini (analytical method 
development, estrogen receptor assay); Hanna Drzewiecka (xCELLigence 
experiments); Martina Jankowski (S9 fraction metabolic stability assay). 
 
Abstract 
Design, synthesis and biological evaluation of a new class of h17βHSD1 inhibitors for the 
treatment of NSCLC are described. Structural modifications turned selective h17βHSD2 
inhibitors into potent and selective h17βHSD1 inhibitors. Compound 15 displays low 
nanomolar h17βHSD1 inhibition, high selectivity against 17βHSD2 and ERs, good in vitro 
and in vivo pharmacokinetics properties, r17βHSD1 inhibition and r17βHSD2. These 
properties make it eligible for an in vivo proof of concept study. 
Introduction 
Lung cancer is the leading cause of death from cancer worldwide.
1
 Non-small-cell lung 
cancer (NSCLC) accounts for more than 85% of the cases, with a predicted 5-years survival 
rate for all stages of lung cancer of 15,9%, a figure which has only slightly improved during 
the past years.
2
 Even if the disease is detected at an early stage and therefore still localized, 
the survival rate is only 49%, demonstrating that relapse and death from lung cancer are 
common. Thus, finding drugs with novel modes of action is an urgent necessity. 
Over the last fifteen years, increasing evidence has demonstrated the pivotal role of the 
estrogen signalling pathway in lung tumorigenesis, in women and men.
3, 4
 Both estrogen 
receptors (ERs) α and β are expressed in NSCLC cell lines, tumor tissues and normal lung-
derived cells.Furthermoreestradiol (E2) can promote the growth of NSCLC cells in vitro 
and in vivo,
5, 6
 and importantly  a significant decrease in the proliferation of NIH-H23 lung 
cancer cells has been observed in vitro for siRNA-mediated knockdown of the ERs.
6 
Different strategies to target the estrogen signalling pathway have shown promising 
results.Fulvestrant, a down-regulator of ER function, displayed decreased tumor volume in 
an in vivo lung tumor xenograft model both alone and in combination with the EGFR 
tyrosine kinase inhibitor gefitinib.
7
 Reduction of estrogen levels through aromatase inhibitor 
anastrozoleinhibited NSCLC growth in vivo in a lung tumor xenograft mouse model
8
 and 
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promising results on the clinical efficacy of exemestane– another aromatase inhibitor - on 
breast cancer as well as NSCLC have been reported.
9
 
The estradiol/estrone (E2/E1) ratio is locally regulated by the action of 17β-hydroxysteroid 
dehydrogenase type 1 (17β-HSD1) and type 2 (17β-HSD2) in the tissues where they are 
expressed. 
10
 Up to date evidence has been presented that both 17β-HSD1 and 17β-HSD1 
are often expressed in NSCLC cells, contributing to tumor progression by regulating the 
E2/E1 ratioin a stimulatory fashion. Consequently theE2/E1 ratio is used as a prognostic 
factor. 
3, 11, 12
 
We have reported about the synthesis of different classes of 17β-HSD113, 14, 15 and 17β-
HSD2 
16; 17; 18
 inhibitors for the treatment of breast cancer and osteoporosis, respectively. In 
light of the fact that 17β-HSD2 mRNA expression is significantly higher in NSCLC cells 
than in breast carcinoma cells and that 17β-HSD2 positive cases are significantly associated 
with better overall survival when compared to 17β-HSD2 negative patients, thus suggesting 
a fundamental protective role of this enzyme in NSCLC,
(3)
we reasoned that a new 17β-
HSD1 inhibitor should have an exceptionally high selectivity over 17β-HSD2, in order to 
show inhibitory effects in  NSCLC cells. 
This work provides the first evidence that it is possible inhibit NSCLC cell proliferation by 
using a highly selective17β-HSD1 inhibitor. 
Results and discussion 
In a previous study we described the optimization of 2,5-thiophene amides as selective 
inhibitors of the human 17βHSD2 (h17βHSD2), only bearing -Me groups on the two phenyl 
rings.
18
 All the possible substitution patterns on the rings were evaluated and compound 1 
turned out to be the best inhibitor (Fig. 1). In the same study it was pointed out that the 
exchange of the thiophene ring by a furane could improve the metabolic stability and 
significantly decrease the h17βHSD2 inhibition, without affecting the human 17βHSD1 
(h17βHSD1) one, as it results by comparison of 1 with 2 (Fig. 1). 
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Figure 1. Design of the new 17βHSD1 inhibitors. 
This effect is interesting for the purposes of the current study, whereas it was a brick wall 
for the development of h17βHSD2 inhibitors. It was also noted that the substitution pattern 
of the -Me groups had a major effect on h17βHSD1 and h17βHSD2 inhibition, with 4,2 and 
2,4 substitution patterns (compound 3 and 4, respectively) leading to the highest in 
h17βHSD1 inhibitory activity in the series (Fig. 1).18 
We designed a series of 2,5-furane amides, with different substituents on ring A and C in 
position 2,4 or 4,2 (compounds 5-8, 7a and 8a, Fig. 1) in order to investigate whether it was 
possible to further improve h17βHSD1 inhibition and selectivity against h17βHSD2, while 
retaining the good metabolic stability already displayed by compound 2. Some more 
derivatives, also substituted in position 2 and/or 5 were designed and synthesized 
(compounds 9a-15a, 9-17 Fig. 1). 
The synthesis of the 2,5-furane derivatives (Compounds 7a-15a and 5-17) is depicted in 
Scheme 1. The 5-bromofuran-2-carbonic acid chloride was obtained from the corresponding 
carboxylic acid 5b by reaction with SOCl2 and subsequently reacted with different anilines 
(Method A), affording the intermediates 5a, 6a and 7b in good yields. The subsequent 
Suzuki coupling (Method B), under microwave irradiation (150 °C, 150 W for 20 minutes), 
provided the desired 2,5-furane derivatives 5, 6, 7a-15a, 16 and 17. The ether cleavage of 
methoxy compounds 7a-15a was performed using boron trifluoride-dimethyl sulphide 
complex, yielding the hydroxy compounds 7-15. 
h17βHSD1 and h17βHSD2 and rat 17βHSD1 and 17βHSD2 (r17βHSD1 and r17βHSD2) 
cell-free assays were performed similarly, by incubating enzyme, tritiated substrate, cofactor 
and inhibitor, according to described procedures.
19-21
 Assay details are available in the 
Supporting Information. 
Compounds 5 and 6 in comparison with the corresponding 2,5-thiophene derivatives 3 
display a decreased inhibition of h17βHSD2 and 4 and 
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comparable h17βHSD1 inhibition (Table 1), thus confirming the importance of the furane 
ring in enhancing the selectivity against the h17βHSD2. This effect might be explained by 
the different Molecular Electrostatic Potential (MEP) induced by the furane ring, which is 
tolerated by the h17βHSD1 enzyme, whereas decreases the affinity for the h17βHSD2. A 
similar effect has already been describe by E, Bey et al..
22
 
A bulkier 4-OMe group on ring A does not affect the h17βHSD1 inhibitory activity, 
whereas a 2-OMe on ring A exerts a negative effect, as it results from comparison of 
compounds 7a and 8a with 5 and 6, respectively (Table 1), suggesting that more space 
might be available around ring A and we therefore decided to exploit this feature for 
investigating the effect of different substituents on the ring in position 2 and 5 (Table 1, 
compounds 9a-15a). 
Scheme 1. Synthesis of 2,5-furane derivatives 7a-15a and 5-17.
a 
 
a
Reagents and conditions:(i) SOCl2, DMF cat., toluene, reflux 4 h; (ii) Et3N, CH2Cl2, room 
temperature, overnight; (iii) DME/EtOH/H2O (1:1:1), Cs2CO3, Pd(PPh3)4, microwave 
irradiation (150°C, 150W, 20 min); (iv) BF3·SMe2, CH2Cl2, room temperature, overnight. 
In all cases (9a-15a, Table 1), but compound 10a the h17βHSD1 inhibitory activity is in the 
range of 50-70% inhibition at 1µM. Compounds 11a and 12a (Table 1) bearing small 
lipophilic substituents in position 3 (Table 1) showed the best inhibition in the set, with 12a 
(h17βHSD1 70% and h17βHSD2 12% inh. at 1 µM) displaying similar h17βHSD1 and 
lower h17βHSD2 inhibition in comparison with the reference compounds 3 (h17βHSD1 
80% and h17βHSD2 53% inh. at 1 µM). 
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Table 1. Inhibition of human 17βHSD1 and 17βHSD2 by biphenyl-2,5-furane without 
hydroxy group. 
 
5, 6, 7a-15a 
 Inh. at 1 µM
a,b 
Cmpd R1 R2 R3 
h17β- 
HSD1
c 
h17β- 
HSD2
d 
5 2-Me -H 4-Me 44% n.i. 
6 4-Me -H 2-Me 45% n.i. 
7a 2-Me -H 4-OMe 24% n.i. 
8a 4-OMe -H 2-Me 49% 18% 
9a 4-OMe 2-Cl 2-Me 16% 13% 
10a 4-OMe 2-Me 2-Me 24% n.i. 
11a 4-OMe 3-F 2-Me 61% 17% 
12a 4-OMe 3-Me 2-Me 70% 12% 
13a 4-OMe 3,5-F 2-Me 27% n.i. 
14a 4-OMe 3,5-Cl 2-Me 53% 30% 
15a 4-OMe 3,5-Me 2-Me 57% 15% 
aMean value of at least two determinations, standard deviation less than 20%. bn.i.: no inhibition (inhibition of <10%). cHuman 
placental, cytosolic fraction, substrate E1[ 500 nM], cofactor NADH[500 µM]. dHuman placental, microsomal fraction, substrate 
E2[500 nM], cofactor NAD+[1500 µM]. 
In a second step we decided to investigate the effect of an hydroxy group either on the A 
or the C ring, keeping the conformational constrain induced by a 2-Me group on one of the 
two rings (Table 2). An hydroxy group decreases the cLogP of a molecule, which is 
correlated to its oral bioavailability,
23
 and might establish an hydrogen bond interaction with 
the enzyme, eventually boosting the inhibitory activity of the molecule. 
The exchange of the 2-Me by 2-OH in compound 5 leads to 7 (Table 2), with worsen 
inhibition and selectivity and therefore it was not further investigated. On the contrary, the 
exchange of the 4-Me by a 4-OH group in compound 6 leads to 8 (Table 2), with a 10-folds 
increase of h17βHSD1 inhibitory activity and a selectivity factor of 52 against the 
h17βHSD2. The effect of the substitution with –Me, -F and –Cl in position 2, 3 and 5 was 
investigated in compounds 9-17 (Table 2). 
The mono-substituted derivatives of 8, all display an IC50 value below 40 nM (Table 2), 
with the 3-Cl (17, IC50 value of 8.9 nM) and 3-Me (12, IC50 value of 7.8 nM) substituted 
compounds showing the highest potency, thus pointing out a preference of the h17βHSD1 
enzyme for lipophilic substituents in position 3 of ring A. Interestingly a 3-Me group also 
increases the selectivity against h17βHSD2 (Table 2, compound 12), indicating that such 
substituent is not tolerated by this enzyme. 
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Among the di-substituted derivatives of 8 (Table 2, 13-15), the 3,5-Cl (14, IC50 value of 
2.9 nM) and the 3,5-Me (15, IC50 value of 5.6 nM) display the highest h17βHSD1 inhibitory 
activity, indicating that the substitution with a second lipophilic group, exert an additive 
positive effect on the potency, if compared to 8. The lipophilicity and electron-withdrawing 
properties of the two -Cl groups of compound 14, results in the best combination for the 
inhibition of the h17βHSD1 enzyme. 14 is the most potent h17βHSD1 inhibitor so far 
described in the literature. By comparison of 12 and 15, it appears that the substitution with 
a second -Me group further decreases the affinity for the h17βHSD2 enzyme, resulting in a 
selectivity factor of 563 (Table 2). Selectivity might be a pivotal issue given that both h17β-
HSD1 and 2 are expressed in NSCLC cells, and therefore the inhibition of h17β-HSD2 
might be counterproductive. 
For compounds 8-17 the inhibitory activity against the rat h17βHSD1 and 2 was also 
determined and expressed as percent of inhibition at 1 µM (Table 2). For the most 
interesting compounds the IC50 values were determined (Table 2, compounds 12-15). 
Compounds 8-11, 16 and 17, all show other too low r17β-HSD1 inhibitory activity or lack 
in selectivity against r17βHSD2 (Table 2). Compound 13 and 14 also display a greater 
affinity for r17βHSD2 than r17βHSD1 (Table 2). On the contrary 12 (IC50 value of 176 nM) 
and 15 (IC50 value of 74 nM), which display the higher selectivity against the h17β-HSD2 
also retain some selectivity against r17βHSD2 and show a good inhibition of the 
r17βHSD1, indicating that the -Me group play a role in the selectivity against both h and 
r17β-HSD2, probably due to its steric hindrance 
The metabolic stability of compound 8 and compound 15 was evaluated using human liver 
microsomes (S9 fraction, assay details are available in the Supporting Information). They 
display an half life of 97 min and 51 min. Considering that the tested 2,5-thiophene 
derivatives (17 compounds tested) display a half life around 20 min
31
 and that the tested 2,5-
furane derivatives (2,8,15) display a half life between 51 and 97 min, it can be concluded 
that the furane ring plays a major role in increasing the stability of these compounds, 
probably decreasing the affinity for the metabolizing enzyme. Compound 15 was also tested 
for its affinity toward the ERα and ERβ according to described methods24 (assay details are 
available in the Supporting Information), resulting in a Relative Binding Affinity (RBA) 
lower than 0.1% for both receptors. Since the RBA value of E1 itself is around 7%,
25
 this 
value is sufficient to assume that the compound should not exert an activity through direct 
interaction with the ERs. The cytotoxicity of 15 was measured through Hek293 cell viability 
in the MTT assay (assay details are available in the Supporting Information). No toxic effect 
were detected up to 6.25 µM, which is more than 1000-folds the IC50 value and thus 
predicting a broad safety windows. In a preliminary in vivo PK study, the compound the 
compound was administered to a femal rat at a dose of 50 µM/Kg, subcutaneously (assay 
details are available in the Supporting Information). After 24h a concentration of 127 nM 
(almost 2-folds the IC50, Table 2) was still detectable, indicating that the compound has a 
sufficient PK profile for an in vivo rat application. 
Results 
 
129 
 
Table 2. Inhibition of human and rat 17β-HSD1 and 17β-HSD2 by biphenyl-2,5-furane 
without hydroxy group. 
 
7                                              8-11 
 IC50 (nM)
a
 or Inh. at 1 µM
a
  IC50 (nM)
a
 or Inh. at 1 µM
a
  
Cmpd R2 h17β-HSD1
b h17β-HSD2c s.f.d r17β-HSD1e r17β-HSD2f s.f.d 
7 - 27% 30% n.d. n.d. n.d. n.d. 
8 -H 80 4144 52 49% 37% n.d. 
9 2-Cl 28 301 11 71% 89% n.d. 
10 2-Me 31 1077 35 37% 50% n.d. 
11 3-F 15 447 30 69% 100% n.d. 
12 3-Me 7.8 1547 198 369 1200 3 
13 3,5-F 18 56 3 291 16 0.05 
14 3,5-Cl 2.9 71 25 176 40 0.2 
15 3,5-Me 5.6 3155 563 74 1341 18 
16 2-F 39 780 20 74% 100% n.d. 
17 3-Cl 8.9 265 30 89% 100% n.d. 
aMean value of at least two determinations, standard deviation less than 20%. bHuman placental, cytosolic fraction, substrate E1[ 500 
nM], cofactor NADH[500 µM]. cHuman placental, microsomal fraction, substrate E2[500 nM], cofactor NAD+[1500 µM]. dn.d.: not 
determined. eRat recombinant enzyme, expressed in HEK 293, substrate [3H]-E1, 10 nM, cofactor NADH, 500 µM. dRat liver, 
microsomal fraction, substrate [3H]-E2, 10 nM, cofactor NAD+, 1500 µM. 
The efficacy of compound 15 was investigated in cellular experiments. For this purpose , 
two NSCLC cell lines Calu-1 and A549 were chosen.  
E1 enhances the proliferation of Calu-1 cell line (Fig. 2, green line versus purple line). 
Compound 15 at the concentartion of 50 nM is able to decrease cell proliferation in the 
presence of E1 to the basal level (blue line) and this effect is stronger when the 
concentration of 15 is higher (red line).  
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Figure 2. Control (DMSO) – purple curve; 5 uM E1 – green curve; 5 uM E1 + 50 nM of 
15 – dark blue curve; 5 uM E1 + 500 nM of 15 – red curve. 
The response of A549 cells is different, compared to the one of Calu-1 cells. E1 is able to 
enhance the proliferation of this cell line too Fig.3, but 15 did not inhibit cell proliferation as 
much as in Calu-1 cell line. At a concentration of 500 nM 15 is able to decrease A549 cells 
proliferation in presence of E1, although cells growth rate is significantly higher in 
comparison to control. This result might be explained by a different E1 metabolism 
pathway, which is able to bypass the 17βHSD1 inhibition. 
 
Figure 3. Control (DMSO) – purple curve; 5 uM E1 – green curve; 5 uM E1 + 50 nM of 
15 – dark blue curve; 5 uM E1 + 500 nM of 15 – red curve. 
 
CONCLUSION 
The aim of this work was the discovery of a new class of selective 17βHSD1 inhibitors, 
which can be suitable for application in both a rat model of lung cancer and humans. We 
described how exchange of the central ring and substituents modulation can turn selective 
h17βHSD2 inhibitors into selective h17βHSD1. Compound 15 displays a high inhibitory 
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activity against h17βHSD1 and exceptional selectivity against h17βHSD2 and the ERs. It is 
also active and selective against the rat enzymes. Compound 15 provided the first 
convincing evidence that inhibition of h17βHSD1 can inhibit NSCLC cell proliferation in 
vitro, thus indicating a new theraupetic option for NSCLC treatment. Furthermore its low 
cytotoxicity and good pharmacokinetics properties in vitro and in vivo, makes 15 the ideal 
candidate for an in vivo proof of concept study. 
EXPERIMENTAL SECTION 
All reagents and solvents were obtained from commercial suppliers and used without 
further purification Column chromatography was performed on silica gel (70-200 μm) and 
reaction progress was monitored by TLC on Alugram SIL G/UV254 (Macherey-Nagel). 
1
H 
NMR and 
13
C NMR spectra were measured on a Bruker AM500 spectrometer (at 500 MHz 
and 125 MHz, respectively) at 300 K and on Bruker Fourier 300 (at 300 MHz and 75 MHz, 
respectively) at 300 K. Chemical shifts are reported in δ (ppm) and coupling constants (J) in 
Hertz (Hz). Melting points (mp) were measured in open capillaries on a Stuart Scientific 
SMP3 apparatus and are uncorrected.All microwave irradiation experiments were carried 
out in a 507 CEM-Discover microwave apparatus.All tested compounds exhibited ≥ 95% 
chemical purity as measured by LC/MS. 
Method A, general procedure for amide formation:  
A mixture of 5-bromofuran-2-carboxylic acid (1eq), thionyl chloride (2.5 eq) and DMF (5 
drops) in toluene (10 mL) was refluxed at 110°C for 4 hours. The reaction mixture was 
cooled to room temperature; the solvent and the excess of thionyl chloride were removed 
under reduced pressure. The corresponding N-methylamine (1 eq) and Et3N (1 eq) in 
CH2Cl2 (10 mL) was added at 0°C under N2 atmosphere to the acyl chloride. After 30 
minutes at 0°C, the ice bath was removed and the solution was warmed up and stirred at 
room temperature overnight. The reaction mixture was extracted twice with CH2Cl2 (2 × 15 
mL); the organic layer was dried over MgSO4, filtered and the solution was concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
using hexanes and EtOAc as eluent or by trituration in a mixture of diethyl ether / petroleum 
ether to afford the desired compound. 
Method B, general procedure for Suzuki-Miyaura coupling: 
In a sealed tube the previously prepared 5-bromo-N-heteroaryl-furan-2-carboxamide 
derivative (1 eq.) was introduced followed by the corresponding boronic acid (1.5 eq.), 
cesium carbonate (3 eq.), tetrakis(triphenylphosphine)palladium (0.02 eq.) and a mixture of 
DME/EtOH/H2O (1:1:1, v:v:v, 3 mL) as solvent. The reactor was flushed with N2 and 
submitted to microwave irradiation (150°C, 150 W) for 20 minutes. After cooling to room 
temperature, a mixture of EtOAc/H2O (1:1, v:v, 2 mL) was added to stop the reaction. The 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layer was washed once 
with brine and once with water, dried over MgSO4, filtered and the solution was 
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concentrated under reduced pressure. The residue was purified by column chromatography 
using hexanes and EtOAc as eluent to afford the desired compound. 
Method C, general procedure fo ether cleavage: 
To a solution of methoxyaryl compounds (1 eq.) in dry dichloromethane (5 mL/mmol of 
reactant), boron trifluoride-dimethyl sulfide complex (6 eq./methoxy function) was added 
dropwise at 0 °C and stirred for 6-14 h at room temperature. After the reaction was finished, 
the reaction mixture was diluted with dichloromethane and 5% aqueous NaHCO3 was added 
until neutral pH was obtained. The aqueous layer wad extracted with dichloromethane. The 
combined organic layers were washes with brine, dried over sodium sulfate, evaporated to 
dryness under reduced pressure. The product was purified by column chromatography using 
EtOAc as eluent to afford the desired compound. 
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2.4.1 Supporting Information 
a) Chemical Methods. Chemical names follow IUPAC nomenclature. Starting materials 
were purchased from Aldrich, Acros, Combi-Blocks or Fluorochem and were used without 
purification. 
Column chromatography was performed on silica gel (70-200 μm) and reaction progress 
was monitored by TLC on Alugram SIL G/UV254 (Macherey-Nagel). Visualization was 
accomplished with UV light. 
1
H NMR and 
13
C NMR spectra were measured on a Bruker AM500 spectrometer (at 500 
MHz and 125 MHz, respectively) at 300 K and on Bruker Fourier 300 (at 300 MHz and 75 
MHz, respectively) at 300K. Chemical shifts are reported in δ (parts per million: ppm), by 
reference to the hydrogenated residues of deuteriated solvent as internal standard: 2.05 ppm 
(
1
H NMR) and 29.8 and 206.3 ppm (
13
C NMR) for CD3COCD3, 7.26 ppm (
1
H NMR) and 
77.0 ppm (
13
C NMR) for CDCl3. Signals are described as br (broad), s (singlet), d (doublet), 
t (triplet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of 
triplets) and m (multiplet). All coupling constants (J) are given in Hertz (Hz).  
Melting points (mp) were measured in open capillaries on a Stuart Scientific SMP3 
apparatus and are uncorrected. 
Mass spectrometry was performed on a TSQ Quantum (ThermoFisher, Dreieich, Germany). 
The triple quadrupole mass spectrometer was equipped with an electrospray interface (ESI). 
The purity of the compounds was assessed by LC/MS. The Surveyor-LC-system consisted 
of a pump, an auto sampler, and a PDA detector. The system was operated by the standard 
software Xcalibur. A RP C18 NUCLEODUR 100-5 (3 mm) column (Macherey-Nagel 
GmbH, Dühren, Germany) was used as stationary phase. All solvents were HPLC grade. In 
a gradient run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) was 
increased from an initial concentration of 0 % at 0 min to 100 % at 15 min and kept at 100 
% for 5 min. The injection volume was 15 µL and flow rate was set to 800 µL/min. MS 
analysis was carried out at a needle voltage of 3000 V and a capillary temperature of 350 
°C. Mass spectra were acquired in positive mode from 100 to 1000 m/z and UV spectra 
were recorded at the wave length of 254 nm and in some cases at 360 nm.  
All microwave irradiation experiments were carried out in a 507 CEM-Discover microwave 
apparatus. 
All tested compounds exhibited ≥ 95% chemical purity as measured by LC/MS. 
Method A, general procedure for amide formation:  
A mixture of 5-bromofuran-2-carboxylic acid (1eq), thionyl chloride (2.5 eq) and DMF (5 
drops) in toluene (10 mL) was refluxed at 110°C for 4 hours. The reaction mixture was 
cooled to room temperature; the solvent and the excess of thionyl chloride were removed 
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under reduced pressure. The corresponding N-methylamine (1 eq) and Et3N (1 eq) in 
CH2Cl2 (10 mL) was added at 0°C under N2 atmosphere to the acyl chloride. After 30 
minutes at 0°C, the ice bath was removed and the solution was warmed up and stirred at 
room temperature overnight. The reaction mixture was extracted twice with CH2Cl2 (2 × 15 
mL); the organic layer was dried over MgSO4, filtered and the solution was concentrated 
under reduced pressure. The residue was purified by silica gel column chromatography 
using hexanes and EtOAc as eluent or by trituration in a mixture of diethyl ether / petroleum 
ether to afford the desired compound. 
Method B, general procedure for Suzuki-Miyaura coupling: 
In a sealed tube the previously prepared 5-bromo-N-heteroaryl-furan-2-carboxamide 
derivative (1 eq.) was introduced followed by the corresponding boronic acid (1.5 eq.), 
cesium carbonate (3 eq.), tetrakis(triphenylphosphine)palladium (0.02 eq.) and a mixture of 
DME/EtOH/H2O (1:1:1, v:v:v, 3 mL) as solvent. The reactor was flushed with N2 and 
submitted to microwave irradiation (150°C, 150 W) for 20 minutes. After cooling to room 
temperature, a mixture of EtOAc/H2O (1:1, v:v, 2 mL) was added to stop the reaction. The 
aqueous layer was extracted with EtOAc (3 × 10 mL). The organic layer was washed once 
with brine and once with water, dried over MgSO4, filtered and the solution was 
concentrated under reduced pressure. The residue was purified by column chromatography 
using hexanes and EtOAc as eluent to afford the desired compound. 
 
Method C, general procedure fo ethe cleavage: 
 
To a solution of methoxyaryl compounds (1 eq.) in dry dichloromethane (5 mL/mmol of 
reactant), boron trifluoride-dimethyl sulfide complex (6 eq./methoxy function) was added 
dropwise at 0 °C and stirred for 6-14 h at room temperature. After the reaction was finished, 
the reaction mixture was diluted with dichloromethane and 5% aqueous NaHCO3 was added 
until neutral pH was obtained. The aqueous layer wad extracted with dichloromethane. The 
combined organic layers were washes with brine, dried over sodium sulfate, evaporated to 
dryness under reduced pressure. The product was purified by column chromatography using 
EtOAc as eluent to afford the desired compound. 
 
5-bromo-N-methyl-N-(o-tolyl)furan-2-carboxamide (6a) 
The title compound was prepared by reaction of 5-bromofuran-2-carboxylic acid (500 mg, 
2.6 mmol), thionyl chloride (0.5 mL, 6.8 mmol) and N,2-dimethylaniline (315 mg, 
2.6mmol) according to method A. The residue was purified by silica gel column 
chromatography (n-hexane/EtOAc70:30) to afford the desired product as grey solid (349 
mg, 45 %).C13H12BrNO2; MW 294; mp: 93 – 95°C; MS (ESI) 294, 296 [M+H]
+
; 
1
H NMR 
(CD3COCD3, 500 MHz) δ2.19 (s, 3H), 3.27 (s, 3H), 5.65 (d, J = 4 Hz, 1H), 6.33 (d, J = 4 
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Hz, 1H), 7.26 (d, J = 8 Hz, 1H), 7.29-7.33 (m, 1H), 7.36 (d, J = 4 Hz, 2H); 
13
C NMR 
(CD3COCD3, 125 MHz) δ 21.2, 38.4, 113.9, 118.9, 125.1, 128.2, 131.1, 138.7, 142.5, 150.6, 
158.3. 
5-bromo-N-methyl-N-(p-tolyl)furan-2-carboxamide (5a) 
The title compound was prepared by reaction of 5-bromofuran-2-carboxylic acid (500 mg, 
2.6 mmol), thionyl chloride (0.5 mL, 6.8 mmol) and N,4-dimethylaniline (317 mg, 2.6 
mmol) according to method A. The residue was purified by silica gel column 
chromatography (n-hexane/EtOAc 70:30) to afford the desired product as yellow solid (459 
mg, 60 %).C13H12BrNO2; MW 294; mp: 114 – 116°C; MS (ESI) 294, 296 [M+H]
+
; 
1
H 
NMR (CD3COCD3, 500 MHz) δ 2.38 (s, 3H), 3.32 (s, 3H), 5.83 (d, J = 4 Hz, 1H), 6.36 (d, J 
= 4 Hz, 1H), 7.26 (d, J = 8 Hz, 1H), 7.29-7.33 (m, 1H), 7.36 (d, J = 4 Hz, 2H); 
13
C NMR 
(CD3COCD3, 125 MHz) δ 21.2, 38.4, 113.9, 118.9, 125.1, 128.4, 131.1, 138.74, 142.5, 
150.6, 158.3. 
 
N-methyl-5-(o-tolyl)-N-(p-tolyl)furan-2-carboxamide (5) 
The title compound was prepared by reaction of 5a (100 mg, 0.34mmol), o-
tolylboronicacid(60 mg, 0.44mmol), cesium carbonate (332 mg, 1.02mmol) and 
tetrakis(triphenylphoshine) palladium (8 mg, 0.02 eq.) according to method B.  The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as colorless solid (49 mg, 47%). C20H19NO2; MW 305; mp: 94-97 °C; 
MS (ESI) 292 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ 2.35 (s, 3H), 2.39 (s, 3H), 3.36 
(s, 3H), 6.54 (d, J = 4 Hz, 1H), 6.58 (d, J = 4 Hz, 1H), 7.02 (d, J = 8 Hz, 1H), 7.11-7.15 (m, 
1H), 7.17-7.22 (m, 4H), 7.26-7.29 (m, 2H); 
13
C NMR (CD3COCD3, 125 MHz) δ 21.1, 21.9, 
38.6, 110.8, 118.9, 126.7, 127.8, 128.0, 129.1, 129.9, 131.0, 132.0, 135.7, 138.1, 143.2, 
147.8, 155.1, 159.3. 
N-methyl-N-(o-tolyl)-5-(p-tolyl)furan-2-carboxamide (6) 
The title compound was prepared by reaction of 6a (100 mg, 0.34mmol), p-
tolylboronicacid(60 mg, 0.44mmol), cesium carbonate (332 mg, 1.02mmol) and 
tetrakis(triphenylphoshine) palladium (8 mg, 0.02 eq) according to method B.  The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to afford 
the desired product as yellow oil (30 mg, 29%). C20H19NO2; MW 305; MS (ESI) 306 
[M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ2.22 (s, 3H), 2.30 ( s, 3H), 3.30 (s, 3H), 6.44 
(d, J= 3Hz, 1H), 6.65 (d, J= 3Hz, 1H), 7.13 (d, J= 8 Hz, 2H), 7.22 (d, J= 8Hz, 2H), 7.27-
7.40 (m, 4H); 
13
C NMR (CD3COCD3, 125 MHz) δ 17.5, 21.2, 37.4, 106.6, 119.1, 125.0, 
128.0, 128.3, 129.1, 130.1, 132.2, 136.7, 139.2, 144.2, 147.7, 156.2, 159.3. 
5-(4-methoxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (8a) 
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The title compound was prepared by reaction of 6a (80 mg, 0.27mmol), (4-
methoxyphenyl)boronic acid (54 mg, 0.35mmol), cesium carbonate (266 mg, 0.82mmol) 
and tetrakis(triphenylphoshine) palladium (6 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to 
afford the desired product as yellow solid (52 mg, 29%). C20H19NO3; MW 321; mp: 92-95 
°C; MS (ESI) 322 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ2.22 (s, 3H), 3.29 ( s, 3H), 
3.80 (s, 3H), 6.43 (d, J= 3Hz, 1H), 6.59 (d, J= 3Hz, 1H), 6.89 (d, J= 8 Hz, 2H), 7.26-7.41 
(m, 7H);
13
C NMR (CD3COCD3, 125 MHz) δ 17.5, 37.3, 55.7, 105.6, 114.9, 119.0, 123.5, 
126.6, 128.2, 129.0, 129.2, 132.1, 136.7, 144.4, 147.6, 156.0, 159.1, 160.9. 
5-(4-hydroxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (8) 
The title compound was prepared by reaction of 8a (50 mg, 0.16 mmol) and BF3·SMe2 (100 
µL, 0.96 mmol) according to method C. The residue was purified silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as yellow solid 
(45 mg, 92%). C19H17NO3; MW 307; mp: 172-175 °C; MS (ESI) 308 [M+H]
+
; 
1
H NMR 
(CD3COCD3, 500 MHz) δ2.22 (s, 3H), 3.29 ( s, 3H), 6.40 (d, J= 3Hz, 1H), 6.54 (d, J= 3Hz, 
1H), 6.80 (d, J= 8 Hz, 2H), 7.19 (d, J= 8 Hz, 2H), 7.28 (dd, J = 2 Hz, 8 Hz, 1H), 7.31-7.41 
(m, 3H), 8.60 (s, 1H);
13
C NMR (CD3COCD3, 125 MHz) δ 17.5, 37.3, 105.1, 116.4, 119.0, 
122.6, 126.7, 128.2, 129.0, 129.1, 132.1, 136.7, 144.4, 147.3, 156.4, 158.8, 159.1. 
N-(4-methoxyphenyl)-N-methyl-5-(o-tolyl)furan-2-carboxamide (7a)  
The title compound was prepared by reaction of 7b (150 mg, 0.48mmol), o-tolylboronic 
acid (85 mg, 0.62mmol), cesium carbonate (473 mg, 1.45mmol) and 
tetrakis(triphenylphoshine) palladium (11 mg, 0.02 eq.) according to method B.  The residue 
was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to afford 
the desired product as yellow solid (91 mg, 59%). C20H19NO3; MW 321;mp : 103 – 106 °C; 
MS (ESI) 322 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ 2.38 (s, 3H), 3.35 (s, 3H), 3.85 
(s, 3H), 6.44 (d, J = 4 Hz, 1H), 6.59 (d, J = 4 Hz, 1H), 7.02 (dd, J = 2 Hz, 7 Hz, 2H), 7.14-
7.15 (m, 2H), 7.19-7.22 (m, 2H), 7.27 (dd,J = 2 Hz, 7 Hz,2H);
13
C NMR (CD3COCD3, 125 
MHz) δ 21.9, 38.7, 55.9, 110.8, 115.6, 118.8, 126.7, 127.9, 129.1, 129.4, 129.9, 132.0, 
135.7, 138.4, 147.8, 155.1, 159.3, 160.0. 
N-(4-hydroxyphenyl)-N-methyl-5-(o-tolyl)furan-2-carboxamide (7) 
The title compound was prepared by reaction of 7a (76 mg, 0.24 mmol) and BF3·SMe2 (150 
µL, 1.43 mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as white solid 
(30 mg, 41%). C19H17NO3; MW 307; mp: 180-182 °C; MS (ESI) 308 [M+H]
+
; 
1
H NMR 
(DMSO-d6, 500 MHz) δ2.34 (s, 3H), 3.28 ( s, 3H), 6.26 (br s, 1H), 6.64 (d, J= 4Hz, 1H), 
6.82 (dd, J= 2Hz, 6 Hz, 2H), 7.14 (dd, J= 2Hz, 6 Hz, 2H), 7.18-7.25 (m,4H), 9.69 (s, 
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1H);
13
C NMR (DMSO-d6, 125 MHz) δ21.3, 38.3, 110.2, 116.0, 117.9, 126.0, 126.7, 128.3, 
128.40, 128.43, 131.2, 134.5, 135.2, 146.1, 153.5, 156.9, 158.2. 
5-(2-fluoro-4-methoxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (16a) 
The title compound was prepared by reaction of 6a (80 mg, 0.27mmol), (2-fluoro-4-
methoxyphenyl)boronic acid (60 mg, 0.35mmol), cesium carbonate (266 mg, 0.82mmol) 
and tetrakis(triphenylphoshine) palladium (6 mg, 0.02 eq.) according to method B. The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to 
afford the desired product as yellow oil (60 mg, 67%). C20H18FNO3; MW 339; MS (ESI) 
340 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ 2.22 (s, 3H), 3.30 (s, 3H), 3.84 (s, 3H), 
6.49 (d, J = 4 Hz, 1H), 6.56 (t, J = 4 Hz, 1H), 6.74-6.59 (m,2H), 6.97 (t, J= 8 Hz, 1H), 7.29-
7.42 (m, 4H); 
13
C NMR (CD3COCD3, 125 MHz) δ17.6, 37.4, 56.3, 102.6, 102.8, 109.9, 
110.0, 111.4, 111.48, 111.52, 111.54, 119.1, 128.0, 128.1, 128.4, 129.17, 129.23, 132.2, 
136.8, 144.4, 145.3, 147.6, 150.2, 159.0, 159.7, 161.7, 162.1, 162.2. 
5-(2-fluoro-4-hydroxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (16) 
The title compound was prepared by reaction of 16a (57 mg, 0.17 mmol) and BF3·SMe2 
(110 µL, 1.01 mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as yellow oil 
(10 mg, 18%). C19H16FNO3; MW 325; MS (ESI) 326 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 
MHz) δ 2.22 (s, 3H), 3.30 (s, 3H), 6.45 (d, J = 4 Hz, 1H), 6.50-6.52 (m, 1H), 6.62-6.66 (m, 
2H), 6.92 (t, J = 8 Hz, 1H), 7.29-7.41 (m, 4H), 9.24 (br s, 1H);
13
C NMR (CD3COCD3, 125 
MHz) δ 17.6, 37.5, 103.9, 104.0, 104.1, 109.5, 109.6, 110.5, 110.6, 112.7, 112.83, 112.85, 
119.2, 128.3, 128.4, 129.18, 129.22, 132.6, 144.3, 147.2, 150.7, 159.2, 159.8, 160.1, 160.2, 
161.8. 
5-(3-chloro-4-hydroxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (17) 
The title compound was prepared by reaction of 6a (80 mg, 0.27mmol), (3-chloro-4-
hydroxyphenyl)boronic acid (61 mg, 0.35mmol), cesium carbonate (266 mg, 0.82mmol) 
and tetrakis(triphenylphoshine) palladium (6 mg, 0.02 eq.) according to method B.  The 
residue was purified by crystallization in ethanol and water, to afford the desired product as 
white solid (36 mg, 39%). C19H16ClNO3; MW 342;mp : 77 – 80 °C; MS (ESI) 342, 344 
[M+H]
+
; 
1
H NMR (DMSO-d6, 500 MHz) δ2.15 (s, 3H), 3.24 (s, 3H), 6.50 (d, J = 4 Hz, 
1H), 6.74 (d, J = 4 Hz, 1H), 6.91 (d, J = 8 Hz, 1H), 7.08 (d, J = 2 Hz, 1H), 7.14 (dd, J = 2 
Hz, 8 Hz, 1H), 7.27-7.40 (m, 4H), 10.52 (s, 3H);
13
C NMR (DMSO-d6, 125 MHz) δ 17.0, 
36.9, 105.7, 116.8, 118.5, 120.2, 121.5, 124.0, 125.3, 127.3, 128.0, 128.3, 131.1, 135.2, 
142.8, 146.0, 153.40, 153.42, 157.7. 
5-(3-fluoro-4-methoxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (11a) 
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The title compound was prepared by reaction of 6a (100 mg, 0.34mmol), (3-fluoro-4-
methoxyphenyl)boronic acid(75 mg, 0.44mmol), cesium carbonate (332 mg, 1.02 mmol) 
and tetrakis(triphenylphoshine) palladium (8 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30), to 
afford the desired product as ayellow oil (75 mg, 65%). C20H18FNO3; MW 339; MS (ESI) 
340 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ 2.22 (s, 3H), 3.30 (s, 3H), 3.89 (s, 3H), 
6.52 (d, J = 3 Hz, 1H), 6.69 (d, J = 3 Hz, 1H), 6.99-7.02 (m, 1H), 7.08-7.13 (m, 2H), 7.30 
(dd, J = 2 Hz, 8 Hz, 1H), 7. 32-7.42 (m, 3H);
13
C NMR (CD3COCD3, 125 MHz) δ17.5, 37.4, 
56.6, 106.7, 112.5, 112.7, 114.70, 114.71, 119.1, 121.46, 121.49, 123.87, 123.93, 128.3, 
129.1, 132.1, 136.7, 144.3, 148.1, 148.76, 148.85, 152.1, 154.1, 154.7, 158.9. 
5-(3-fluoro-4-hydroxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (11) 
The title compound was prepared by reaction of 11a (60 mg, 0.18 mmol) and BF3·SMe2 
(110 µL, 1.06 mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as yellow solid 
(55 mg, 95%). C19H16FNO3; MW 325; mp: 190-192 °C; MS (ESI) 326 [M+H]
+
; 
1
H NMR 
(CD3COCD3, 500 MHz) δ 2.22 (s, 3H), 3.30 (s, 3H), 6.49 (d, J = 4 Hz, 1H), 6.64 (d, J = 4 
Hz, 1H), 6.93-7.00 (m, 2H), 7.04 (d, J = 8 Hz, 1H), 7.30 (dd, J = 2 Hz, 8 Hz, 1H), 7.32-7.42 
(m, 3H), 8.98 (s, 1H);
13
C NMR (CD3COCD3, 125 MHz) δ17.5, 37.4, 106.3, 112.7, 112.9, 
118.9, 119.0, 119.2, 121.72, 121.75, 123.17, 123.22, 128.3, 129.1, 132.1, 136.7, 144.3, 
146.1, 146.2, 147.8, 151.4, 153.3, 155.03, 155.05, 159.0. 
5-(4-methoxy-3,5-dimethylphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (15a) 
The title compound was prepared by reaction of 6a (500 mg, 1.70mmol), (4-methoxy-3,5-
dimethylphenyl)boronic acid(367 mg, 2.04mmol), cesium carbonate (1662 mg, 5.10 mmol) 
and tetrakis(triphenylphoshine) palladium (39 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to 
afford the desired product asyellow solid (75 mg, 65%). C22H23NO3; MW 349; mp : 128-
132 °C MS (ESI) 350 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ 2.22 (s, 9H), 3.30 (s, 
3H), 3.68 (s, 3H), 6.62 (d, J = 3 Hz, 1H), 6.64 (d, J = 3 Hz, 1H), 6.94 (brs, 2H), 7.29 (dd, J 
= 2, 8 Hz, 1H), 7.33-7.43 (m, 3H);
13
C NMR (CD3COCD3, 125 MHz) δ16.11, 16.16, 17.6, 
37.5, 60.6, 106.4, 119.3, 125.6, 126.3, 128.3, 129.2, 132.1, 132.2, 136.8, 144.6, 148.1, 
156.0, 158.4, 159.1;IR (cm
-1
) 1626, 2856, 2924, 2981, 3049. 
5-(3,5-difluoro-4-methoxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (13a) 
The title compound was prepared by reaction of 6a (500 mg, 1.70mmol), (3,5-difluoro-4-
methoxyphenyl)boronic acid(383 mg, 2.04mmol), cesium carbonate (1662 mg, 5.10 mmol) 
and tetrakis(triphenylphoshine) palladium (39 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 70:30) to 
afford the desired product asyellow oil (236 mg, 39%). C20H17F2NO3; MW 357; mp : 70-72 
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°C; MS (ESI) 357.9, 358.5, 359.2[M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ 2.23 (s, 3H), 
3.31 (s, 3H), 3.97 (s, 3H), 6.64 (d, J = 4 Hz, 1H), 6.84 (d, J = 4 Hz, 1H), 6.89 (d, J = 9 Hz, 
2H), 7.30-7.43 (m, 4H);
13
C NMR (CD3COCD3, 125 MHz)δ17.6, 37.5, 62.4, 108.6, 108.87, 
108.92, 109.1, 119.3, 125.9, 126.0, 126.1, 128.4, 129.2, 129.3, 132.2, 136.8, 137.2, 144.3, 
148.9, 153.2, 155.80, 155.85, 157.76, 157.81, 158.8;IR (cm
-1
) 1625, 2847, 2921. 
5-(3,5-dichloro-4-methoxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (14a) 
The title compound was prepared by reaction of 6a (500 mg, 1.70mmol), (3,5-dichloro-4-
methoxyphenyl)boronic acid (450 mg, 2.04mmol), cesium carbonate (1662 mg, 5.10 mmol) 
and tetrakis(triphenylphoshine) palladium (39 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 80:20) to 
afford the desired product asyellow solid(438 mg, 39%). C20H17Cl2NO3; MW 390; mp : 
114-117 °C MS (ESI) 390, 392[M+H]
+
; 
1
H NMR (CD3COCD3, 300 MHz) δ 2.25 (s, 3H), 
3.33 (s, 3H), 3.89 (s, 3H), 6.78 (d, J = 4 Hz, 1H), 6.94 (d, J = 4 Hz, 1H), 7.24 (s, 2H), 7.31-
7.46 (m, 4H);
13
C NMR (CD3COCD3, 75 MHz) δ17.6, 37.5, 61.3, 109.0, 119.4, 125.2, 128.3, 
128.4, 129.1, 129.5, 130.5, 132.2, 136.7, 144.3, 149.3, 152.5, 152.8, 158.7. 
5-(4-methoxy-2-methylphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (10a) 
The title compound was prepared by reaction of 6a (500 mg, 1.70mmol), (4-methoxy-2-
methylphenyl)boronic acid(339 mg, 2.04mmol), cesium carbonate (1662 mg, 5.10 mmol) 
and tetrakis(triphenylphoshine) palladium (39 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 90:10) to 
afford the desired product aswhite solid (247 mg, 41%). C21H21NO3; MW 335; mp : 90-93 
°C MS (ESI) 336[M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ2.22 (s, 3H), 2.35 (s, 3H), 
3.29 (s, 3H), 3.79 (s, 3H), 6.33 (d, J = 3 Hz, 1H), 6.42 (d, J = 3 Hz, 1H), 6.72 (dd, J = 2 Hz, 
8 Hz, 1H), 6.78 (s, 1H), 6.99 (d, J = 7 Hz, 1H), 7.27-7.40 (m, 4H);
13
C NMR (CD3COCD3, 
125 MHz) δ17.6, 22.1, 37.4, 55.6, 109.4, 112.4, 117.2, 118.6, 122.8, 128.4, 129.1, 129.2, 
129.6, 132.3, 136.7, 137.6, 144.4, 147.2, 155.6, 159.3, 160.6;IR (cm
-1
) 1639, 2835, 2859, 
2936, 2960, 3052. 
5-(4-methoxy-3-methylphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (12a) 
The title compound was prepared by reaction of 6a (500 mg, 1.70mmol), (4-methoxy-3-
methylphenyl)boronic acid(339 mg, 2.04mmol), cesium carbonate (1662 mg, 5.10 mmol) 
and tetrakis(triphenylphoshine) palladium (39 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 90:10) to 
afford the desired product ascolorless oil (213 mg, 37%). C21H21NO3; MW 335; MS (ESI) 
336 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ2.15 (s, 3H), 2.22 (s, 3H), 3.29 (s, 3H), 
3.83 (s, 3H), 6.51 (d, J = 3 Hz, 1H), 6.57 (d, J = 3 Hz, 1H), 6.87 (d, J = 8 Hz, 1H), 7.02 (s, 
1H), 7.18-7.19 (m, 1H), 7.28 (dd, J = 1 Hz, 9 Hz, 1H), 7.32-7.42 (m, 3H);
13
C NMR 
(CD3COCD3, 125 MHz) δ16.2, 17.6, 37.4, 55.9, 105.5, 111.1, 119.2, 123.1, 124.3, 127.3, 
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127.5, 128.3, 129.1, 129.2, 132.2, 136.8, 144.5, 147.6, 156.4, 159.1, 159.2;IR (cm
-1
) 1627, 
2838, 2933, 3052. 
5-(2-chloro-4-methoxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (9a) 
The title compound was prepared by reaction of 6a (500 mg, 1.70mmol), (2-chloro-4-
methoxyphenyl)boronic acid(380 mg, 2.04mmol), cesium carbonate (1662 mg, 5.10 mmol) 
and tetrakis(triphenylphoshine) palladium (39 mg, 0.02 eq.) according to method B.  The 
residue was purified by silica gel column chromatography (n-hexane/ethyl acetate 90:10) to 
afford the desired product aswhite solid (150 mg, 25%). C21H18ClNO3; MW 356; mp : 92-
94 °C; MS (ESI) 356, 358[M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ2.22 (s, 3H), 3.30 (s, 
3H), 3.85 (s, 3H), 6.51 (d, J = 3 Hz, 1H), 6.85-6.90 (m, 2H), 6.95 (d, J = 9 Hz, 1H), 7.00-
7.01 (m, 1H), 7.28-7.41 (m, 4H);
13
C NMR (CD3COCD3, 125 MHz) δ17.6, 37.5, 56.2, 111.2, 
114.4, 116.4, 118.7, 121.7, 128.4, 129.16, 129.22, 130.2, 131.8, 132.3, 136.8, 144.4, 147.7, 
152.1, 159.0, 161.0;IR (cm
-1
) 1619, 2844, 2915, 2944, 2996. 
5-(4-hydroxy-3,5-dimethylphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (15) 
The title compound was prepared by reaction of  15a (260 mg, 0.74 mmol) and BF3·SMe2 
(470 µL, 4.44 mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as yellow solid 
(74 mg, 30%). C21H21NO3; MW 335; mp: 175-178 °C; MS (ESI) 336 [M+H]
+
; 
1
H NMR 
(CDCl3, 300 MHz) δ 2.22-2.23 (m, 9H), 3.37 (s, 3H), 6.32 (d, J = 3 Hz, 1H), 6.48 (d, J = 3 
Hz, 1H), 6.88 (brs, 2H), 7.21-7.23 (m, 1H), 7.28-7.35 (m, 3H);
13
C NMR (CDCl3, 125 MHz) 
δ 16.51, 16.55, 17.6, 37.5, 105.0, 119.4, 122.4, 125.2, 125.5, 128.3, 129.1, 129.2, 132.2, 
136.8, 144.6, 147.4, 154.9, 156.9, 159.3; IR (cm
-1
) 1592, 1614, 2912, 2952, 3274. 
5-(3,5-difluoro-4-hydroxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (13) 
The title compound was prepared by reaction of  13a (180 mg, 0.50 mmol) and BF3·SMe2 
(320 µL, 3.00 mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as yellow solid 
(140 mg, 81%). C19H15F2NO3; MW 343; mp: 176-178 °C; MS (ESI) 344, 345[M+H]
+
; 
1
H 
NMR (CD3COCD3, 500 MHz) δ 2.22 (s, 3H), 3.31 (s, 3H), 6.59 (d, J = 3 Hz, 1H), 6.75 (d, J 
= 3Hz, 1H), 6.88 (d, J = 7 Hz, 2H), 7.30-7.42 (m, 4H), 9.25 (s, 1H);
13
C NMR (CD3COCD3, 
125 MHz) δ17.6, 37.5, 107.5, 108.48, 108.54, 108.6, 108.7, 119.31, 121.97, 122.05, 122.13, 
128.4, 129.2, 129.3, 132.2, 134.9, 135.0, 135.2, 136.8, 144.3, 148.4, 152.57, 152.63, 153.9, 
154.50, 154.55, 158.9;IR (cm
-1
) 1623, 2930, 3056. 
5-(3,5-dichloro-4-hydroxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (14) 
The title compound was prepared by reaction of  14a (240 mg, 0.61mmol) and BF3·SMe2 
(476 µL, 3.66mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as orange solid 
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(117 mg, 51%). C19H15Cl2NO3; MW 376; mp: 134-137 °C; MS (ESI) 376, 378 [M+H]
+
; 
1
H 
NMR (CD3COCD3, 500 MHz) δ2.23 (s, 3H), 3.31 (s, 3H), 6.71 (d, J = 3 Hz, 1H), 6.80 (d, J 
= 3 Hz, 1H), 7.19 (s, 2H), 7.30 (d, J = 8 Hz, 1H), 7.34-7.43 (m, 3H), 9.08 (s, 1H);
13
C NMR 
(CD3COCD3, 125 MHz) δ17.6, 37.5, 107.5, 119.4, 123.4, 124.1, 125.0, 128.3, 129.1, 129.5, 
132.2, 136.7, 144.3, 148.6, 150.0, 153.2, 158.9;IR (cm
-1
) 1620, 2853, 2923, 2957, 3129. 
5-(4-hydroxy-2-methylphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (10) 
The title compound was prepared by reaction of 10a (200 mg, 0.60mmol) and BF3·SMe2 
(468 µL, 3.60mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40) to afford the desired product as white solid 
(178 mg, 92%). C20H19NO3; MW 321; mp: 219-221 °C; MS (ESI) 322 [M+H]
+
; 
1
H NMR 
(CD3SOCD3, 500 MHz) δ 2.15 (s, 3H), 2.23 (s, 3H), 3.23 (s, 3H), 6.20 (d, J = 3 Hz, 1H), 
6.42 (d, J = 3 Hz, 1H), 6.55 (d, J = 7 Hz, 1H), 6.62 (s, 1H), 6.83 (d, J = 8 Hz, 1H), 7.26-7.38 
(m, 4 HH), 9.64 (s, 1H);
13
C NMR (CD3SOCD3, 125 MHz) δ 17.0, 21.3, 30.6, 36.9, 108.1, 
113.0, 117.6, 117.8, 119.8, 127.4, 128.1, 128.4, 131.2, 135.2, 136.3, 142.8, 145.1, 154.6, 
157.5, 158.0;IR (cm
-1
) 1616, 2853, 2920, 2966, 3056, 3243. 
5-(4-hydroxy-3-methylphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (12) 
The title compound was prepared by reaction of  12a (224 mg, 0.67 mmol) and BF3·SMe2 
(420 µL, 4.02 mmol) according to method C. The residue was purified by crystallization in 
water and ethanol to afford the desired product as green solid (140 mg, 65%). C20H19NO3; 
MW 321; mp: 183-186 °C; MS (ESI) 322 [M+H]
+
; 
1
H NMR (CD3COCD3, 500 MHz) δ2.16 
(s, 3H), 2.22 (s, 3H), 3.29 (s, 3H), 6.47 (d, J = 3 Hz, 1H), 6.51 (d, J = 3 Hz, 1H), 6.79 (d, J = 
8 Hz, 1H), 6.98 (s, 1H), 7.06 (d, J = 8 Hz, 1H), 7.28 (dd, J = 1 Hz, 8 Hz, 1H), 7.32-7.42 (m, 
3H), 8.91 (s, 1H);
13
C NMR (CD3COCD3, 125 MHz) δ16.1, 17.6, 37.4, 104.9, 115.8, 119.3, 
122.2, 124.1, 125.6, 127.7, 128.3, 129.1, 129.2, 132.2, 136.7, 144.5, 147.2, 156.9, 157.2, 
159.2;IR (cm
-1
) 1573, 2907, 3132. 
5-(2-chloro-4-hydroxyphenyl)-N-methyl-N-(o-tolyl)furan-2-carboxamide (9) 
The title compound was prepared by reaction of 9a (120 mg, 0.34 mmol) and BF3·SMe2 
(265 µL, 2.04 mmol) according to method C. The residue was purified by silica gel column 
chromatography (n-hexane/ethyl acetate 60:40)to afford the desired product as pink solid 
(89 mg, 77%). C19H16ClNO3; MW 342; mp: 198-201 °C; MS (ESI) 342, 344[M+H]
+
; 
1
H 
NMR (CD3SOCD3, 500 MHz) δ2.15 (s, 3H), 3.24 (s, 3H), 6.36 (d, J = 3 Hz, 1H), 6.70 (dd, 
J = 2 Hz, 9 Hz, 1H), 6.80-6.82 (m, 2H), 6.86 (d, J = 3 Hz, 1H), 7.28-7.39 (m, 4H), 10.2 (s, 
1H);
13
C NMR (CD3SOCD3, 125 MHz) δ16.9, 36.9, 109.7, 114.7, 116.9, 117.9, 118.5, 
127.4, 128.1, 128.2, 129.2, 130.3, 131.2, 135.2, 142.7, 145.6, 151.1, 157.8, 158.3;IR (cm
-1
) 
1562, 2691, 2775, 2877, 2993, 3064. 
b) Biological methods 
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[2,4,6,7-
3
H]-E2 and [2,4,6,7-
3
H]-E1 were purchased from Perkin-Elmer, Boston. Quickszint 
Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. Other chemicals 
were purchased from Sigma, Roth or Merck. 
h17β-HSD1 and h17β-HSD2 enzyme preparation. Cytosolic (h17β-HSD1) and 
microsomal (h17β-HSD2) fractions were obtained from human placenta according to 
previously described procedures.
1-3
 Fresh tissue was homogenized and the enzymes were 
separated from the mitochondria, cell membrane,nucleus and other rests by fractional 
centrifugation at 1000 g, 10.000 g and 150.000 g. The pellet fraction containing the 
microsomal h17β-HSD2 was used for the determination of h17β-HSD2 inhibition, while 
h17β-HSD1 was obtained after precipitation with ammonium sulfate from the cytosolic 
fraction for use of testing of h17β-HSD1 inhibition. Aliquots containing h17β-HSD1 or 
h17β-HSD2 were stored frozen. 
r17β-HSD1 and r17β-HSD2 enzyme preparation. Recombinant rat 17β-HSD1 enzyme 
was produced by transfection of HEK 293 cells with a rat 17β-HSD1 expression plasmid 
[coding sequences and NM_012851 in pCMV6Entry vector, OriGene Technologies, Inc.]. 
48 hours after transfection cells were homogenized by sonication (3 x 10 s) in a buffer 
containing saccharose (40 mMTris, 250 mMsaccharose, 5 mM EDTA, 7 mM DTT, 1 mM 
PMSF, pH 7.5). Cell lysate was centrifuged (1000 g, 15 min, 4°C) and 20% glycerol was 
added to the supernatant before aliquots were frozen and stored at -70°C.
4
 Microsomal 17β-
HSD2 fractions were obtained from rat tissues.
5
 Fresh tissue was homogenized and 
centrifuged. The pellet fraction contains the microsomal 17β-HSD2 and was used for the 
determination of E1 formation. 
Inhibition of h17β-HSD2 and r17β-HSD2 in cell-free assay.Inhibitory activities were 
evaluated following an established method with minor modifications.
6, 7
 Briefly, the enzyme 
preparation was incubated with NAD
+
 [1500 µM] in the presence of potential inhibitors at 
37 °C in a phosphate buffer (50 mM) supplemented with 20% of glycerol and EDTA 1mM. 
Inhibitor stock solutions were prepared in DMSO. Final concentration of DMSO was 
adjusted to 1% in all samples. The enzymatic reaction was started by addition of a mixture 
of unlabelled- and [
3
H]-E2 (final concentration: 500 nM, 0.11 µCi). After 20 min, the 
incubation was stopped with HgCl2 and the mixture was extracted with ether. After 
evaporation, the steroids were dissolved in acetonitrile/water (45:55). E1 and E2 were 
separated using acetonitrile/water (45:55) as mobile phase in a C18 RP chromatography 
column (Nucleodur C18, 3µm, Macherey-Nagel, Düren) connected to a HPLC-system 
(Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and quantification of 
the steroids were performed using a radioflow detector (Berthold Technologies, Bad 
Wildbad). The conversion rate was calculated according to the following equation: 
%conversion = (%E1/(%E1+%E2))×100. Each value was calculated from at least two 
independent experiments. 
Results 
 
145 
 
Inhibition of h17β-HSD1 and r17β-HSD1 in cell-free assay.The 17β-HSD1 inhibition 
assay was performed similarly to the h17β-HSD2 test. The human cytosolic enzyme was 
incubated with NADH [500 µM] while the rat recombinant enzyme was reacted with 
NADPH [500 µM].Test compound and a mixture of unlabelled- and [
3
H]-E1 (final 
concentration: 500 nM, 0.15 µCi) were added and mixed for 10 min at 37°C. Further 
treatment of the samples and HPLC separation was carried out as mentioned above for 
h17β-HSD2. 
Estrogen receptor affinity in a cell-free assay.The binding affinity of compound 15 to 
ERα and ERβ was determined according to the recommendations of the US Environmental 
Protection Agency (EPA) by their Endocrine Disruptor Screening Program (EDSP)
8
 using 
recombinant human proteins. Briefly, 1 nM of ERα and 4 nM of ERβ, respectively, were 
incubated with [
3
H]-E2 (3 nM for ERα and 10 nM for ERβ) and test compound for 16-20 h 
at 4°C.  
The potential inhibitors were dissolved in DMSO (5% final concentration). Evaluation of 
non-specific-binding was performed with unlabeled E2 at concentrations 100-fold of [
3
H]-
E2 (300 nM for ERα and 1000 nM for ERβ). After incubation, ligand-receptor complexes 
were selectively bound to hydroxyapatite (83.5 g/LinTE-buffer). The bound complex was 
washed three times and resuspended in ethanol. For radiodetection, scintillator cocktail 
(Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples were measured in a 
liquid scintillation counter (1450 LSC & Luminescence Counter, Perkin Elmer). 
From these results the percentage of [
3
H]-E2 displacement by the compounds was 
calculated. The plot of % displacement versus compound concentration resulted in 
sigmoidal binding curves. The compound concentrations necessary to displace 50% of the 
receptor bound [
3
H]-E2 were determined. Unlabeled E2 IC50 values were determined in 
each experiment and used as reference. The E2 IC50determined  were 3±20% nM for ERα 
and 10±20% nM for ERβ.Relative Binding Affinity was determined by applying the 
following equation: RBA[%] = (IC50(E2)/IC50(compound)) ∙ 100.
10
 This results in a RBA 
value of 100% for E2. After the assay was established and validated, a modification was 
made to increase throughput. Compounds were tested at concentrations of 1000 times the 
IC50(E2). Compounds with less than 50% displacement of [
3
H]-E2 at a concentration of 
1000 timesIC50(E2) were classified as RBA <0.1%. 
Metabolic Stability in a cell-free assay. Compounds 15 were tested according to 
established method.
9-11
For evaluation of phase I and II metabolic stability 1 µM compound 
was incubated with 1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 2 mM 
NADPH regenerating system, 1 mM UDPGA and 0.1 mM PAPS at 37°C for 0, 5, 15 and 60 
minutes at a final volume of 100 µL. The incubation was stopped by precipitation of S9 
enzymes with 2 volumes of cold acetonitrile containing internal standard. Concentration of 
the remaining test compound at the different time points was analyzed by LC-MS/MS and 
used to determine half-life (t1/2). 
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MTT-Cytotoxicity assay.The number of living cells was evaluated measuringthe reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide(MTT). Experiments were 
performed in96-well cell culture plates in DMEM supplemented with 10% FCS. Cells were 
incubated for 66 h with 6.25, 12.50, 25, 50, and 100 µM of test compound at37 
◦
C in a 
humidified atmosphere at 5% CO2. For cleavage reactionMTT-solution (5mg/mL in PBS) 
was added and incubation wascontinued for another 66 h. Reaction stop and cell lysis were 
carriedout by addition of sodium dodecyl sulphate (SDS) in 0.01N HCl(10%). The produced 
blue formazan was quantifiedspectrophotometricallyat 590nm as described by Denizot and 
Lang
12
withminor modifications. 
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3. Final Discussion 
The present study aimed at the accomplishment of two main goals: 1) The optimization of 
the drug-like properties ofin house 17β-HSD2 inhibitors for the development of a lead 
candidate which might be suitable for both an in vivo proof of concept in a mouse model of 
osteoporosis and for further development as a therapeutic (Part One). 2) Discovery of a 
new class of potent and selective human and rat 17β-HSD1 inhibitors, with good Phase I 
and II metabolic stability which might be used in a rat model of EDD (Part Two). 
Part One. 
In order to increase the chances of a compound to survive  clinical trials, the medicinal 
chemist must optimize not only its pharmacological properties, but also its drug-like 
properties. 
Drug-like properties is a term which refers to a large variety of characteristics of a molecule 
which, if carefully tuned, increase its chances of becoming a successful drug product and it 
includes: appropriate structural properties (i.e. hydrogen bonding,  etc.), physicochemical 
properties (i.e. solubility, chemical stability, lipophilicity etc.), biochemical properties (i.e. 
metabolic stability, PPB) pharmacokinetics and toxicity (i.e. clearance, LD50, etc.). 
In the effort to efficiently optimize our in house 17β-HSD2 inhibitors, a pharmacological 
flowchart (Figure 9) was elaborated in order to obtain the desired drug-like properties. In 
addition the desired molecule must be suitable for an in vivo study in an animal model of 
osteoporosis. 
In chapter 2.I, the main focus was put on the metabolic stability of the inhibitors. In order to 
find out the potential sites of metabolism, eleven 2,5-thiophene amide inhibitors (I.1-I.11) 
were tested for their phase I and II metabolic stability using liver S9 fraction. In this study, 
none of the tested inhibitors showed a satisfying metabolic stability and it was concluded 
that the methyl group onthe A ring is less prone to metabolic degradation than the methoxy 
group and the phenolic hydroxy substituent on both the A and C rings is subject to fast 
metabolism. Combining this information with the knowledge that the thiophene is a 
potential site of metabolism and that the lipophilicity also play an important role in 
metabolic stability, several different compounds were designed and synthesized. Doing this 
we kept in mind the SAR data obtained from previous studies. 
The exchange in compounds I.1 (IC50= 58 nM) of both methoxy groups on rings A and C by 
methyl moieties led to compound I.12 (IC50= 52 nM), with comparable inhibitory activity, 
thus confirming the previously observed SAR data about the equivalency of methoxy and 
methyl groups with regard to 17β-HSD2 inhibition. Despite the preliminary study on 
metabolic stability indicated that the methyl group on the A ring is less prone to metabolic 
degradation than the methoxy group, the parallel exchange of both methoxy, realised in 
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compound I.12, did not bring the desired improvement (Table 2), probably because of a 
switch of the responsible metabolizing enzyme. 
On the other hand, replacement of the thiophene by a furane or by a benzene resulted in 
much more stable compounds I.31 and I.35, respectively (Table 2), indicating that the 
thiophene plays an important role inthe metabolic fate of this class of compounds. 
The strategy of lowering the cLogP of compound I.12 (cLogP= 3.38) was also successful. 
In fact the pyrazole I.27 (cLogP= 2.46) was, in comparison to I.12, much more stable 
(Table 2). 
Compound I.41 (Table 2), bearing a free carboxamide moiety, was also tested for metabolic 
stability, and was found to be  exceptionally stable in comparison to the methylated analog 
I.5 (Table 2). It was not clear whether the methyl group on the N-Me amide is the metabolic 
reactive site or whether it only promotes metabolism atanother site of the molecule. 
Table 2. Half-life of representative compounds measured in Human Liver Microsomes S9 
fraction. 
 
compd Ring B R1 R2 R3 
Inhibitor
c
 
t1/2(min)
a,b
 
I.1 
 
3-OMe 3-OMe -Me 17 
I.12 3-Me 3-Me -Me 19 
I.41 2-F, 3-OMe 3-OMe -H 117 
I.31 
 
3-Me 3-Me -Me 92 
I.35 
 
- - -Me >120 
I.27  - - - 82 
aExtrapolated value. Mean of at least two determinations, standard deviation less than 25%.  
b 1 mg/ml pooled mammalian liver S9 fraction (BD Gentest), 2 mM NADPH regenerating system, 1 mM UDPGA and 0.1 mM 
PAPS at 37°C for 0, 5, 15 and 60 minutes.  
cInhibitor tested at a final concentration of 1 µM. 
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Among the metabolically stable compounds I.27, I.31, I.35 and I.41 described in Chapter 
2.I, I.35 was the only one retaining 17β-HSD2 inhibitory activity, with an IC50 value of 
1126 nM. 
The metabolic fate of compounds I.1, I.2 and I.12 was studied. The main metabolic 
pathway for all the compounds was found to be a oxidation of the left part of the molecule, 
resulting in either hydroxylation or de-methylation reactions (Figure 14). 
In order to identify the exact oxidation site for I.12, all its potential metabolites were 
synthesized for comparison and a metabolic pathway for this compound in human S9 
fraction was outlined. The principal metabolic reaction was revealed to be the hydroxylation 
of the methyl group of ring A. 
Although this study clearly indicated that the central thiophene of compound I.12 did not 
constitute a metabolic reactive site, it was also demonstrated that modulation of I.12 
metabolic rate was achievable by modification of the central ring.I.35, bearing a central 1,4- 
substituted phenyl ring, resulted in exceptional high metabolic stability and it was the 
starting point for following inhibitory activity optimizationstudy, as described in chapter 
2.II. 
 
 
Figure 14. Metabolic fate of compounds I.1, I.2 and I.12 
The goal of the work described in chapter 2.II was the discovery of new potent and selective 
inhibitors of both h17β-HSD2 and m17β-HSD2 and therefore suitable for an in vivo study in 
a mouse model of osteoporosis. 
In order to develop an optimization strategy, a comparative SAR was elaborated by testing 
25 previously described h17β-HSD2 inhibitors, belonging to the 2,5-thiophene amide, 1,3-
phenyl amide and 1,4 phenyl amide classes (Figure 15). 
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Figure 15. Previously described h17β-HSD2 inhibitors tested for m17β-HSD2 inhibition. 
For all the tested 2,5-thiophene and the 1,3-phenyl amides both the nature of substituents on 
ring A and C and their substitution pattern influenced h17β-HSD2 inhibition, whereas they 
did not seem not exert an effect on the h17β-HSD2 enzyme, suggesting that inhibitors in 
these classes might have different binding modes in the two isozymes. 
In contrast, compound I.35, bearing a 1,4-disubstituted phenyl moiety as central ring, 
showed moderate inhibition of both h17β-HSD2 and m17β-HSD2, as well as exceptional 
metabolic stability in the human liver S9 fraction, with a half life> 120 min. Therefore, it 
constituted the starting point for the design of a small library of inhibitors where the 
substitution pattern and the physicochemical nature of substituents on rings A and C were  
varied. 
Inhibitors belonging to the 1,4-phenyl amide class similarly inhibited both h17β-HSD2 and 
h17β-HSD2. The different substituents introduced on rings A and B had comparable effects 
on the inhibitory activity in both 17β-HSD2 isoforms, in contrast with what was observed 
for 2,5-thiophene and 1,3-phenyl amides. 
It is therefore likely that 1,4-phenyl amide derivatives bind in or very close to one of the 
conserved regions of the SDR superfamily members, such as the Rossmann fold or the 
catalytic triad. 
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Table 3. Human and mouse 17β-HSD2 and human h17β-HSD1 inhibition of representative 
1,4-phenyl amides. 
 
Cmpd R1 R2 
Inhibition 
IC50 (nM)
a or % inh. at 1µMa,c 
s.f.
d,f
 
 
Inhibition 
IC50 (nM)
a or % inh. at 1µMa,c 
17β-HSD2b 17β-HSD1c 17β-HSD2f,g 
I.35 3-Me 3-Me 1100 nM 11500 nM 10 50% 
II.6a 3-Me 3-OMe 260 nM 6400 nM 25 260 
II.7a 3-OMe 3-OMe 330 nM 6400 nM 20 290 
II.17a 3-Me, 4-Me 3-OMe 300 nM 13300 nM 44 140 
II.25 - - 260 nM 31000 118 190 
aMean value of at least two determinations, standard deviation less than 20% except for 11a (hHSD2): 26%, 7(hHSD1):25%,. 
bHuman placental, microsomal fraction, substrate E2[500 nM], cofactor NAD+[1500 µM]. cHuman placental, cytosolic fraction, 
substrate E1[ 500 nM], cofactor NADH[500 µM]. ds.f. (selectivity factor)=IC50(17β-HSD1)/IC50(17β-HSD2). 
en.i.: no inhibition 
(inhibition of <10%).fn.d.: not determined. gMouse liver microsomal fraction, substrate E2 [500 nM], cofactor NAD+ [1500 µM]. 
Compounds II.6a, II.7a, II.17a and II.25 displayed significantly improved h17β-HSD2 and 
m17β-HSD2 inhibitory activity and selectivity over h17β-HSD1 (Table 3). They all showed 
no inhibition of m17β-HSD1 at a concentration of 1 µM, suggesting a good selectivity over 
this enzyme, as well. 
Seven of the newly synthesized 1,4-phenyl amides were tested for metabolic stability, using 
human liver S9 fraction. With the exception of compound II.25, they all revealed an 
exceptional metabolic stability, suggesting that this isa positive characteristic of the whole 
class. Since compound II.25was the only one bearing a hydroxyl group as well as the only 
tested compound which was metabolically unstable, it is likely to be subject to Phase II 
metabolism at this functional group. 
Inhibitory activity assay, using the human mammary tumor cell line MDA-MB-231, for 
compounds II.6a, II.17a and II.25 also revealed that these inhibitors can permeate the 
membrane and are able to inhibit the enzyme in a concentration dependent manner. 
Compounds II.6a, II.7a, II.17a and II.25 were also tested for their affinity toward the ERα 
and ERβ, resulting in a very low binding affinity (RBA< 0,1%). 
In conclusion compound II.17a resulted in the best pharmacological profile, with strong 
inhibition of both h17β-HSD2 and m17β-HSD2 and selectivity toward the respective type 1 
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enzymes and the ERs. It also displayed good cellular inhibitory activity, high metabolic 
stability and good physicochemical parameters (MW= 345 and cLogP= 4.75) which are 
predictor for a good oral bio-availability. 
Although compound II.17a seemed to meet most of the requirements of our 
pharmacological flowchart, it was later found to exert some cytotoxicity. In fact only 34% 
of the cells treated with 6.25 µM of II.17a were still alive in an MTT assay. 
 
Therefore in chapter III is a successful strategy is described to address cytotoxicity and keep 
up  potency and selectivity of the lead II.17a. 
In order to achieve these goals, it was decided to disrupt the aromaticity and linearity of the 
biphenyl moiety. Four different classes of compounds were therefore explored (Figure 16): 
(1) the 4-phenoxybenzamides, compounds III.7a and III.1-III.7; (2) the 
phenylcyclohexene, compound III.8; (3) the phenylpiperazin-1-yl sulfonyls, compounds 
III.9a-III.11a and III.9-III.11; (4) the phenypiperazin-1-yl methanones, compounds 
III.12a-III.15a and III.12-III.14. 
Figure 16. Structure overview of four different classes of inhibitors designed to address 
II.17a cytotoxicity. 
In the class of 4-phenoxybenzamides, compounds III.3, III.4 and III.7a displayed similar 
or better h17β-HSD2 inhibitory activity and selectivity, in comparison to II.17a (Table 4),  
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demonstrating that the linear shape of the 1,4-phenyl amide class is not necessary for 
inhibition. 
Also the phenylcyclohexene III.8 displayed similar inhibitory activity and a more than 4-
fold higher selectivity over h17β-HSD1 in comparison to II.17a (Table 4), indicating that  
the aromaticity of the central ring is not needed for h17β-HSD2 inhibition. 
On the other hand, all the tested piperazine derivatives III.9a-III.11a, III.9-III.11, III.12a-
III.15a and III.12-III.14 showed weak or no inhibition of h17β-HSD2. Probably the 
introduction of the hydrophilic piperazine ring or the sulphonamide function condensed in 
the piperazine ring, which makes the molecule shorter, are responsible for the loss in 
inhibitory activity. 
Table 4. Human 17β-HSD2 and 17β-HSD1 inhibition of III.3, III.4III.7a and III.8. 
 IC50 (nM)
a
 or Inh. at 1 µM
a 
 
Cmpd R1 R2 17β-HSD2
b 17β-HSD1c s.f.d 
II.17a - - 75% (300nM) n.i. (13300) 44 
III.3 3-Me -Me 300 16100 54 
III.4 4-Me -Me 160 26300 168 
III.7a 4-OMe -OMe 310 9600 31 
III.8 - - 290 60100 209 
aMean value of at least two determinations, standard deviation less than 20%. bHuman placental, microsomal fraction, substrate 
E2[500 nM], cofactor NAD+[1500 µM]. cHuman placental, cytosolic fraction, substrate E1[ 500 nM], cofactor NADH[500 µM]. 
dn.d.: not determined. 
The evaluation of cell viability in HEK293 cells for compounds III.3, III.4, III.7a (LD50~ 
25 µM) and III.8 (LD50> 12 µM), revealed a much improved safety profile for all the 
compounds, when compared to II.17a(LD50< 6.25 µM).  
Compound III.4 also displayed improved h17β-HSD2 inhibitory activity and selectivity, 
confirming it as new lead compound (Figure 17). 
 
Figure 17. New lead compound for h17β-HSD2 inhibition. 
Part Two. 
In chapters 2.I-2.III,the laborious process of obtaining potent 17β-HSD2 inhibitors, with 
significant selectivity over 17β-HSD1, together with well defined pharmacological 
properties, aimed to assure the “drug-likeness” of the new chemical  entities is described. 
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In chapter 2.IV, a strategy to reverse the inhibitory activity of 17β-HSD2 inhibitors in 
favour of 17β-HSD1 is presented. The metabolic stability information, gained in the 
previous studies (chapter 2.I and 2.II) were also integrated in the inhibitor design process, in 
order to obtain metabolically stable compounds. 
In the frame of the 17β-HSD2 project, the class of 2,5-thiophene inhibitors was extensively 
studied. Compound I.12, turned out to be a potent and selective h17β-HSD2 inhibitor, 
although it is metabolically unstable. Exchange of the thiophene by a furane ring, improved 
the metabolic stability strongly, as it results by comparison of I.12 and I.31 (t1/2= 19 min 
and 92 min, respectively). In addition only the 2,4 and the 4,2 substitution on ring A and C 
were favourable for h17β-HSD1 inhibitory activity. 
A small series of biphenyl-2,5-furane amides were synthesized, without hydroxy group on 
the phenyls. They inhibited h17β-HSD1 potently and selectively, with IV.12a (70% and 
12% inhibition of h17β-HSD1 and h17β-HSD2 at 1 µM, respectively) being the best 
compound in the series. The design concept with regard to the inversion of inhibitory 
activity was therefore confirmed as correct. 
Another small library of biphenyl-2,5-furane amides, with an hydroxy group on the A ring 
was also synthesized and tested (Table 5). All the compounds in this series showed 
exceptionally high h17β-HSD1 inhibitory activity, in comparison to the analogues not 
bearing the hydroxy function, thus suggesting that the hydroxy significantly contributes to 
the interaction with the enzyme. In particular IV.12 and IV.15 were also very selective over 
h17β-HSD2 (Table 5, selectivity factor= 198 and 563, respectively), indicating that the 
methyl groups in meta position are not tolerated by this enzyme.   
The hydroxyl derivatives were also tested against the rat 17β-HSD1 (r17β-HSD1) and 17β-
HSD2 (r17β-HSD2) enzymes (Table 5). Most of them were very potent in inhibiting r17β-
HSD1, but only compound IV.15 was also selective over r17β-HSD2. 
Table 5. Inhibition of human and rat 17β-HSD1 and 17β-HSD2 by biphenyl-2,5-furane 
without hydroxy group. 
 
 IC50 (nM)
a
 or Inh. at 1 µM
a
  IC50 (nM)
a
 or Inh. at 1 µM
a
  
Cmpd R2 h17β-HSD1
b h17β-HSD2c s.f.d r17β-HSD1e r17β-HSD2f s.f.d 
IV.8 -H 80 4144 52 49% 37% n.d. 
IV.9 2-Cl 28 301 11 71% 89% n.d. 
IV.10 2-Me 31 1077 35 37% 50% n.d. 
IV.11 3-F 15 447 30 69% 100% n.d. 
IV.12 3-Me 7.8 1547 198 369 1200 3 
IV.13 3,5-F 18 56 3 291 16 0.05 
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IV.14 3,5-Cl 2.9 71 25 176 40 0.2 
IV.15 3,5-Me 5.6 3155 563 74 1341 18 
IV.16 2-F 39 780 20 74% 100% n.d. 
IV.17 3-Cl 8.9 265 30 89% 100% n.d. 
aMean value of at least two determinations, standard deviation less than 20%. bHuman placental, cytosolic fraction, substrate E1[ 500 
nM], cofactor NADH[500 µM]. cHuman placental, microsomal fraction, substrate E2[500 nM], cofactor NAD+[1500 µM]. dn.d.: not 
determined. eRat recombinant enzyme, expressed in HEK 293, substrate [3H]-E1, 10 nM, cofactor NADH, 500 µM. dRat liver, 
microsomal fraction, substrate [3H]-E2, 10 nM, cofactor NAD+, 1500 µM. 
Compounds IV.8 and IV.15 also displayed high metabolic stability (t1/2= 97 min and 51 
min, respectively). Considering that the seventeen 2,5-thiophene amides tested for 
metabolic stability displayed a mean half-life of 20 min and that the three tested 2,5-furane 
amides displayed an half-life between 51 and 97 min, it can be concluded, that the furane 
ring plays a major role in increasing the stability of these compounds, probably by 
decreasing the cLogP and therefore also the affinity for the metabolizing enzyme. 
Compound IV.15 was the most interesting compound in the series and was therefore tested 
for its affinity toward the ERs, and was found to display low affinity with an RBA value 
lower than 0.1%. 
The effect of IV.15 was then investigated in two NSCLC cell lines. The ability of 
compound IV.15 of inhibiting the E1-induced growth of Calu-1 cells at low nanomolar 
concentration provided the first convincing evidence, that h17β-HSD1 is a suitable target 
for the treatment of NSCLC, thus opening new horizons for facing this lethal disease. 
Also cytotoxicity was evaluated for this compound in the MTT assay. No toxic effect was 
detected up to 6.25 µM which is more than 1000-folds the IC50 value. A broad safety 
window in vivo can therefore be expected. 
Data obtained in a preliminary PK study in the rat, indicated sufficient concentration of the 
compound after 24h. This observation, together with high h17β-HSD1 and r17β-HSD1 
inhibitory activity and selectivity over h17β-HSD2, r17β-HSD2 and ERs, as well as with the 
low cytotoxicity, makes IV.15 a good candidate for an in vivo proof of concept study in a 
rat model of non-small lung cell cancer. 
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